Clinical Reviewer: Tina Mongeau
STN: 125731/0

BLA Clinical Review Memorandum
Application Type
STN
CBER Received Date
PDUFA Goal Date
Division / Office
Priority Review
Reviewer Name(s)

Review Completion/
Stamped Date

Biologics License Application
125731/0
October 8, 2020
June 8, 2021
Division of Vaccines and Related Product Applications
(DVRPA)/Office of Vaccines Research and Review (OVRR)
Yes
Tina Khoie Mongeau, MD, MPH
Medical Officer, Clinical Review Branch 1 (CRB1)

June 8, 2021
R. Douglas Pratt, MD, MPH
Associate Director for Medical Affairs, DVRPA/OVRR

Supervisory Concurrence

Lucia Lee, MD
CRB1 Team Leader

Applicant
Established Name
(Proposed) Trade Name
Pharmacologic Class
Formulation, including
Adjuvants, etc.

Dosage Form and Route of
Administration
Dosing Regimen
Indications and Intended
Population(s)

Orphan Designated

Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Pneumococcal 20-valent Conjugate Vaccine (Diphtheria
CRM197 Protein)
Prevnar 20
Vaccine
• 2.2 µg of each of Streptococcus pneumoniae serotypes
1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C,
19A, 19F, 22F, 23F, and 33F saccharides and 4.4 µg of
S. pneumoniae serotype 6B saccharides
• ~51 µg diphtheria cross reactive material (CRM197)
carrier protein*
• 125 µg aluminum as aluminum phosphate adjuvant
* CRM protein is approximate and dependent on the
saccharide-to-protein ratio of the saccharides used
in the formulation
Suspension for intramuscular injection
Single dose
Active immunization for the prevention of pneumonia and
invasive disease caused by S. pneumoniae serotypes 1, 3,
4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A,
19F, 22F, 23F, and 33F in adults ≥18 years of age
No
i

Clinical Reviewer: Tina Mongeau
STN: 125731/0

TABLE OF CONTENTS
GLOSSARY ......................................................................................................................... 5
1. EXECUTIVE SUMMARY ..................................................................................................... 7
1.1 Demographic Information: Subgroup Demographics and Analysis Summary .................. 12
1.2 Patient Experience Data .................................................................................................... 12

2. CLINICAL AND REGULATORY BACKGROUND.................................................................... 12
2.1 Disease or Health-Related Condition(s) Studied............................................................... 12
2.2 Currently Available, Pharmacologically Unrelated Treatment for Proposed Indications ... 13
2.3 Safety and Efficacy of Pharmacologically Related Products............................................. 14
2.4 Previous Human Experience with the Product (Including Foreign Experience)................ 15
2.5 Summary of Pre- and Post-submission Regulatory Activity Related to the Submission... 16
2.6 Other Relevant Background Information ........................................................................... 17

3. SUBMISSION QUALITY AND GOOD CLINICAL PRACTICES ................................................. 18
3.1 Submission Quality and Completeness ............................................................................. 18
3.2 Compliance With Good Clinical Practices And Submission Integrity ................................ 18
3.3 Financial Disclosures ......................................................................................................... 19

4. SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES ......... 20
4.1 Chemistry, Manufacturing, and Controls ........................................................................... 20
4.2 Assay Validation ................................................................................................................ 20
4.3 Nonclinical Pharmacology/Toxicology ............................................................................... 20
4.4 Clinical Pharmacology ....................................................................................................... 22
4.4.1 Mechanism of Action ................................................................................................ 22
4.5 Statistical ........................................................................................................................... 22
4.6 Pharmacovigilance ............................................................................................................ 22

5. SOURCES OF CLINICAL DATA AND OTHER INFORMATION CONSIDERED IN THE REVIEW .... 22
5.1 Review Strategy ................................................................................................................ 22
5.2 BLA/IND Documents That Serve as the Basis for the Clinical Review ............................. 23
5.3 Table of Studies/Clinical Trials .......................................................................................... 24
5.5 Literature Reviewed ........................................................................................................... 26

6. DISCUSSION OF INDIVIDUAL STUDIES/CLINICAL TRIALS ................................................... 27
6.1 Study B7471007 ................................................................................................................ 27
6.1.1 Objectives ................................................................................................................ 28
6.1.2 Design Overview ...................................................................................................... 30
6.1.3 Population ................................................................................................................ 31
6.1.4 Study Treatments or Agents Mandated by the Protocol .......................................... 32
6.1.6 Sites and Centers..................................................................................................... 33
6.1.7 Surveillance/Monitoring ............................................................................................ 33
6.1.8 Endpoints and Criteria for Study Success ............................................................... 34
6.1.9 Statistical Considerations & Statistical Analysis Plan .............................................. 34
6.1.10 Study Population and Disposition .......................................................................... 36
6.1.11 Efficacy Analyses ................................................................................................... 44
6.1.12 Safety Analyses ..................................................................................................... 53
6.1.13 Study Summary and Conclusions .......................................................................... 66
6.2 Study B7471008 ................................................................................................................ 66
6.2.1 Objectives ................................................................................................................ 67
6.2.2 Design Overview ...................................................................................................... 67
6.2.3 Population ................................................................................................................ 68
6.2.4 Study Treatments or Agents Mandated by the Protocol .......................................... 68

ii

Clinical Reviewer: Tina Mongeau
STN: 125731/0
6.2.6 Sites and Centers..................................................................................................... 69
6.2.7 Surveillance/Monitoring ............................................................................................ 69
6.2.8 Endpoints and Criteria for Study Success ............................................................... 69
6.2.9 Statistical Considerations & Statistical Analysis Plan .............................................. 69
6.2.10 Study Population and Disposition .......................................................................... 70
6.2.11 Efficacy Analyses ................................................................................................... 74
6.2.12 Safety Analyses ..................................................................................................... 77
6.2.13 Study Summary and Conclusions .......................................................................... 82
6.3 Study B7471006 ................................................................................................................ 83
6.3.1 Objectives ................................................................................................................ 83
6.3.2 Design Overview ...................................................................................................... 84
6.3.3 Population ................................................................................................................ 85
6.3.4 Study Treatments or Agents Mandated by the Protocol .......................................... 85
6.3.6 Sites and Centers..................................................................................................... 85
6.3.7 Surveillance/Monitoring ............................................................................................ 85
6.3.8 Endpoints and Criteria for Study Success ............................................................... 86
6.3.9 Statistical Considerations & Statistical Analysis Plan .............................................. 86
6.3.10 Study Population and Disposition .......................................................................... 86
6.3.11 Efficacy Analyses ................................................................................................... 90
6.3.12 Safety Analyses ..................................................................................................... 95
6.3.13 Study Summary and Conclusions .......................................................................... 99
6.4 Study B7471002 ................................................................................................................ 99
6.5 Study B7471005 .............................................................................................................. 100
6.6 Study B7471001 .............................................................................................................. 101

7. INTEGRATED OVERVIEW OF EFFICACY ......................................................................... 105
8. INTEGRATED OVERVIEW OF SAFETY ............................................................................ 106
8.1 Safety Assessment Methods ........................................................................................... 106
8.2 Safety Database .............................................................................................................. 107
8.2.1 Studies/Clinical Trials Used to Evaluate Safety ..................................................... 107
8.2.2 Overall Exposure, Demographics of Pooled Safety Populations........................... 107
8.3 Caveats Introduced by Pooling of Data Across Studies/Clinical Trials ........................... 107
8.4 Safety Results ................................................................................................................. 108
8.4.1 Deaths .................................................................................................................... 108
8.4.2 Nonfatal Serious Adverse Events .......................................................................... 108
8.4.3 Study Dropouts/Discontinuations ........................................................................... 108
8.4.4 Common Adverse Events ...................................................................................... 108
8.4.6 Systemic Adverse Events ...................................................................................... 108
8.4.7 Local Reactogenicity .............................................................................................. 109
8.6 Safety Conclusions .......................................................................................................... 109

9. ADDITIONAL CLINICAL ISSUES ...................................................................................... 110
9.1 Special Populations ......................................................................................................... 110
9.1.1 Human Reproduction and Pregnancy Data ........................................................... 110
9.1.2 Use During Lactation ............................................................................................. 111
9.1.3 Pediatric Use and PREA Considerations ............................................................... 111
9.1.4 Immunocompromised Patients .............................................................................. 112
9.1.5 Geriatric Use .......................................................................................................... 112

iii

Clinical Reviewer: Tina Mongeau
STN: 125731/0

10. CONCLUSIONS .......................................................................................................... 112
11. RISK-BENEFIT CONSIDERATIONS AND RECOMMENDATIONS ........................................ 113
11.1 Risk-Benefit Considerations .......................................................................................... 113
11.2 Risk-Benefit Summary and Assessment ....................................................................... 116
11.4 Recommendations on Regulatory Actions .................................................................... 116
11.5 Labeling Review and Recommendations ...................................................................... 116
11.6 Recommendations on Postmarketing Actions............................................................... 116

iv

Clinical Reviewer: Tina Mongeau
STN: 125731/0

GLOSSARY
ABCs
ACIP
AE
BLA
CAP
CAPiTA
CBER
CDC
CI
CFR
COPD
CRF
CRM197
CSF
CSR
cTnI
cTnT
DMC
DVRPA
ECG
EOP2
FDA
FIH
GERD
GMFR
GMT
IND
IPD
IR
ISS
LL
LLOQ
MedDRA
NCT
NDCMC
OPA
OVRR
PCRU
PCV7
PCV13
PCV20
PeRC
PPSV23
PREA
PS
PT
SAE
sBLA

Active Bacterial Core surveillance
Advisory Committee on Immunization Practices
adverse event
Biologics License Application
community-acquired pneumonia
Community Acquired Pneumonia Immunization Trial in Adults
Center for Biologics Evaluation and Research
Centers for Disease Control and Prevention
confidence interval
Code of Federal Regulations
chronic obstructive pulmonary disease
case report form
cross-reacting material 197 (carrier protein)
cerebrospinal fluid
clinical study report
cardiac troponin I
cardiac troponin T
Data Monitoring Committee
Division of Vaccines and Related Products Applications
electrocardiogram
end of Phase 2
Food and Drug Administration
first-in-human
gastrointestinal esophageal reflux disease
geometric mean fold rise
geometric mean titer
Investigational New Drug (application to the FDA)
invasive pneumococcal disease
Information Request
Integrated Summary of Safety
lower limit
lower limit of quantitation
Medical Dictionary for Regulatory Activities
National Clinical Trial
newly diagnosed chronic medical condition
opsonophagocytic activity
Office of Vaccines Research and Review
Pfizer Clinical Research Unit
Prevnar 7-valent pneumococcal conjugate vaccine
Prevnar 13-valent pneumococcal conjugate vaccine
Prevnar 20-valent pneumococcal conjugate vaccine
Pediatric Review Committee
Pneumovax 23-valent pneumococcal polysaccharide vaccine
Pediatric Research Equity Act
polysaccharide
Preferred Term
serious adverse event
Supplemental Biologics License Application
5

Clinical Reviewer: Tina Mongeau
STN: 125731/0

SD
SOC
STN
Tdap
U.S.
VT

standard deviation
System Organ Class
Submission Tracking Number
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine,
adsorbed
United States
vaccine type

6

Clinical Reviewer: Tina Mongeau
STN: 125731/0

1. Executive Summary
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., submitted this Biologics License
Application (BLA) for their Pneumococcal 20-valent Conjugate Vaccine (proposed proprietary
name, Prevnar 20), which is a successor to their Pneumococcal 13-valent Conjugate Vaccine
(Diphtheria CRM197 Protein; Prevnar 13). Prevnar 20 is composed of capsular polysaccharides
derived from the 13 Streptococcus pneumoniae serotypes contained in Prevnar 13 (1, 3, 4, 5,
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and from 7 additional pneumococcal serotypes (8,
10A, 11A, 12F, 15B, 22F, and 33F), each individually conjugated to non-toxic diphtheria cross
reactive material (CRM197) protein. The proposed indications for Prevnar 20 (PCV20) are for the
active immunization of adults 18 years of age and older for the prevention of pneumonia and
invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A,
12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The proposed regimen consists of a single
intramuscular injection.
Under this BLA, Wyeth is seeking traditional approval for the invasive pneumococcal disease
(IPD) indication for all 20 serotypes in PCV20, as well as for the pneumonia indication for the
Prevnar 13 (PCV13) serotypes in the vaccine. Wyeth has also submitted an accelerated
approval request for the pneumonia indication for the 7 new non-PCV13 serotypes in the
vaccine.
Background
Streptococcus pneumoniae is a leading cause of disease and death among older adults in the
United States (U.S.). S. pneumoniae colonize the nasopharynx and can cause non-invasive
disease (e.g., non-bacteremic pneumonia) as well as invasive disease (e.g., bacteremia and
meningitis) in adults. Non-bacteremic pneumococcal pneumonia is a more common
pneumococcal disease manifestation than IPD in adults.
Currently, there are two pneumococcal vaccines licensed and available in the U.S. for the
prevention of pneumococcal disease in adults, Pneumovax® 23 (Pneumococcal Vaccine,
Polyvalent: Merck Sharp & Dohme Corp.) and PCV13.
Pneumovax 23, a pneumococcal polysaccharide vaccine (PPSV23), is approved for the
prevention of pneumococcal disease caused by the 23 vaccine serotypes in persons ≥50 years
of age and persons ≥2 years of age who are at increased risk of pneumococcal disease. Each
0.5 mL dose contains 25 μg of purified (unconjugated) capsular polysaccharide from each of 23
pneumococcal serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19A, 19F, 20, 22, 23F, and 33F) (Pneumovax 23, prescribing information). Available data
suggest that the PPSV23 vaccine protects adults and the elderly against IPD, however no
consistent vaccine effect has been observed for prevention of pneumonia (Gruber et al. 2008;
Conaty et al. 2004). PPSV23 has been the only pneumococcal vaccine licensed in the U.S. for
adults for the prevention of pneumococcal disease caused by the 7 new serotypes in PCV20.
These 7 serotypes are responsible for a substantial proportion of the current burden of invasive
and noninvasive pneumococcal disease in adults globally.
PCV13 was the first pneumococcal conjugate vaccine licensed for use in adults in the United
States. It is a glycoconjugate vaccine consisting of purified capsular polysaccharide antigens of
13 S. pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F)
individually linked to non-toxic diphtheria CRM197 protein. On December 30, 2011, the Center for
Biologics Evaluation and Research (CBER) approved PCV13 for active immunization for the
7

Clinical Reviewer: Tina Mongeau
STN: 125731/0

prevention of invasive disease and pneumonia caused by the thirteen S. pneumoniae serotypes
contained in the vaccine in persons ≥50 years of age based on an immunologic surrogate
endpoint (opsonophagocytic activity (OPA) titer) as defined in the Accelerated Approval
regulations (21 CFR 601.41). As a condition of accelerated approval, Wyeth completed a
postmarketing study that confirmed and described the efficacy of PCV13 for the approved
indications. On July 11, 2016, CBER approved a Supplemental BLA (sBLA) to expand the use
of PCV13 for the approved indications to adults 18 through 49 years of age based on
immunologic bridging studies.
PCV20 Clinical Development Program
IPD Indication
The PCV20 Phase 3 clinical development program uses an approach in which vaccine
effectiveness against IPD caused by the 20 vaccine serotypes and against pneumonia caused
by the 13 pneumococcal serotypes in PCV13 is inferred in adults ≥60 years of age from
immunologic comparability (using an agreed-upon pre-specified non-inferiority criterion) to
pneumococcal vaccines licensed in the U.S. CBER agreed that PCV20 effectiveness in younger
age groups (18 through 49 and 50 through 59) could be supported by immunobridging to the
established effectiveness in adults 60 through 64 years. A randomized, active-controlled
efficacy trial of PCV20 was not considered feasible due to the sample size that would be
required. A placebo-controlled trial was also considered not ethically justifiable in the U.S.
where, at the time of PCV20 development, PCV13 was recommended routinely for adults ≥65
years of age, as well as for adults <65 years of age with certain underlying medical conditions
that increase the risk of serious pneumococcal disease.
Pneumonia Indication
Although there is no established immune correlate of protection in adults (i.e., a threshold for an
immune marker predictive of protection against pneumococcal disease applicable to all
serotypes), the basis of the agreed upon licensure approach relies on the acceptance of OPA
antibody titer as an established immunologic parameter that can be used to support traditional
approval of new, higher valency pneumococcal conjugate vaccines for the prevention of IPD
caused by any vaccine serotype, and the prevention of pneumonia caused by the 13 serotypes
in PCV13. CBER considered this approach acceptable for PCV20 because: 1) OPA reflects
relevant in vivo mechanisms of protection against pneumococcal disease; 2) efficacy against
pneumonia caused by PCV13 serotypes had been confirmed in a clinical endpoint study
(6115A1-3006; NCT 00744263); and 3) PCV20 and PCV13 vaccines have nearly identical
manufacturing processes for the 13 common serotypes. A similar approach was used to support
the initial licensure of PCV13 in infants and young children (see Section 2.3) for the prevention
of IPD caused by the 13 vaccine serotypes and the prevention of otitis media caused by the
original 7 serotypes in Prevnar (PCV7) (the first U.S.-licensed pneumococcal conjugate vaccine
that was approved for use in infants and toddlers based on efficacy confirmed in clinical
endpoint studies).
CBER did not consider immunogenicity data alone as sufficient to support a non-invasive
disease indication (i.e., pneumonia or otitis media) for non-PCV13 serotypes in PCV20,
because antibody levels have not been found to be indicative of prevention of non-invasive
pneumococcal disease.
Similar to the PCV13 licensure approach for the adult pneumonia indication, approval of PCV20
for the prevention of pneumonia in adults caused by the 7 new serotypes is based on an
8

Clinical Reviewer: Tina Mongeau
STN: 125731/0

immunologic surrogate endpoint (OPA titer), as defined in the Accelerated Approval regulations
(21 CFR 601.41), that is reasonably likely to predict prevention of pneumococcal pneumonia
caused by the 7 new vaccine serotypes in PCV20. This regulation applies to biologics intended
to treat or prevent serious or life-threatening illnesses and that provide meaningful therapeutic
benefit to patients over existing treatments (21 CFR 601.40). CBER considers protection of
adults ≥18 years of age from non-bacteremic pneumococcal pneumonia to be a meaningful
therapeutic benefit over existing treatments (i.e., PCV13 and PPSV23). Because pneumococcal
pneumonia is a serious condition and PCV20 will provide meaningful therapeutic benefit to
patients over existing treatments, the proposed indication meets the qualifying criteria for
accelerated approval. As a condition of accelerated approval, Wyeth will conduct a postapproval real-world observational effectiveness study as a confirmatory study to verify and
describe the clinical benefit for the prevention of pneumonia caused by the 7 new serotypes (8,
10A, 11A, 12F, 15B, 22F, and 33F) in adults ≥ 65 years of age. CBER agreed that it would be
reasonable to target adults ≥ 65 years of age for enrollment in the confirmatory study because
of their higher rates of pneumococcal pneumonia. CBER considered that if PCV20 effectiveness
against pneumonia due to the 7 new serotypes was confirmed in adults ≥ 65 years of age, it
would be reasonable to infer vaccine effectiveness in adults 60 through 64 years of age. CBER
also agreed that PCV20 vaccine effectiveness against pneumonia due to the 7 new serotypes in
adults 18 through 49 years and adults 50 through 59 years of age could be bridged to the
effectiveness in adults 60 through 64 years of age.
This application includes data obtained from 7048 immunocompetent adults ≥18 years of age in
the U.S. and Sweden enrolled in 6 clinical trials; 4552 received PCV20, and 2496 received an
active control vaccine (Table 1).
Phase 3 Non-inferiority Immunogenicity Study
Study B7471007 was the Phase 3 non-inferiority immunogenicity trial evaluating a single dose
of PCV20 in pneumococcal-vaccine-naïve adults ≥18 years of age (Section 6.1). Effectiveness
was inferred via non-inferiority comparisons to one of two U.S.-licensed pneumococcal vaccines
(PCV13 or PPSV23) based on functional OPA titers to each of the 20 vaccine serotypes as
measured by a microcolony OPA assay. PCV13 was selected as the active control for the noninferiority comparisons for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
(contained in both PCV13 and PCV20). PPSV23 was selected as an active control for the noninferiority comparisons for serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F (contained in both
PPSV23 and PCV20). PCV13 was also the active control for safety. For the primary
immunogenicity objectives, non-inferiority comparisons between PCV20 and the respective
active control were performed in subjects ≥60 years of age (Cohort 1). The secondary
objectives aimed to bridge immune responses to PCV20 in younger cohorts (18 through 49
years and 50 through 59 years) to PCV20 responses in subjects 60 through 64 years of age in
the older cohort (Cohort 1 subset).
For the primary endpoint analyses in adults ≥60 years of age, 19 of the 20 vaccine serotypes
met the pre-specified 2-fold non-inferiority criterion (Tables 9 and 10). For serotype 8, the lower
limit (LL) of the 95% CI for the GMT ratio (GMTPCV20/GMTactive control) was 0.49, which was only
slightly less than the pre-specified LL of 0.5. In supportive secondary analyses, 77.8% of
subjects ≥60 years of age achieved a ≥4-fold increase in anti-serotype 8 OPA titers (Table 14).
The effectiveness of PCV20 in each of the younger cohorts (18 through 49 years of age and 50
through 59 years of age) was demonstrated by immunobridging to the established effectiveness
in 60 through64-year-old subjects (Cohort 1 subset). The lower limit of the 95% CI for the GMT
9

Clinical Reviewer: Tina Mongeau
STN: 125731/0

ratio (GMT18-49/50-59/GMT60-64 years) was >0.5 for each of the 20 vaccine serotypes (Tables 11 and
12).
Phase 3 Study in Adults Previously Immunized with PCV13 and/or PPSV23
Study B7471006 was a descriptive safety and immunogenicity study of PCV20 in adults ≥65
years of age previously vaccinated with PPSV23, previously vaccinated with PCV13, or
previously vaccinated with PCV13 followed by PPSV23 (Section 6.3). OPA GMTs in participants
who received PPSV23 1 to 5 years prior to Prevnar 20 were diminished compared to OPA
GMTs in participants who received PCV 13 at least 6 months previously and compared to OPA
GMTs in participants who received PCV13 followed by PPSV23, with the last PPSV23 dose
given at least 1 year prior to PCV20. The safety and tolerability profile of PCV20 was generally
similar in participants with different prior pneumococcal vaccine history and was generally
similar to PCV13 and PPSV23 control groups.
Phase 3 Lot Consistency Study
Wyeth satisfactorily demonstrated manufacturing consistency based on comparisons of OPA
GMTs between three different manufacturing scale lots of PCV20 in study B7471008 (Section
6.2.11.1 Table 26).
Safety Across All Submitted Studies
A total of 7,048 immunocompetent adults ≥18 years of age were evaluated for safety in six
PCV20 pre-licensure trials. This includes 3,928 subjects and 2,247 subjects who received
PCV20 or active control, respectively, in one of 5 randomized, double-blinded, active controlled
clinical trials conducted in pneumococcal vaccine naïve adults ≥18 years of age in the U.S. and
Sweden (172 subjects ≥65 years of age were randomized/enrolled in Sweden). In a sixth
descriptive, open-label study in adults ≥65 years of age in the U.S. and Sweden, safety was
evaluated in adults previously immunized with a pneumococcal vaccine prior to enrollment (624
PCV20 recipients and 245 active control recipients in B7471006).
Overall, the safety profile of PCV20 in adults was generally consistent with the known safety
profile of U.S.-licensed PCV13 (the active control for safety). The most frequently reported
adverse reactions were injection site pain, muscle pain, fatigue, headache and joint pain (Tables
15-20). Adverse reaction rates were highest among subjects in the youngest age cohort (18
through 49) and decreased with increasing age. The vast majority of reactions (≥97%) were mild
or moderate in severity. No vaccine related serious adverse events were reported by study
participants.
Pediatric Assessment and Pediatric Research Equity Act
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), this application for a new
active ingredient is required to contain an assessment of the safety and effectiveness of the
product for the claimed indications in all pediatric age groups, unless the requirement is waived,
deferred, or inapplicable.
Wyeth requested a full waiver of the pediatric study requirement in persons from birth through
16 years of age for the pneumonia indication, because the necessary studies are impossible or
highly impracticable (505B(a)(4)(A)(i) of the Act). Wyeth requested a partial waiver of the
pediatric study requirement in infants from birth to <6 weeks of age for the invasive
pneumococcal disease indication, because PCV20 does not represent a meaningful therapeutic
benefit over existing therapies for pediatric patients in this age group, and Prevnar 20 is not
likely to be used by a substantial number of pediatric patients in this age group (section
10

Clinical Reviewer: Tina Mongeau
STN: 125731/0

505B(a)(4)(B)(iii) of the Act). Wyeth is requesting a deferral of pediatric studies in persons 6
weeks through 16 years of age to support the invasive pneumococcal disease indication on the
basis that Prevnar 20 is ready for approval for use in adults and the pediatric studies have not
been completed (505B(a)(3)(A)(i) of the Act). Deferred studies to support U.S. licensure in
pediatric age groups consist of three trials in children and adolescents 6 weeks through 17
years of age (studies B7471011, B7471013 and B7471014). Please see Section 11.6 for
timelines for conducting each of these three required pediatric postmarketing studies under
PREA. The Pediatric Study Plan was presented to FDA’s Pediatric Review Committee (PeRC)
on May 4, 2021. The committee agreed with the Pediatric Study Plan, including the full waiver,
partial waiver, and deferral requests and the proposed timelines for each protocol submission,
study completion and report submission.
Postmarketing Plans
Wyeth agrees to carefully monitor for any unanticipated risks in surveillance systems and
postmarketing adverse reaction reports (i.e., routine pharmacovigilance).
As a condition of accelerated approval for prevention of pneumococcal pneumonia, Wyeth is
required to conduct a post-approval confirmatory study to verify and describe the clinical benefit
of PCV20 in adults ≥65 years of age. Wyeth submitted a protocol for study B7471015 (STN
125731/0.8) to fulfill this postmarketing requirement. Study B7471015 is a Phase 4, multicenter,
real-world study using a test-negative design to evaluate the effectiveness of PCV20 against
radiologically-confirmed community-acquired pneumonia (CAP) caused by the 7 new serotypes
(8, 10A, 11A, 12F, 15B, 22F, and 33F) in adults ≥65 years of age. The initial protocol synopsis
was received on April 5, 2019, and initial CBER comments dated November 8, 2020 and July
20, 2020 were incorporated into a draft protocol which was submitted to this BLA. Further
discussions between CBER and Wyeth will be needed post-approval to finalize the protocol.
Postmarketing studies that Wyeth is required to conduct under PREA following licensure include
studies B7471011, B7471013 and B7471014. These studies have been initiated and are
ongoing. Study B7471011 will evaluate the safety and effectiveness of a 4-dose series of
PCV20 administered in the U.S. at 2, 4, 6 and 12 months of age in infants 6 weeks through 12
months of age. Study B747103 will evaluate the safety of 2, 4, 6, and 12-month schedule of
PCV20 in infants in the U.S., Europe, and Canada. Study B7471014 will evaluate the safety and
effectiveness of PCV20 in children and adolescents 15 months through 17 years of age. The
protocols for each of these studies were submitted in 2020. Please see Section 11.6 for the
agreed upon timelines for study report submission.
A safety and immunogenicity trial of PCV20 co-administered with seasonal inactivated influenza
vaccine in adults ≥65 years of age is currently ongoing. (b) (4)
Clinical Reviewer Conclusion/Recommendation
The clinical data submitted in this application support approval of PCV20 for active
immunization for the prevention of invasive disease and pneumonia caused by serotypes 1,3, 4,
5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults ≥18 years of age.
The approval of PCV20 for the prevention of pneumonia in adults ≥18 years of age caused by
the 7 new vaccine serotypes (8, 10A, 11A 12F, 15B, 22F, and 33F) is based on the accelerated
approval regulations. As a condition of accelerated approval, Wyeth is required to conduct a
postmarketing study (B7471015) to verify and describe the clinical benefit of PCV20 in
11

Clinical Reviewer: Tina Mongeau
STN: 125731/0

preventing pneumococcal pneumonia caused by the 7 new vaccine serotypes in adults ≥65
years of age and has provided a satisfactory plan to do so.
1.1 Demographic Information: Subgroup Demographics and Analysis Summary
For each Phase 3 study, the demographic characteristics were reviewed individually (Sections
6.1.10.1.1, 6.2.10.1.1, and 6.3.10.1.1).
Within the Phase 3 studies, subgroup analyses by age (B7471007 only), sex (B7471007,
B7471008, B7471006), race (B7471007 and B7471008) and country (B7471007 only) were
conducted when the numbers of subjects in the subgroup were large enough to provide a
meaningful interpretation of the data.
Immunogenicity Subgroup Analyses
• Age: Serotype-specific OPA GMTs generally decreased in older age groups in study
B7471007.
• Sex: In Cohorts 1 (≥ 60 years) and 2 (50-59 years) of study B7471007, serotype-specific
OPA GMTs for the 20 vaccine serotypes were generally higher among females
compared to males. In Cohort 3 (18-49 years) of study B7471007, in study B7471008,
and study B7471006, OPA GMTs appeared similar with no clear trend when comparing
those achieved by females and males.
• Race: (study B7471007 and B7471008): In Cohort 1 of study B7471007 and in study
B7471008, serotype-specific OPA GMTs for the 20 vaccine serotypes generally
appeared similar with no clear trend across racial subgroups. In Cohorts 2 and 3,
serotype-specific OPA GMTs for the 20 vaccine serotypes were generally lower among
Black subjects compared to White subjects.
• Country: In study B7471007 subjects ≥65 years of age, serotype-specific OPA GMTs for
the 20 vaccine serotypes generally appeared similar between country subgroups.
Safety Subgroup Analyses
• Age: Rates of injection site reactions generally decreased with age in study B7471007.
With the exception of fever, rates of systemic adverse reactions (including use of
antipyretic or pain medication) generally decreased with increasing age; the rate of fever
was generally highest in the eldest age subgroup (≥80 years).
• Sex: Rates of solicited local and systemic adverse events were generally more frequent
among females than males, although this varied by study and by age cohort within study
B7471007.
• Race: Solicited local and systemic adverse events were generally less frequent among
Black subjects compared to White subjects, although this varied by study and by age
cohort within study B7471007.
1.2 Patient Experience Data
Patient experience data was not submitted as part of this application.
2. Clinical and Regulatory Background
2.1 Disease or Health-Related Condition(s) Studied
Streptococcus pneumoniae is a leading cause of disease and death among older adults in the
U.S. S. pneumoniae colonize the nasopharynx and can cause non-invasive disease (e.g., non12

Clinical Reviewer: Tina Mongeau
STN: 125731/0

bacteremic pneumonia) as well as invasive disease (e.g., bacteremia and meningitis) in adults.
IPD is defined by isolation of S. pneumoniae from a normally sterile site (i.e., blood,
cerebrospinal, pleural or peritoneal fluid). The most common manifestations of IPD in adults
aged 50 years and older include invasive (bacteremic) pneumonia, bacteremia without a focus,
and meningitis (Neuzil and Jackson 2008; Gruber et al. 2008). Among patients hospitalized with
community-acquired pneumonia, approximately 5%-10% will have pneumococcal bacteremia
(Neuzil and Jackson 2008). Non-bacteremic pneumococcal pneumonia remains a more
common disease manifestation, accounting for approximately 13%-34% of pneumonia
hospitalizations among adults (Gruber et al. 2008).
Adults at highest risk for serious pneumococcal disease include those with immunosuppressive
conditions, functional or anatomic asplenia, renal disease, and age ≥65 years of age. Other
conditions that increase the risk in adults include chronic heart disease, lung disease (including
asthma), liver disease, smoking cigarettes, alcoholism, a CSF leak, and having a cochlear
implant (Gierke 2021b).
Currently, 100 different serotypes have been identified, which vary both by the chemical
structure of their seroreactive capsular polysaccharides and in their ability to cause disease,
with the majority of invasive disease caused by a relatively limited number of serotypes (Ganaie
et al. 2020). The presence of antibiotic resistance in a proportion of pneumococcal isolates can
further complicate treatment and in some cases lead to treatment failure and/or worse clinical
outcomes.
PCV20 is intended to prevent IPD and pneumococcal pneumonia caused by the 20
pneumococcal serotypes contained in the vaccine. The 7 non-PCV13 serotypes included in
PCV20 (8, 10A, 11A, 12F, 15B, 22F and 33F) were selected based on their relative prevalence
as a cause of IPD, their general geographic distribution and other factors such as presence of
antibiotic resistance (11A, 15B), association with outbreaks (8, 12F), and greater disease
severity such as meningitis or with relatively high mortality (10A, 11A, 22F). Wyeth noted that
serotypes 22F, 11A, 33F, 8 and 15B were the 5 most prevalent causes of IPD in the U.S.
according to Active Bacterial Core surveillance (ABCs) data from the Center for Disease Control
and Prevention (CDC). 1 Based on ABCs data, the 7 new serotypes were isolated from
approximately 30% of IPD cases in adults ≥19 years of age from 2017-2018 (Gierke 2021a).
Altogether, the 20 serotypes in PCV20 were isolated from approximately 55%-64% of all IPD
cases among adults during this same time period (Gierke 2021a). Serotype 15B, which is
closely related to 15C 2, has been shown to contribute 1.5% of IPD in adults ≥65 years of age.
The proportion of all-cause CAP caused by serotypes contained in PCV20 has been estimated
to be 7.1% in 2014-2016 and 6.3% in 2019-2020 based on preliminary data from Wyeth
presented by the CDC (Gierke 2021a).
2.2 Currently Available, Pharmacologically Unrelated Treatment for Proposed Indications
Available therapy for IPD and pneumococcal pneumonia in adults includes antibiotic therapy,
however treatment has been complicated by increased frequency of antibiotic-resistant strains.

1

STN 125731/0.1, module 2 Clinical Overview, p16.

2 Serotype 15B and 15C capsules differ structurally by the presence of an O-acetyl group in 15B, while

15C isolates express small and variable amounts of O-acetylation. This difference can only be detected
biochemically, as the capsular polysaccharide biosynthetic pathways for both serotypes are the same.

13

Clinical Reviewer: Tina Mongeau
STN: 125731/0

2.3 Safety and Efficacy of Pharmacologically Related Products
Two pneumococcal vaccines are currently licensed and available in the U.S. for the prevention
of pneumococcal disease in adults.
Pneumovax 23, the 23-valent pneumococcal polysaccharide vaccine (PPSV23), was licensed in
the U.S. in 1983 (Pneumovax 23, prescribing information). It replaced an earlier 14-valent
formulation that had been licensed in 1977. PPSV23 is approved for use in persons ≥50 years
of age and persons ≥2 years of age who are at increased risk of pneumococcal disease. Each
0.5 mL dose contains 25 μg of purified capsular polysaccharide from each of 23 pneumococcal
serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22,
23F, and 33F) (Pneumovax 23, prescribing information). These polysaccharide antigens are
thought to be T-independent antigens that stimulate mature B-lymphocytes, but not Tlymphocytes.
Licensure of PPSV23 was based on demonstrated efficacy of earlier 6-valent, 12-valent, and
13-valent polysaccharide vaccines and immunogenicity and safety data from a 22-valent and
23-valent vaccine formulation. One randomized controlled trial in adults ≥55 years of age with
chronic medical conditions who received a 14-valent pneumococcal polysaccharide vaccine did
not support vaccine efficacy for nonbacteremic pneumonia (Simberkoff et al. 1986). Available
data suggest that the PPSV23 vaccine protects adults and the elderly against IPD, however no
consistent vaccine effect has been observed for prevention of pneumonia (Gruber et al. 2008;
Conaty et al. 2004). Please refer to the Pneumovax 23 package insert for details regarding its
efficacy and safety profile (Pneumovax 23, prescribing information).
Prevnar 13 (PCV13) was the first pneumococcal conjugate vaccine licensed for use in adults in
the U.S. It is a glycoconjugate vaccine consisting of purified capsular polysaccharide antigens of
13 S. pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F)
individually linked to non-toxic diphtheria CRM197 protein. On December 30, 2011,CBER
approved PCV13 for active immunization for the prevention of invasive disease and pneumonia
caused by the 13 S. pneumoniae serotypes contained in the vaccine in persons ≥50 years of
age based on a serological endpoint (OPA titer) as defined in the Accelerated Approval
regulations (21 CFR 601.41). As a condition of accelerated approval, Wyeth completed a
postmarketing study that confirmed and described the efficacy of Prevnar 13 for the approved
indications. On July 11, 2016, CBER approved a sBLA to expand the use of Prevnar 13 for the
approved indications to adults 18-49 years of age based on immunologic bridging studies.
Clinical efficacy of PCV13 in adults was assessed in a randomized, double-blind, placebocontrolled study (study 6115A1-3006; NCT00744263) conducted over approximately 4 years in
the Netherlands (Prevnar 13, prescribing information). A total of 84,496 subjects 65 years and
older received a single dose of PCV13 or placebo. PCV13 demonstrated statistically significant
vaccine efficacy in preventing first episodes of vaccine-type pneumococcal community-acquired
pneumonia (VT-CAP) (45.6%; 95.2% CI 21.8, 62.5), non-bacteremic/non-invasive VT-CAP
(45%; 95% CI 14.2, 65.3), and vaccine-type IPD (75%; 95% CI 41.1, 90.9). VT-CAP was
defined as the presence of ≥2 specified clinical criteria (chest x-ray consistent with CAP as
determined by a central committee of radiologists; and positive VT-specific urinary antigen
detection assay or isolation of VT S. pneumoniae from blood or other sterile site). Nonbacteremic/noninvasive CAP was defined as an episode of VT-CAP for which the culture results
for blood or any other sterile site were negative for S. pneumoniae. IPD was defined as the
presence of VT S. pneumoniae from a sterile site. Please refer to the PCV13 package insert for
additional details regarding the PCV13 efficacy and safety profile.
14

Clinical Reviewer: Tina Mongeau
STN: 125731/0

ACIP Recommendations for Pneumococcal Vaccinations
The Advisory Committee on Immunization Practices (ACIP) recommends PCV13 in series with
PPSV23, given 8 weeks apart, for adults aged ≥19 years of age with certain medical conditions
that increase the risk of pneumococcal disease (i.e., those with an immunocompromising
condition, cerebrospinal fluid (CSF) leak, or cochlear implant) and who have not previously
received PPSV23. This 8-week interval was selected to minimize the time during which an atrisk individual would be left unprotected from IPD caused by serotypes unique to PPSV23 and
to provide enhanced opportunity for compliance with a multi-dose regimen (Bennett et al. 2021).
For immunocompetent adults ≥65 years of age, the ACIP recommends a routine single dose of
PPSV23. Shared decision-making is recommended regarding administration of PCV13 to
persons aged ≥65 years of age who do not have an immunocompromising condition, CSF leak,
or cochlear implant, and who have not previously received PCV13 (Matanock et al. 2019). If a
decision is made to administer PCV13, it should be administered before PPSV23; clinical
studies have demonstrated a higher OPA antibody response to serotypes common to both
vaccines when the conjugate vaccine is given first (Kobayashi et al. 2015).
For immunocompetent adults ≥65 years of age, the ACIP-recommended interval between
sequential administration of PCV13 and PPSV23 in adults is as follows (Kobayashi et al. 2015):
•
•
•

For immunocompetent adults ≥65 years of age who are pneumococcal vaccine naïve,
PPSV23 should be administered ≥1 year after an initial dose of PCV13
For immunocompetent adults who previously received PPSV23 at age ≥65 years,
PCV13 should be administered ≥1 year after the prior dose of PPSV23
For immunocompetent adults ≥65 years of age who previously received PPSV23 prior
to 65 years of age and for whom an additional dose of PPSV23 is indicated when
aged ≥65 years of age, a second dose of PPSV23 should be administered ≥1 year
after PCV13 and ≥5 years after the last dose of PPSV23.

In a review of previous clinical studies evaluating the safety and immunogenicity of the
sequential administration of PCV7 or PCV13 followed by PPSV23 among immunocompetent
adults, the ACIP concluded that 1) shorter intervals (e.g., 8 weeks) may be associated with
increased local reactogenicity when compared with longer intervals, and 2) longer intervals
(e.g., ≥1 year) may lead to higher antibody responses against serotypes in both vaccines
compared with a single dose of PCV13 or PPSV23 (Kobayashi et al. 2015). Studies have
demonstrated that OPA titers elicited by PCV13 when given one year after an initial dose of
PPSV23 were lower for shared serotypes (hyporesponsive immune response 3) compared to
corresponding OPA titers in pneumococcal vaccine-naïve adults (Bennet et al. 2012; STN
125324/262 clinical review executive summary; PCV13 package insert).
2.4 Previous Human Experience with the Product (Including Foreign Experience)
At this time, PCV20 is not approved/authorized for use in any country. PCV13 was first
approved in the U.S. in 2010. Please refer to the PCV13 prescribing information regarding
previous human experience with PCV13 (Prevnar 13, prescribing information). Please also refer
to the postmarketing/pharmacovigilance review of Dr. Phillip Blanc in the Office of Biostatistics
and Epidemiology.

3

The hyporesponsive phenomenon is an inability to mount an immune response following a second
vaccination that is greater than or equal to the corresponding response after a primary vaccination.

15

Clinical Reviewer: Tina Mongeau
STN: 125731/0

2.5 Summary of Pre- and Post-submission Regulatory Activity Related to the Submission
During an end-of-Phase 2 meeting, Wyeth and CBER came to an agreement on the Phase 3
clinical development program and approach to support licensure of PCV20 for the IPD indication
in adults 18 years of age and older. A randomized, active-controlled efficacy trial of PCV20
evaluating prevention of pneumococcal disease was not considered feasible by Wyeth due to
the sample size that would be required. A placebo-controlled trial was also not ethically
justifiable in the U.S. where PCV13 was recommended routinely for adults ≥65 years of age as
well as for adults <65 years of age with certain underlying conditions that increase their risk of
pneumonia or invasive disease caused by the 13 S. pneumoniae serotypes contained in the
vaccine.
Although there is no established immune correlate of protection in adults (i.e., a threshold level
of an immune marker of protection for pneumococcal disease), a licensure approach was
agreed upon as described below for each proposed indication. The basis of the agreement
relies on following: 1) OPA reflects relevant in vivo mechanisms of protection against
pneumococcal disease; 2) efficacy against pneumonia caused by PCV13 serotypes has been
confirmed in an adult clinical endpoint study (6115A1-3006; NCT 00744263); and 3) PCV20 and
PCV13 vaccines have nearly identical manufacturing processes for the 13 common serotypes.
IPD Indication
CBER has agreed that clinical development of new polysaccharide-based pneumococcal
vaccines (conjugated and non-conjugated) can use an approach in which vaccine effectiveness
against IPD is inferred from immunologic comparability to licensed pneumococcal vaccines
using OPA as an established immunologic parameter that can be used to support traditional
approval for the prevention of IPD caused by the 20 vaccine serotypes.
Pneumonia Indication
For the 13 original serotypes, PCV20 effectiveness against pneumonia was supported by
comparable OPA antibody responses to PCV13 and nearly identical manufacturing processes
for PCV20 and PCV13 vaccines. A similar approach was used to support the approval of
PCV13 in infants for the prevention of otitis media due to the 7 original serotypes in Prevnar
(PCV 7) (STN 125324/0).
CBER has not agreed to accept immunogenicity data alone to support a pneumonia or otitis
media indication, because 1) there is no scientific consensus regarding serologic criteria for
assessing effectiveness of new pneumococcal conjugate vaccines against noninvasive disease,
and 2) antibody levels have not been found to be indicative of prevention of non-invasive
pneumococcal disease.
In a letter dated November 8, 2019, CBER agreed to Wyeth’s proposal for the initial approval of
PCV20 for the pneumonia indication in adults for the 7 new vaccine serotypes to be based on
an immunological surrogate endpoint (OPA titer), as defined in the accelerated approval
regulation (601.41) considered reasonably likely to predict prevention of pneumococcal
pneumonia caused by the 7 new vaccine serotypes. Since pneumococcal pneumonia is a
serious condition and PCV20 will provide meaningful therapeutic benefit to patients over
existing treatments (see Section 2.3), the proposed indication met the qualifying criteria for
accelerated approval. As a condition of accelerated approval, Wyeth will conduct a postapproval real-world observational effectiveness study as a confirmatory study to verify and
describe clinical benefit for the prevention of pneumonia caused by the 7 new serotypes in
PCV20 (study B7471015). The initial protocol synopsis was received on April 5, 2019, and initial
16

Clinical Reviewer: Tina Mongeau
STN: 125731/0

CBER comments dated November 8, 2020 and July 20, 2020 were incorporated into a final draft
protocol which was submitted to this BLA.
PCV20 Regulatory Timeline
• Feb 7, 2013: Pre-IND meeting to discuss clinical and CMC plans for early clinical trials.
• Aug 2013: CBER informed of delay in IND submission due to unexpected repeat-dose
tox study findings (cardiac-related toxicity in (b) (4)
rabbits).
• Dec 16, 2014: Type C meeting to discuss findings from initial repeat-dose toxicity study
and subsequent investigations with a (b) (4) 20-valent conjugate vaccine
• Jan 14, 2015: Original Master File submission received with 24 rabbit studies (18
historical and 6 new) for consolidated review by CBER.
• May 7, 2015: Type C meeting to discuss proposed first-in-human (FIH) Phase 1 study
in 50-64-year-old adults. CBER concluded available data were inadequate to support
initiation of the proposed FIH study. A re-analysis of the toxicity findings was requested.
• Oct 13, 2015: Internal meeting to discuss toxicology reanalysis and root cause analysis.
• Oct 19, 2015: Type C meeting to discuss toxicology reanalysis and root cause analysis.
CBER informed of initiation of saline only study. 4 CBER proposed an additional
toxicology study with improved study design that could be conducted in parallel with a
FIH clinical trial with cardiac monitoring. Phase 1 study clinical comments issued.
• May 24, 2016: Internal CBER meeting to discuss saline-only study results.
• Jun 2, 2016: Type C meeting to discuss results from a saline-only study and Wyeth’s
proposal to conduct a FIH study with cardiac monitoring.
• Jun 21, 2016: MF Amendment 13 – FIH, Phase 1 Protocol synopsis.
• Aug 2, 2016: Consult obtained from Division of Cardiovascular and Renal Products.
• Aug 15, 2016: Internal meeting to discuss Phase 1 protocol and cardiology consult
• Aug 30, 2016: CBER issued comments regarding FIH, Phase 1 protocol synopsis.
• Jun 19, 2017: agreement to proceed to Phase 2 trials
• Sep 18, 2018: End-of-Phase 2 meeting
2.6 Other Relevant Background Information
Evolution of ACIP Recommendations for Pneumococcal Vaccination of Adults
On June 20, 2012, following approval of PCV13 for use in adults (via accelerated approval
licensure pathway) the ACIP recommended routine use of PCV13 for adults ≥19 years of age
with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear
implants. PCV13 was to be administered in addition to PPSV23, the vaccine that was already
recommended at the time for these groups of adults. For those previously vaccinated with ≥1
dose of PPSV23, a dose of PCV13 was to be administered ≥1 year after the last PPSV23 dose
(Matanock et al. 2019). For those who had not previously received PCV13 or PPSV23, a dose
of PCV13 was to be administered first followed by a dose of PPSV23 at least 8 weeks later
(Bennett et al. 2012). The PCV13/PPSV23 sequence is preferred, based on studies
demonstrating a better response to serotypes common to both vaccines when the conjugate
vaccine is given first (Bennet et al. 2012; Kobayashi et al. 2015).

4

At the Oct 19, 2015 Type C meeting, Wyeth informed CBER about a planned saline-only study. This
study was conducted without CBER input or support. CBER stated that a saline-only study would not
address the Agency’s concerns and would therefore be of limited use and not alleviate the need for an
additional toxicology study(ies) or cardiac monitoring during the first-in-human clinical study. CBER also
indicated that results from the saline-only study could not be used to support regulatory decision making.

17

Clinical Reviewer: Tina Mongeau
STN: 125731/0

On August 13, 2014, following the completion of the CAPiTA trial (which confirmed clinical
benefit of PCV13 in adults ≥50 years of age), the ACIP recommended routine use of PCV13 in
series with PPSV23 given 6-12 months apart (minimum acceptable interval of 8 weeks) for all
adults ≥65 years of age (Tomczyk et al. 2014). The ACIP also recommended that all adults ≥65
years of age previously immunized with PPSV23 should receive a dose of PCV13 ≥1 year after
the last PPSV23 dose. The recommended intervals were based on available evidence from
immunogenicity studies which evaluated intervals of 2, 6, or 12 months or 3-4 years between
PCV7 or PCV13 and PPSV23 (Kobayashi et al. 2015). The ACIP recognized that, while in the
short term, routine PCV13 use among adults ≥65 years of age was warranted, continued
indirect effects from PCV13 use in children (i.e., reduced disease burden among adults through
reduced carriage and transmission of serotypes from vaccinated children) might limit the utility
of this recommendation. Therefore, ACIP proposed to reevaluate this recommendation for
routine PCV13 use in adults ≥65 years of age and older 4 years after implementation and revise
as needed (Tomczyk et al. 2014).
On June 25, 2015, to harmonize pneumococcal vaccination recommendations, the ACIP
changed the recommended interval between PCV13 followed by PPSV23 from 6-12 months to
≥1 year for immunocompetent adults ≥65 years of age (Kobayashi et al. 2015). This change
resulted in harmonization with the 1-year interval for the PPSV23-PCV13 sequence in the same
age group. This change was also based on data suggesting that 1) shorter intervals (e.g., 8
weeks) may be associated with increased local reactogenicity when compared with longer
intervals, and 2) longer intervals (e.g., ≥1 year) may lead to an improved immune response
against serotypes in both vaccines compared with a single dose of PCV13 or PPSV23. The
ACIP continued to recommend an 8-week interval between an initial dose of PCV13 and a
subsequent dose of PPSV23 in persons ≥2 years of age with medical conditions that increase
the risk of pneumococcal disease.
In June 2019, after reviewing evidence accrued during the preceding 3 years and costeffectiveness analysis, ACIP voted to rescind the recommendation for routine PCV13 use
among adults ≥65 years of age and to recommend use of PCV13 based on shared decision
making for adults ≥ 65 years of age who do not have an immunocompromised condition,
cerebrospinal fluid leak or cochlear implant and who have not previously received PCV13
(Matanock et al. 2019). This decision was based on a review of accrued evidence which
showed that the incidence of PCV13-type disease had been reduced to historically low levels
among adults ≥ 65 years of age through PCV13 indirect effects, such that the implementation of
a PCV13 recommendation for all adults ≥ 65 years of age in 2014 had a minimal impact on
PCV13-type disease at the population level in this age group and the cost-effectiveness
analysis no longer supported this routine recommendation in this age group. The ACIP’s
recommendation for PPSV23 and the recommended interval between PCV13 and PPSV23
remained unchanged.
3. SUBMISSION QUALITY AND GOOD CLINICAL PRACTICES
3.1 Submission Quality and Completeness
The submission of this BLA was adequately organized and integrated to accommodate the
conduct of a complete clinical review without unreasonable difficulty.
3.2 Compliance With Good Clinical Practices And Submission Integrity
The six studies provide in this BLA were conducted in accordance with Good Clinical Practices
and according to the requirement of 21 CFR Part 56 (Institutional Review Boards) and 21 CFR
18

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Part 50 (Informed Consent). A total of 984 investigators participated in studies submitted to this
BLA. Bioresearch Monitoring (BIMO) inspections were issued for the following three clinical
study sites that participated in the conduct of study protocol B7471007: site 1004 in Wilmington,
NC (192 enrolled); site 1015 in Salt Lake City, UT (175 enrolled); and 1028 in St. Louis, MO
(134 enrolled). These sites were selected based upon previous BIMO inspection history,
sponsor-reported adverse events, protocol deviations and total number of subjects enrolled.
They comprise about 12.9% (501/3889) of the total subjects enrolled under protocol B7471007.
The inspections did not reveal substantive problems impacting the data submitted in the
application. Please refer to the CBER BIMO review memo for more details.
3.3 Financial Disclosures
Covered clinical studies: B7471002, B7471005, B7471006, B7471007, B7471008
Was a list of clinical investigators provided?
Total number of investigators identified: 984

Yes

No

Number of investigators who are sponsor employees (including both full-time and parttime employees): 0
Number of investigators with disclosable financial interests/arrangements (Form FDA
3455): 5a
If there are investigators with disclosable financial interests/arrangements, identify the
number of investigators with interests/arrangements in each category (as defined in
21 CFR 54.2(a), (b), (c) and (f)):
Compensation to the investigator for conducting the study where the value
could be influenced by the outcome of the study: 0
Significant payments of other sorts: 1
Proprietary interest in the product tested held by investigator: 0
Significant equity interest held by investigator in sponsor of covered study: 4
Is an attachment provided with details of the disclosable financial
interests/arrangements?
Yes
No
Is a description of the steps taken to minimize potential bias provided?
Yes
No
a
A consolidated Form FDA 3455 (Disclosure statement) listed three investigators (Dr. Nicola P. Klein, Dr. Susan
Edwards, and Dr. Peter J. Winkle) with disclosable financial interests as only 1 Form 3455 is to be submitted for each
investigator with financial information to disclose. However, because investigators must fill out a financial disclosure form
for each study that they take part in and because one of these investigators (Dr. Susan Edwards) participated in three
studies, Dr. Susan Brown and was counted 3 times by Wyeth in the count of total investigators (i.e., she was counted as
3 of the 984 investigators). Thus, the total number of investigators with disclosable financial interests is five (Dr. Klein,
Dr. Winkle, and Dr. Edwards counted three times).

Three investigators had disclosable financial interests to disclose:
•
•
•

Dr. Nicola P. Klein (study B7471008, center 1028);
Dr. Susan Edwards (study B7471006 center 1028, B7471007 center 1048, and
study B7471008 center 1016); and
Dr. Peter J. Winkle (study B7471002 center 1006).

Dr. Klein reported other significant payments totaling (b) (4)
; these payments were for
clinical and research collaborations. Wyeth notes that all investigator-initiated research grants
associated with clinical investigators are paid directly to the Institution rather than to the
19

Clinical Reviewer: Tina Mongeau
STN: 125731/0

individual clinical investigator. Drs. Edwards and Winkle reported significant equity interest
totaling (b) (4)
as of February 13, 2019, and (b) (4)
as of September 15, 2017.
The five investigators with disclosable financial interests (n=5/984) represented 0.5% of the 984
total investigators who participated in covered clinical studies.
Efforts reported to eliminate bias for the covered studies consisted of the following:
•
•
•
•
•
•
•

Randomized, double-blind and multicenter study design as well as pre-specified
statistical methods and employment of a statistical analysis plan
Frequent monitoring of investigator trial sites and auditing of study sites
Validity of data collected was confirmed by standard monitoring procedures
Data processing involved cleaning checks (querying data through electronic edit
checks) to ensure that errors were identified and corrected
Data were reviewed by clinicians and queries were generated in case of
inconsistencies during the course of the trial
The study report underwent review by the project team and Quality Control; and
Study sites performing safety evaluations were determined acceptable based on
appropriate certification or historical performance and/or qualifications and
credentials.

Reviewer Comment: The clinical team has concluded that the financial disclosure
information would be unlikely to impact the quality of the study data.
4. SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES
4.1 Chemistry, Manufacturing, and Controls
The CBER product reviewers concluded that this submission is complete, and they recommend
approval of PCV20. The CMC reviewers noted that there have been no significant changes to
the approved manufacturing processes for CRM197 with either casamino acid-yeast extract
based medium (CRM197-CY) or defined medium (CRM197-DM). Under the new license for
PCV20, (b) (4)
Both
processes are currently approved for manufacture of PCV13. There have been no significant
changes to the approved processes for the production of the 13 serotypes common to PCV13,
although some of the analytical methods and parameters have evolved. Manufacture of the
seven new polysaccharide serotypes differs in several ways from the PCV13 serotypes. Please
refer to the CMC review for more details. PCV20 is presented in the same syringes and
stoppers as PCV13.
4.2 Assay Validation
4.3 Nonclinical Pharmacology/Toxicology
The toxicology reviewer concluded that this submission is acceptable with regards to nonclinical
toxicology, and no toxicologic issues identified would preclude approval of this BLA. There was
no clinically-relevant evidence of maternal toxicity (to include female fertility) or teratology when
PCV20 was administered to pregnant rabbit does. The clinical relevance and translatability of
the non-clinical cardiac toxicity findings observed in a repeat-dose toxicity study performed in
rabbits to human subjects should be considered inconclusive (see information below). The
toxicology review does not include a recommendation to include these rabbit findings within the
20

Clinical Reviewer: Tina Mongeau
STN: 125731/0

PCV20 prescribing information (i.e., Section 13.2). The tox reviewer recommends postmarketing
surveillance for cardiac symptoms and further exploration of the cardiac changes in rabbits
could be considered. Please refer to the detailed toxicology review by Dr. Andrew O’Carroll for
more information.
Reviewer Comments:
• Wyeth proposes routine postmarketing safety surveillance (consisting of
monitoring for any unanticipated risks in surveillance systems and postmarketing
adverse reaction reports), which will include an assessment for cardiac-related
safety signals. The clinical team and pharmacoepidemiology team agree with the
proposed postmarketing plan.
• According to 21 CFR 201.57 (c)(14)(ii), Section 13.2 of the prescribing
information must include significant animal data necessary for the safe and
effective use of the drug in humans. Given the lack of any cardiac-related clinical
findings in the human trials (including the Phase 1 study B7471001 which
included cardiac monitoring), this information is not viewed as necessary for the
safe and effective use of PCV20.
Background on Non-Clinical Cardiac Toxicity Findings
During the pre-IND stage of PCV20 development, unexpected cardiac findings (diffuse, patchy
areas of inflammation and/or irreversible necrosis) were identified on histopathology in a small
number of otherwise healthy-appearing rabbits in the initial repeat-dose toxicity study that were
not observed following PCV13. A consolidated review was subsequently conducted of 18
historical rabbit studies and six new studies with the pneumococcal conjugate vaccines
(submitted to MF (b) (4) to investigate this finding. Overall, cardiac findings were observed
following administration of (b) (4)
, and 20-valent investigational vaccine
formulations and following administration of aluminum phosphate adjuvant (plus vaccine
excipients) without any pneumococcal antigen. No similar findings were seen with saline alone.
Several Type C meetings were held between December 2014 and June 2016 to discuss this
finding, a toxicology reanalysis and root cause analysis 5 in addition to the proposed Phase 1
first-in-human study (listed in Section 2.5).
Because the non-clinical data available were not definitive on the causal relationship between
the toxicology findings and the investigational products, CBER informed Wyeth that cardiac
monitoring and risk mitigation would be necessary in their Phase 1 first-in-human clinical trial.
On June 21, 2016, Wyeth submitted to MF (b) (4) a protocol synopsis with cardiac monitoring.
CBER obtained an intercenter consult within CBER’s Division of Cardiovascular and Renal
Products with specific questions regarding the adequacy of the proposed cardiac monitoring in
study B7471001. After reviewing the protocol synopsis and obtaining consultant feedback,
CBER issued comments regarding the proposed protocol synopsis to Wyeth on August 30,
2016. No safety concerns were identified in this Phase 1 study, including no cardiac-related
safety findings. Please see Section 6.6 for the results from this study.

5

The root cause analysis was meant to determine whether any CMC changes to components of the
pneumococcal conjugate vaccine matrix might have accounted for the tox findings.

21

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Reviewer Comment: Study B7471001, which incorporated cardiac monitoring, did not
identify evidence of any abnormalities in cTnI (a sensitive marker of cardiac tissue
damage) or other cardiac-related safety concerns in human subjects. Further studies
were not required to include cardiac monitoring due to lack of safety concerns in the
Phase 1 study. See Section 6.6 for more details regarding study B7471001.
4.4 Clinical Pharmacology
4.4.1 Mechanism of Action
PCV20 elicits an opsonophagocytic antibody response. Nonclinical and clinical data support
OPA, as measured by a microcolony OPA assay. The OPA assay 6 provides an in vitro
measurement of the ability of serum antibodies to eliminate pneumococci by promoting
complement-mediated phagocytosis and is believed to reflect relevant in vivo mechanisms of
protection against pneumococcal disease. Microcolony OPA titers are expressed as the
reciprocal of the highest serum dilution resulting in 50% reduction in the number of bacterial
colony-forming units, when compared with the control without test serum. No specific threshold
of OPA titer has been identified that correlates with protection against IPD or pneumonia in
adults.
4.5 Statistical
The statistical reviewer concludes that, from the statistical perspective, the submitted clinical
study results support the approval of this BLA. The statistical reviewer also concludes that the
validation reports for the 7 new serotypes in PCV20 appear to be acceptable. Please refer to the
two detailed statistical reviews (one covering non-clinical assay data and one covering clinical
data) by Dr. Ruoxuan Xiang for more information.
4.6 Pharmacovigilance
The pharmacovigilance reviewer concluded that the proposed pharmacovigilance plan (i.e.,
routine postmarketing safety surveillance consisting of monitoring for any unanticipated risks in
surveillance systems and postmarketing adverse reaction reports) is adequate to monitor
postmarketing safety. Please refer to the detailed review by Dr. Phillip Blanc.
5. SOURCES OF CLINICAL DATA AND OTHER INFORMATION CONSIDERED IN THE REVIEW
5.1 Review Strategy
This review covers data submitted from 6 clinical trials evaluating PCV20 in adults and focuses
on the three Phase 3 trials submitted to BLA 125731: 1) Study B7471007, which evaluated
safety and effectiveness of PCV20 in pneumococcal vaccine-naïve adults ≥18 years of age; 2)
study B7471008, which evaluated safety and manufacturing consistency of PCV20 in 18-49year-old adults; and 3) study B7471006, which was a descriptive, open-label study of PCV20 in
adults ≥65 years of age who had previously received PCV13, PPSV23 or both PCV13 and
PPSV23. An integrated summary of safety, consisting of safety data from each of the Phase 3
studies submitted to this BLA, was also evaluated.

6

OPA assays quantitatively assess functional anti-S. pneumoniae antibodies by measuring complementmediated bacterial killing in reactions containing serially diluted test sera, complement (baby rabbit
serum), and phagocytes (differentiated HL-60 cells).

22

Clinical Reviewer: Tina Mongeau
STN: 125731/0

5.2 BLA/IND Documents That Serve as the Basis for the Clinical Review
The following modules of the BLA 125731/0.1 were reviewed:
•
•
•
•
•
•
•
•

m1.3 Administrative Information
m1.6 Correspondence Regarding Meetings
m1.9 Pediatric Administrative Information
m1.14 Labeling
m1.16 Risk Management Plan
m1.17 Postmarketing Studies
m2 Common Technical Document Summaries
m5 Clinical Study Reports

Amendments (Am) reviewed in the BLA are provided below by amendment number:
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Am 7: Updated Draft Prescribing Information, Submitted 1/8/2021
Am 8: Draft protocol for Phase 4 Test-Negative Design Study (B7471015),
Submitted 1/15/21
Am 11: Response to 1/14/21 Clinical Information Request (IR), Submitted
1/28/2021
Am 17: Response to 2/1/21 IR regarding clinical datasets, Submitted 2/23/21
Am 22: Response to 3/3/21 IR with clarifications on 1/14 response, Submitted
3/10/21
Am 23: Response to 3/1/21 IR with clarifications on 2/1 Response, Submitted
3/11/21
Am 26: Response to 3/18/21 IR with updates to deferred pediatric study dates
Am 30: Response to Phase 4 Study B7471015 comments, Submitted 4/20/21
Am 32: Labeling Responses, Submitted
Am 33: Responses to P4 Study B7471015 comments and labeling comments,
Submitted 5/5/21
Am 35: PMC and PMR commitments, Submitted 5/20/21
Am 37: Labeling responses, Submitted 5/25/21
Am 40: Labeling responses, Submitted 6/3/21
Am 41: Labeling responses, Submitted 6/4/21

23

Clinical Reviewer: Tina Mongeau
STN: 125731/0

5.3 Table of Studies/Clinical Trials
Table 1. Clinical Studies Submitted in Support of Efficacy and Safety Determinations for Prevnar 20 (PCV20), Total N=7048 (PCV20:
N=4552; Control: N=2496)
Study
(Country)
Study Groups/
Number
NCT #
Study Description
Study Population
Vaccine Schedule
Vaccinated
Total
B7471007
Phase 3, randomized, doublePneumococcal vaccine-naïve
Cohort 1
Cohort 1
PCV20:
(U.S. and
blind safety and
adults
PCV20/saline:
2176
• PCV20 then saline
≥18 years of age
Control:
Sweden)
immunogenicity study with an
1507
one month later
NCT03760146 age-based 3-cohort design
1713
PCV13/PPSV23:
• PCV13 then
1490
• Among 60-64-year-old adults Cohort 1: ≥60 yearsa
PPSV23 one
Cohort 2
(Cohort 1 subset):
month later
PCV20: 334
noninferiority comparisons to Cohort 2: 50-59 years
PCV13: 111
PCV13 and PPSV23
Cohorts 2 and 3
Cohort 3
• Among 18-59-year-old adults: Cohort 3: 18-49 years
PCV20 or PCV13
PCV20: 335
immunobridging to 60-64-year
PCV13: 112
old Cohort 1 subset
B7471008
Phase 3, randomized, doublePneumococcal vaccine-naïve
PCV20 Lot 1
Lot 1: 488
PCV20:
(U.S.)
blind lot consistency study with adults 18-49 years of age
PCV20 Lot 2
Lot 2: 489
1463
NCT03828617 a 4-arm parallel design
PCV13: 245
PCV20 Lot 3
Lot 3: 486
PCV13
PCV13: 245
B7471006
Phase 3, randomized, openPneumococcal experienced
Cohort A
Cohort A
PCV20: 624
(U.S. and
label descriptive safety and
adults
PCV20 or PCV13
PCV20: 253
Control: 249
Sweden)
immunogenicity study in adults ≥65 years of age
PCV13: 122
NCT03835975 ≥65 years of age with a
Cohort B
Cohort B
• Cohort A: PPSV23 ≥1 year and
PCV20 or PPSV23
PCV20: 246
3-cohort design based on prior
≤5 years prior to study; no prior
PPSV23: 127
pneumococcal vaccination
PCV13
Cohort C
Cohort C
status
• Cohort B: PCV13 ≥6 months
PCV20
PCV20: 125
prior to study; no prior PPSV23
• Cohort C: prior PCV13 and
PPSV23 (PPSV23 ≥1 year prior
to study)
B7471002
Phase 2, randomized,
60-64 years of age,
PCV20: 221
• PCV20 then saline 221
(U.S.)
controlled, double-blind safety
pneumococcal vaccine naïve
Control: 222
1 month later
NCT03313037 and immunogenicity study
222
• PCV13 then
PPSV23 1 month
later

24

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Study
(Country)
NCT #
B7471001
(U.S.)
NCT02955160
B7471005
(U.S.)
NCT03642847

Study Description
Phase 1, first-in-human,
controlled, randomized,
observer-blind safety and
immunogenicity study
Phase 1b, randomized,
controlled, double-blind safety
and immunogenicity study

Study Population
18-49 years of age,
pneumococcal vaccine naïve

Study Groups/
Vaccine Schedule
PCV20
Tdap (active control)

Number
Vaccinated
33
33

18-49-year-old adults of Japanese
descent, pneumococcal vaccine
naïve

PCV20
c7vPnC
PCV13

35
34
34

Total
PCV20: 33
Control: 33

PCV20: 35
PCV13: 34

NCT #: ClinicalTrials.gov study identification code. PCV13: Prevnar 13; PPSV23: Pneumovax 23; Tdap: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
adsorbed manufactured by Sanofi Pasteur. c7vPnC: investigational complementary 7-valent pneumococcal conjugate vaccine manufactured by Pfizer.
Note: In Phase 3 trials, the OPA assay was validated for all vaccine serotypes. MedDRA version 22.1 coding dictionary was applied in all Phase 3 studies.
a
Enrollment in Cohort 1 was stratified by age. A total of 993 and 992 subjects 60-64 years of age were vaccinated with PCV20/saline and PCV13/PPSV23, respectively and a total of
514 and 498 subjects ≥65 years of age were vaccinated with PCV20/saline or PCV13/PPSV23, respectively within Cohort 1.
Source: STN 125731/0.1, Module 5.2, Tabular Listing of al Clinical Studies

25

Clinical Reviewer: Tina Mongeau
STN: 125731/0

5.5 Literature Reviewed
Bennett, NM, CG Whitney, M Moore, T Pilishvili, and KL Dooling, 2012, Use of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for
adults with immunocompromising conditions: recommendations of the Advisory Committee on
Immunization Practices (ACIP).
Conaty, S, L Watson, J Dinnes, and N Waugh, 2004, The effectiveness of pneumococcal
polysaccharide vaccines in adults: a systematic review of observational studies and comparison
with results from randomised controlled trials, Vaccine, 22(23-24):3214-3224.
Fathi, A, MM Addo, and C Dahlke, 2020, Sex differences in immunity: Implications for the
development of novel vaccines against emerging pathogens, Frontiers in Immunology, 11:3469.
Fischinger, S, CM Boudreau, AL Butler, H Streeck, and G Alter, 2019, Sex differences in
vaccine-induced humoral immunity, Seminars in immunopathology, Springer, 41(2).
Ganaie, F, JS Saad, L McGee, AJ van Tonder, SD Bentley, SW Lo, RA Gladstone, P Turner, JD
Keenan, and RF Breiman, 2020, A new pneumococcal capsule type, 10D, is the 100th serotype
and has a large cps fragment from an oral streptococcus, MBio, 11(3).
Gierke, R, 2021a, Current Epidemiology of Pneumococcal Disease and Pneumococcal Vaccine
Coverage among Adults (ACIP Presentation).
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/24-25/02Pneumococcal-Gierke.pdf.
Gierke, R, AP Wodi, and M Kobayashi, 2021b, The Pink Book Pneumococcal Disease.
Available at: https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html#pneumoniae.
Gruber, MF, D Pratt, and M Haase, 2008, Licensing of Pneumococcal Conjugate Vaccines for
Children and Adults: Regulatory Perspective from the European Medicines Agency and the U.S.
Food and Drug Administration, Pneumococcal Vaccines 183-196.
Klein, SL and A Pekosz, 2014, Sex-based biology and the rational design of influenza
vaccination strategies, The Journal of infectious diseases, 209 (suppl_3):S114-S119.
Kobayashi, M, NM Bennett, R Gierke, O Almendares, MR Moore, CG Whitney, and T Pilishvili,
2015, Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory
Committee on Immunization Practices (ACIP), Morbidity and Mortality Weekly Report,
64(34):944-947.
Matanock, A, G Lee, R Gierke, M Kobayashi, A Leidner, and T Pilishvili, 2019, Use of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among
adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization
Practices, Morbidity and Mortality Weekly Report, 68(46):1069.
Neuzil, K and L Jackson, 2008, Pneumococcal Polysaccharide Vaccines, Vaccines, Plotkin, S.,
W. Orenstein and P. Offit, Philadelphia, PA: Saunders, Elsevier, 5: 571.
Nuorti, JP and C Whitney, 2010, Updated recommendations for prevention of invasive
pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine
(PPSV23), Morbidity and mortality weekly report, 59(34):1102-1106.
O’Brien KL, Hochman M, and Goldblatt D, 2007, Combined schedules of pneumococcal
conjugate and polysaccharide vaccines: is hyporesponsiveness and issue? The Lancet, 7:597606.
Pneumovax 23 prescribing information, 2020, Merck & Co., Inc, accessed May 21, 2020,
https://www.fda.gov/media/80547/download.
Poolman J and Borrow R. Hyporesponsiveness and its clinical implications after vaccination
with polysaccharide or glycoconguate vaccines, 2011, Expert Rev Vaccines, 10(3):307-322.
26

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Prevnar 13 prescribing information, 2017, Wyeth Pharmaceuticals, Inc, accessed May 21, 2020,
https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/PackageInsert------Prevnar-13.pdf.
Simberkoff, MS, AP Cross, M Al-Ibrahim, AL Baltch, PJ Geiseler, J Nadler, AS Richmond, RP
Smith, G Schiffman, and DS Shepard, 1986, Efficacy of pneumococcal vaccine in high-risk
patients, New England Journal of Medicine, 315(21):1318-1327.
Tomczyk, S, NM Bennett, C Stoecker, R Gierke, MR Moore, CG Whitney, S Hadler, and T
Pilishvili, 2014, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal
polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory
Committee on Immunization Practices (ACIP), MMWR. Morbidity and mortality weekly report,
63(37):822.
6. DISCUSSION OF INDIVIDUAL STUDIES/CLINICAL TRIALS
6.1 Study B7471007
Study B7471007 was designed to evaluate the safety and immunogenicity of a single dose of
PCV20 when administered to pneumococcal vaccine-naïve adults ≥18 years of age enrolled into
1 of 3 age-based cohorts. Cohort 1 subjects (≥60 years of age) were randomized 1:1 to receive
either PCV20 followed by saline placebo approximately one month later (PCV20/saline) or
PCV13 followed by PPSV23 approximately one month later (PCV13/PPSV23). Cohort 2
subjects (50 through 59 years) and Cohort 3 subjects (18 through 49 years) were randomized
3:1 to receive PCV20 or PCV13. The study aimed to provide noninferiority comparisons of the
OPA GMTs induced by PCV20 relative to PCV13 for the 13 matched serotypes and the OPA
GMTs induced by PCV20 relative to PPSV23 for the 7 new serotypes among subjects ≥ 60
years of age (Cohort 1). The study was also designed to bridge serotype-specific OPA GMTs
induced by PCV20 among younger adult cohorts 2 and 3 (18 through 49 years of age and 50
through 59 years of age, respectively) to the corresponding OPA GMTs induced by PCV20
among adults 60 through 64 years of age (Cohort 1 subset). This study was conducted between
December 12, 2018 and April 9, 2020; a total of 3,889 subjects were vaccinated. The clinical
study report was dated June 11, 2020.
Reviewer Comment: The study design, objectives, endpoints and success criteria for
study B7471007 were discussed and agreed to during an EOP2 meeting on September
18, 2018.
Non-inferiority comparisons to licensed pneumococcal vaccines were performed in
pneumococcal-vaccine naïve adults ≥60 years of age. An age-bridging strategy was
considered more suitable than administering PPSV23 to healthy adults <60 years of
age, due to concerns about hyporesponsiveness (i.e., reduced OPA titers to serotypes
common to both vaccines when PCV13 is administered after an initial dose of PPSV23)
(Poolman et al, 2011), (O’Brien et al, 2007), (STN 125324/262 Clinical Review). This
age-bridging strategy, bridging OPA titers from adults 18 through 49 years and 50
through 59 years of age to the corresponding titers from adults 60 through 64 years of
age, was based on the approach used to evaluate PCV13 effectiveness in adults 50
years and older (STN 125324/262). The 60 through 64-year age group was also
selected, because it was considered a more stringent comparator relative to the ≥ 60year age group due to immunosenescence, which results in declining immune function
with increasing age.

27

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Two non-inferiority trials were conducted to support the initial licensure of PCV13 in
adults 50 years of age and older (accelerated approval pathway). One trial was
conducted in pneumococcal vaccine naïve adults 18 through 64 years of age (data in
adults 18 through 49 were not ready for submission at the time of initial licensure of
PCV13 in adults) and the second trial was conducted in adults ≥70 years of age
previously immunized with at least 1 dose of PPSV23 at least 5 years prior to
enrollment. In the trial conducted in 18 through 64-year-old pneumococcal vaccine naïve
adults, non-inferiority comparisons of PCV13 to PPSV23 were limited to adults 60
through 64 years of age. This was because adults 50 through 59 years of age were not
given PPSV23 as a comparator, because of the risk of hyporesponsiveness (decreased
immune responses with repeat vaccinations later in life). PCV13 effectiveness in the 18
through 49 and 50 through 59-year age groups were supported by immunobridging
analyses comparing responses to those achieved by 60 through 64-year-old adults.
6.1.1 Objectives
Primary Safety Objective
•
•

To describe the safety profile of PCV20 in adults 18 years of age and older.
Primary safety endpoints:
− Reported prompted local reactions (injection site redness, swelling and pain) within
10 days after vaccination
− Reported prompted systemic events (fever, headache, fatigue, muscle pain, and
joint pain) within 7 days after vaccination
− Reported AEs within1 month after vaccination.
− Reported serious adverse events (SAEs) and newly diagnosed chronic medical
condition (NDCMCs) within 6 months after vaccination

Primary Immunogenicity Objectives
1. To demonstrate that the immune responses to the 13 serotypes in PCV13 (1, 3, 4, 5, 6A,
6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) induced by PCV20 in adults 60 years of age and
older (Cohort 1) are noninferior to the immune response induced by PCV13.
•
•

Primary endpoint: serotype-specific opsonophagocytic activity (OPA) titers 1
month after the respective vaccination (PCV20 or PCV13)
Noninferiority criterion: Noninferiority was declared for a serotype if the lower
bound of the 2-sided 95% CI for the geometric mean titer (GMT) ratio
(GMTPCV20/GMTPCV13) was >0.5 (2-fold criterion).

2. To demonstrate that the immune responses to the 7 additional serotypes (8, 10A, 11A, 12F,
15B, 22F, and 33F) induced by PCV20 in adults 60 years of age and older (Cohort 1) are
noninferior to the immune response induced by PPSV23.
•

•

Primary endpoint: serotype-specific OPA titers 1 month after the respective
vaccination (PCV20 or PPSV23). Note: for the 7 new serotypes, OPA titers were
measured 1 month after PCV20 and 1 month after PPSV23 (i.e., 2 months after
the initial dose of PCV13).
Noninferiority criterion: Noninferiority was declared for a serotype if the lower
bound of the 95% CI for the GMT ratio (GMTPCV20/GMTPPSV23) was >0.5 (2-fold
criterion).

28

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Reviewer Comment: CBER agreed to the primary study objectives, endpoints and
success criteria, as described above, after reviewing the final protocol received on
November 5, 2018. The 2-fold non-inferiority criterion (LL of 95% CI > 0.5) was
agreed to as the most appropriate criterion because the OPA assay variability made a
smaller margin impracticable. Of note, a 2-fold non-inferiority criterion was also prespecified in the PCV13 prelicensure non-inferiority studies supporting the approval for
the use of PCV13 in adults.
Secondary Immunogenicity Objectives
1. To compare the immune responses to the 20 serotypes in PCV20 induced in adults 50-59
years of age (Cohort 2) to the corresponding immune responses induced by PCV20 in
adults 60-64 years of age (Cohort 1 subset).
•

Primary endpoint: serotype-specific OPA titers 1 month after vaccination with
PCV20
Immune-bridging success criterion: Success was declared for a serotype if the
lower bound of the 2-sided 95% CI for the GMT ratio (GMT50-59 years/GMT60-64
years) was >0.5 (2-fold criterion).

•

2. To compare the immune responses to the 20 serotypes in PCV20 induced in adults 18-49
years of age (Cohort 3) to the corresponding immune responses induced by PCV20 in
adults 60-64 years of age (Cohort 1 subset).
•

Primary endpoint: serotype-specific OPA titers 1 month after vaccination with
PCV20
Immune-bridging success criterion: Success was declared for a serotype if the
lower bound of the 2-sided 95% CI for the GMT ratio (GMT18-49 years/GMT60-64
years) was >0.5 (2-fold criterion).

•

3. To describe the immune responses to PCV20 in adults ≥60 years of age (Cohort 1), 50-59
years of age (Cohort 2), and 18-49 years of age (Cohort 3).
•

−
−
−

Secondary endpoints:
≥4-fold rise in serotype-specific OPA titers from pre- to 1 month post-vaccination
Fold rise in serotype-specific OPA titers from pre- to 1 month post-vaccination
Serotype-specific OPA titers ≥ lower limit of quantitation (LLOQ 7) 1 month after
vaccination

7 The LLOQ is defined as the lowest sample concentration that can be measured by the assay with
acceptable accuracy, linearity and precision.

29

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Reviewer Comment: Among the secondary endpoints listed under secondary objective
#3, this review focuses on the % of subjects achieving a ≥4-fold rise in serotype-specific
OPA titers from pre- to 1 month post-vaccination. A 4-fold rise in OPA antibody titers has
historically been considered to be an acceptable vaccine response in the evaluation of
pneumococcal serotypes (e.g., the evaluation of a ≥4-fold rise in antibody against
serotype 6A in Prevnar 13; sBLA 125324/1196). However, the a) geometric mean of the
fold rise (GMFR) in serotype-specific OPA titers from pre- to 1 month post-vaccination
and b) serotype-specific OPA titers ≥ LLOQ at 1 month post-vaccination are not
considered by CBER to be the best measures of vaccine response to support vaccine
effectiveness. In addition, the proportion of subjects achieving serotype-specific assay
LLOQs reflects the adequacy of the serotype-specific assay.
Exploratory Objectives
1. To further describe the immune responses to PCV20 in adults ≥60 years of age, 50-59 years
of age, and 18-49 years of age
•

Exploratory endpoints:
≥4-Fold rise in pneumococcal serotype 15C OPA titer from before to 1 month after
vaccination
− Pneumococcal serotype 15C OPA titer ≥ LLOQ 1 month post-vaccination
− Pneumococcal serotype 15C OPA titer 1 month after vaccination
− Fold rise in pneumococcal serotype 15C OPA titer from before to 1 month after
vaccination
−

Reviewer Comment: Serotype 15C is not a polysaccharide (PS) conjugate contained in
PCV20, but the 15C capsular PS is structurally related to the vaccine serotype 15B. The
PS of serotype 15B shares the identical PS structure to 15C except that the 15B PS is
O-acetylated. Thus, immunization with PCV20, which contains the PS conjugate of 15B
has the potential to induce functional antibodies against both the PS backbone structure
shared by both 15B and 15C and the epitope(s) unique to 15B. The capacity of PCV20
to elicit cross-reactive functional responses to 15C was explored in the Phase 3 trials.
2. To describe the immune responses to the 20 serotypes induced by PCV20 in adults ≥18
years of age with underlying medical conditions or other factors that put them at increased
risk for serious pneumococcal infection (e.g., asthma, diabetes mellitus, chronic lung
disease, cigarette smoking)
•

Exploratory endpoint: Serotype-specific OPA titers 1 month after vaccination (for
participants with an increased risk for serious pneumococcal infection)

Reviewer Comment: Exploratory objective 2 results are not included in this review,
because the results are not considered clinically significant. Subjects with the noted risk
factors are considered immunocompetent and are thus expected to elicit similar levels of
serotype-specific OPA antibodies compared to adults without the noted risk factors.
6.1.2 Design Overview
Study B7471007 was a Phase 3, randomized, double-blind, multicenter study conducted in the
U.S. and Sweden. A total of 3,880 pneumococcal vaccine-naïve adults ≥18 years of age were to
be enrolled into 1 of 3 age-based cohorts (Table 2). The randomization ratio was 1:1 in Cohort
1, and 3:1 in Cohorts 2 and 3. All subjects enrolled in Sweden were ≥65 years of age.
30

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 2. Planned Enrollment and Vaccinationa, Study B7471007
Cohort
Age
Vaccination #1
Vaccination #2
Number
(Years)
Day 1
Day 28-42
1
≥60
PCV20
Saline
1
≥60
PCV13
PPSV23
2
50-59
PCV20
2
50-59
PCV13
3
18-49
PCV20
3
18-49
PCV13
-

Planned #
of Subjects
1500b
1500b
330
110
330
110

a

All injections were 0.5 mL and administered intramuscularly in the deltoid of the non-dominant arm.
Enrollment in Cohort 1 was stratified by age, targeting 1,000 subjects 60-64 years of age and 500 subjects ≥65 years of age
in each treatment group. Among ≥65-year-old subjects, enrollment targeted ~700 subjects 65-69 years, ~200 subjects 70-79
years and ~100 subjects ≥80 years of age.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Protocol Table 3, p27.
b

Vaccination 1 (PCV20 or PCV13) was administered in a double-blind fashion as the PCV20 and
PCV13 vaccines were identical in appearance and the pre-filled syringes were packaged in
blinded cartons. Vaccination 2 (PPSV23 or saline) was prepared by and administered by a thirdparty unblinded site staff member who did not participate in subject assessments, as saline and
PPSV23 do not appear the same. Serology testing was also performed in a blinded fashion. All
other study site staff and investigators as well as Wyeth were blinded until the last subject
completed the final telephone call and the database was locked. Only one analysis was
performed after final database lock; this final analysis included all planned safety and
immunogenicity analyses.
The duration of subject participation was approximately 6 months after the first vaccination
(PCV20 or PCV13) and included 3 study visits and 1 telephone contact as follows:
•
•
•
•

Visit 1 (Day 1): Informed consent, Vaccination 1, blood draw for immunogenicity
Visit 2 (Day 28 to 42 post-Vaccination 1): Vaccination 2, blood draw for
immunogenicity
Visit 3 (Day 28 to 42 post-Vaccination 2): blood draw for immunogenicity
6-Month Safety Telephone Contact (168-196 days after Vaccination 1)

6.1.3 Population
Individuals were eligible for enrollment if they met all of the study inclusion criteria and none of
the exclusion criteria. Selected key inclusion and exclusion criteria are listed below. Vaccination
was to be temporarily delayed for eligible subjects until 1) resolution of any febrile (body
temperature ≥38.0oC) or other acute illness within 48 hours before study vaccination, 2) at least
14 days passed after receipt of any non-live vaccine or least 28 days passed after any live
vaccine, and 3) at least 28 days passed since discontinuation of any short term (<14 days)
systemic corticosteroid use. Immunogenicity blood draws planned at visits 1-3 were to be
temporarily delayed as needed until at least 72 hours after any receipt of antibiotic therapy.
Key Inclusion Criteria
1. Adult males and females 18 years of age and older
a. Cohort 1: 60 years of age and older
b. Cohort 2: 50-59 years of age
c. Cohort 3: 18-49 years of age
2. Adults determined by clinical assessment, including medical history and clinical judgment, to
be eligible for the study, including adults with preexisting stable disease, defined as disease
not requiring significant change in therapy in the previous 6 weeks or hospitalization for
worsening disease within 12 weeks before receipt of investigational product.
31

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Key Exclusion Criteria
1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned
receipt through study participation.
2. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction
(e.g., anaphylaxis) to any component of PCV20, PCV13, or any other diphtheria toxoid–
containing vaccine or PPSV23.
3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive
pulmonary disease requiring supplemental oxygen, end-stage renal disease with or without
dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator’s
opinion, excluded the participant from participating in the study.
4. Other acute or chronic medical or psychiatric condition including recent (within the past year)
or active suicidal ideation or behavior or laboratory abnormality that may have increased the
risk associated with study participation or investigational product administration or may have
interfered with the interpretation of study results and, in the judgment of the investigator,
would have made the participant inappropriate for entry into this study.
5. History of microbiologically proven invasive disease caused by S. pneumoniae.
6. Participants who received treatment with immunosuppressive therapy, including cytotoxic
agents or systemic corticosteroids, or planned receipt through the last blood draw. If
systemic corticosteroids had been administered short term (<14 days) for treatment of an
acute illness, participants should not have been enrolled into the study until corticosteroid
therapy had been discontinued for at least 28 days before investigational product
administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes)
corticosteroids were permitted.
7. Participants with known or suspected immunodeficiency or other conditions associated with
immunosuppression, including, but not limited to, immunoglobulin class/subclass
deficiencies, generalized malignancy, human immunodeficiency virus infection, leukemia,
lymphoma, or organ or bone marrow transplant.
8. Receipt of blood/plasma products or immunoglobulins from 60 days before investigational
product administration or planned receipt through study participation.
6.1.4 Study Treatments or Agents Mandated by the Protocol
PCV20 and PCV13 vaccines were supplied as single-use prefilled syringes. PPSV23 and saline
placebo were supplied as packaged vials. Each study treatment was to be administered
intramuscularly in the deltoid muscle of the non-dominant arm.
PCV20 is a sterile liquid suspension for IM administration of capsular polysaccharide antigens of
S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,
22F, 23F, and 33F each individually conjugated to nontoxic variant of diphtheria toxin (CRM197)
as a carrier protein. The vaccine is formulated to contain 2.2 µg of each saccharide, except for
4.4 µg of 6B, per 0.5 mL dose. The vaccine contains (b) (4) succinate buffer, (b) (4) sodium
chloride, (b) (4) polysorbate 80, and 0.125 mg aluminum as aluminum phosphate, per 0.5 mL
dose. Lot number: T82473.
PCV13 contains saccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,
19A, 19F, and 23F individually conjugated to CRM197. The vaccine is formulated to contain
2.2 µg of each saccharide, except for 4.4 µg of 6B, per 0.5 mL dose. The vaccine contains
succinate buffer, (b) (4) sodium chloride, (b) (4) polysorbate 80, and 0.125 mg aluminum
as aluminum phosphate, per 0.5 mL dose. The PCV13 polysaccharide intermediates and
vaccine substances were manufactured according to the approved Prevnar 13 commercial
(b)
(4)

32

Clinical Reviewer: Tina Mongeau
STN: 125731/0

process, and the formulation and filling processes are similar; but they are performed at a
different scale than the commercial process. Lot number: W73014.
PPSV23 is a clear, sterile solution consisting of a mixture of purified capsular polysaccharides
from 23 serotypes of S. pneumoniae: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,
17F, 18C, 19F, 19A, 20 22F, 23F and 33F. The vaccine is formulated to contain 25 µg of each
of the 23 purified polysaccharide serotypes per 0.5 mL dose of vaccine in an isotonic saline
solution containing 0.25% phenol as a preservative. Lot numbers: R022111, R007722.
Placebo is a sterile normal saline solution for injection (0.9% sodium chloride injection). Lot
number: AN-LDM.
Non-study Vaccines
The name and date of administration of any permitted non-study vaccinations were recorded in
the case report form (CRF). Licensed inactivated influenza vaccine was permitted >14 days
prior to or >14 days after study product injection. Receipt of any other licensed non-study
vaccine (except pneumococcal vaccine which was prohibited in this study) was permitted after
Visit 3 (Cohort 1 only) or after Visit 2 (Cohorts 2 and 3). Prophylactic antipyretics were permitted
but not recommended on the day prior to or the day of investigational product administration.
6.1.6 Sites and Centers
Study B7471007 was conducted at a total of 61 sites; 54 sites in the U.S. and 7 sites in
Sweden. The numbers of subjects randomized/enrolled were 3,730 and 172 in the U.S. and
Sweden, respectively.
Reviewer Comment: All subjects who enrolled in Sweden in studies B7471007 and
B7471006 were ≥65 years of age. CBER agreed to enrollment of subjects from
European clinical study sites, as Wyeth foresaw difficulty in enrolling the targeted
number of pneumococcal vaccine-naïve adults ≥65 years of age in the U.S., where ACIP
recommendations for adults ≥65 years of age include routine vaccination with PPSV23
in addition to shared decision making for administration of PCV13 to persons ≥65 years
of age.
6.1.7 Surveillance/Monitoring
Safety Monitoring
Safety monitoring in study B7471007 included monitoring for the following:
1. Immediate adverse reactions within 30 minutes after each vaccination
2. Solicited 8 local reactions through 10 days 9 after Vaccination 1 (injection site erythema,
edema and pain),
3. Solicited systemic adverse events and use of antipyretic/pain medication through 7 days 10
after Vaccination 1 (headache, tiredness, muscle pain, joint pain and fever),
8

Subjects were given a digital thermometer, a measuring device and an electronic diary (e-diary) to
record prompted local reactions and systemic adverse events daily in their e-diary. One measuring device
unit = 0.5 cm (measuring range: 1 to 21+ units). The highest temperature for each day was to be
recorded in the e-diary. In the event of fever on day 7, temperature was to be collected daily until
resolution.
9
Study days 1 through 10 (day 1 = day of vaccination)
10
Study days 1 through 7 (day 1 = day of vaccination)

33

Clinical Reviewer: Tina Mongeau
STN: 125731/0

4. Unsolicited adverse events through 1 month after each vaccination, and
5. SAEs and newly diagnosed chronic medical conditions through 6 months after
Vaccination 1.
Solicited local reactions and solicited systemic adverse events were graded according to a prespecified toxicity grading scale (see Tables 15-20 in Section 6.1.12.2). Severity was not
collected for use of antipyretic or pain medication. Grade 4 assessments were only to be made
by the investigator and recorded as AEs in the CRF. The need for an unscheduled visit was
considered for subjects with a ≥ grade 3 injection site reaction within 10 days post-vaccination
or any grade 4 systemic reaction during 7 days post-vaccination.
Immunogenicity Monitoring
Blood samples for immunogenicity assessments were collected from all subjects prior to and 1
month after Vaccination 1. In Cohort 1 subjects only, blood samples for immunogenicity were
also collected 1 month after Vaccination 2. OPA titers for all serotypes present in PCV20 were
determined on all sera collected prior to and 1 month after Vaccination 1. OPA titers for the 7
additional serotypes only (8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined on sera
collected 1 month after Vaccination 2 in Cohort 1. In addition, OPA titers were tested for nonvaccine serotype 15C in a random subset of subjects.
6.1.8 Endpoints and Criteria for Study Success
Please see Section 6.1.1 of the clinical review.
6.1.9 Statistical Considerations & Statistical Analysis Plan
Sample Size Calculations
•

•

A total of 2,000 subjects 60-64 years of age were planned in Cohort 1 to ensure
~1,800 evaluable subjects in this age group and to provide the study with 72%
power to demonstrate noninferiority in serotype-specific OPA GMT ratios for all 20
serotypes. Please refer to the statistical review for details regarding sample size
calculations.
A total of 440 subjects were planned in Cohorts 2 and 3 to ensure >90% power to
demonstrate noninferiority in serotype-specific OPA GMT ratios between each of
the younger age cohorts and the subjects 60-64 years of age from Cohort 1
(Cohort 1 subset).

Statistical Considerations
•

•

For the primary study objective (primary analyses), calculation of OPA GMT ratios
and CIs for each serotype used a linear regression model that included terms for
age, corresponding baseline OPA titer, sex, smoking status, and vaccine group.
The unadjusted serotype-specific OPA GMT ratio and CI were also calculated for
each serotype.
For the secondary study objective (secondary bridging analyses), calculation of
OPA GMT ratios and CIs for each serotype used a regression model that included
terms for the corresponding baseline OPA titer, sex, smoking status and cohort.
Two separate regression models were fitted for comparing results from the
younger cohort to results from Cohort 1. Unadjusted serotype-specific OPA GMT
ratios and CIs were also calculated for each of the serotypes as a supportive
approach.
34

Clinical Reviewer: Tina Mongeau
STN: 125731/0

•
•

Missing assay results were not replaced or imputed.
Serotype-specific OPA titers below the corresponding serotype-specific assay
LLOQ were set to 0.5 x LLOQ for analysis (Source: STN 125731.1 module
5.3.5.1, Study B7471007 Statistical Analysis Plan).
o The LLOQs by serotype are as follows:
 Serotype 1: (b) (4)
 Serotype 3:
 Serotype 4:
 Serotype 5:
 Serotype 6A (b) (4)
 Serotype 6B
 Serotype 7F:
 Serotype 8: (b) (4)
 Serotype 9V: (b) (4)
 Serotype 10A
 Serotype 11A
 Serotype 12F
 Serotype 14:
 Serotype 15B: (b) (4)
 Serotype 18C:
 Serotype 19A:
 Serotype 19F:
 Serotype 22F:
 Serotype 23F:
 Serotype 33F:
 Serotype 15C:

Analysis Timing
A single final analysis conducted after the database lock included all planned safety and
immunogenicity analyses.
Safety Analysis
The safety objectives were evaluated by descriptive summary statistics for each primary safety
endpoint for each vaccine group and each cohort.
Analysis Populations
•

The safety population included all subjects who received at least 1 dose of
PCV20, PCV13, PPSV23, or saline and had safety follow-up. Subjects were
included in the vaccine group corresponding to the vaccine actually received.

•

Three evaluable immunogenicity populations were defined for the analysis of
immunogenicity results. Subjects were included in the evaluable vaccine group
corresponding to their randomized assignment.
−
−
−

Evaluable 13-matched immunogenicity population: primary analysis population for
results of the 13-matched serotypes in Cohort 1.
Evaluable 7-additional immunogenicity population: primary analysis population for
results of the 7 additional serotypes in Cohort 1.
Evaluable-20 immunogenicity population: primary analysis population for
immunogenicity results in Cohorts 2 (50-59 years) and 3 (18-49 years); defined for
35

Clinical Reviewer: Tina Mongeau
STN: 125731/0

comparisons between the Cohort 1 subset (subjects 60-64 years of age) and either
Cohort 2 or Cohort 3 subjects.
Evaluable 13-Matched Population Criteria
1.
2.
3.
4.
5.

Received the assigned vaccination at Visit 1 (PCV20 or PCV13) as randomized
Enrolled in appropriate cohort based on age at Visit 1 (i.e., ≥60 years or age in Cohort 1)
Had Visit 2 blood draw within 27 to 49 days after Vaccination 1.
Had ≥1 valid and determinate OPA titer for any of the 13 matched serotypes at Visit 2
Had no major protocol deviations as determined by the clinician.

Evaluable 7-Additional Population Criteria
1. Received Vaccination 1 if randomized to the PCV20/saline group or received both
vaccinations as randomized if randomized to the PCV13/PPSV23 group
2. Enrolled in appropriate cohort based on age on the day of first vaccination
3. Had either the Visit 2 blood draw within 27 to 49 days after Vaccination 1 (PCV20 for the
PCV20/saline group or the Visit 3 blood draw within 27 to 49 days after Vaccination 2
(PPSV23) for the PCV13/PPSV23 group
4. Had ≥1 valid and determinate OPA titer for any of the 7 additional serotypes at either Visit 2
for the PCV20/saline group or Visit 3 for the PCV13/PPSV23 group.
5. Had no major protocol deviations as determined by the clinician.
Evaluable-20 Population Criteria
1.
2.
3.
4.
5.

Received the assigned Vaccination at Visit 1 as randomized
Enrolled in appropriate cohort based on age on the day of first vaccination
Had Visit 2 blood draw within 27 to 49 days after Vaccination 1
Had ≥1 valid and determinate OPA titer for any of 20 serotypes for Visit 2
Had no major protocol deviations as determined by the clinician.

The all-available immunogenicity population included all subjects who received ≥1 dose of
PCV20, PCV13, PPSV23, or saline and had ≥1 valid and determinate OPA titer after any
vaccination. This population was the secondary analysis population for immunogenicity results.
Subjects were included in all-available vaccine group corresponding to their randomized
assignment.
•

•

For cohort-specific analysis, the need for all-available analyses was assessed
separately for each cohort. If there was <5% difference in sample size between
the all-available and evaluable populations, then only the evaluable population
was used for the immunogenicity analyses.
For cross-cohort analysis where Cohort 2 or 3 was compared to the Cohort 1
subset (subjects 60-64 years of age), if either cohort in the comparison had <5%
difference in sample size between the all-available and evaluable populations,
analyses would be based on the evaluable populations only.

6.1.10 Study Population and Disposition
A total of 3009 subjects were randomized in Cohort 1; 2,997 received PCV20 or PCV13 and
2,835 (94.2%) completed the study (Table 8). A total of 445 subjects were randomized and
vaccinated in Cohort 2, and 432 (97.1%) completed the study. In Cohort 3, a total of 448
subjects were randomized, 447 were vaccinated, and 423 (94.4%) completed the study.

36

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.1.10.1 Populations Enrolled/Analyzed
Section 6.1.9 defines this study’s populations enrolled and analyzed. The proportions of
subjects in Cohort 1 included in the evaluable 13-matched, evaluable 7-additional, and allavailable immunogenicity analysis populations were similar in the PCV20/saline and
PCV13/PPSV23 groups (Table 3). Similarly, the proportion of subjects in Cohorts 2 and 3
included in the evaluable-20 immunogenicity populations were similar in the PCV20/saline and
PCV13/PPSV23 groups (Table 4). The most common reason for exclusion from each of the
evaluable immunogenicity populations (13-matched, 7-additional, and evaluable-20) was not
having blood collected within the pre-specified time window. No analyses in Cohorts 1, 2 or 3
were conducted using the all-available immunogenicity analysis population due to a ≤5%
difference in sample size between the all-available population and each of the evaluable
populations.
Table 3. Immunogenicity Analysis Populations, Cohort 1 (≥60 Years), Study B7471007
PCV20/Saline PCV13/PPSV23
Total
Group/Reason for Exclusion
na (%)
na (%)
na (%)
Randomizedb
1514 (100.0)
1495 (100.0)
3009 (100.0)
Evaluable 13-Matched Immunogenicity
1435 (94.8)
1420 (95.0)
2855 (94.9)
Population
60-64 years of age
945 (62.4)
948 (63.4)
1893 (62.9)
≥65 years of age
490 (32.4)
472 (31.6)
962 (32.0)
Subjects excludedc from evaluable 13-matched
79 (5.2)
75 (5.0)
154 (5.1)
immunogenicity population
Didn’t receive assigned Vaccination 1 as
7 (0.5)
5 (0.3)
12 (0.4)
randomized
Didn’t have Visit 2 (V2) blood collection within
66 (4.4)
60 (4.0)
126 (4.2)
27 to 49 days after Vaccination 1
Didn't have at least 1 valid OPA titer for any of
48 (3.2)
43 (2.9)
91 (3.0)
the 13-matched serotypes at V2
Had any other major protocol deviationsd
15 (1.0)
19 (1.3)
34 (1.1)
Evaluable 7-Additional Immunogenicity
1433 (94.6)
1383 (92.5)
2816 (93.6)
Population
60-64 years of age
945 (62.4)
917 (61.3)
1862 (61.9)
≥65 years of age
488 (32.2)
466 (31.2)
954 (31.7)
Subjects excludedc from evaluable 7-additional
81 (5.4)
112 (7.5)
193 (6.4)
immunogenicity population
Didn’t receive Vaccination 1 if randomized to
PCV20/saline group or both vaccinations as
7 (0.5)
50 (3.3)
57 (1.9)
randomized if randomized to PCV13/PPSV23
Didn’t have blood collected 27 to 49 days after
Vaccination 1 for PCV20/saline group or after
66 (4.4)
81 (5.4)
147 (4.9)
Vaccination 2 for PCV13/PPSV23 group
No valid and determinate OPA titer for any of 7
additional serotypes at V2 for PCV20/saline
50 (3.3)
61 (4.1)
111 (3.7)
group or Visit 3 for PCV13/PPSV23 group
Had any other major protocol deviationsd
15 (1.0)
34 (2.3)
49 (1.6)

37

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Group/Reason for Exclusion
All-Available Immunogenicity Population
60-64 years of age
≥65 years of age
Subjects excludedc from all-available
immunogenicity population
Did not receive ≥1 dose of study vaccine
Didn’t have valid and determinate OPA titer
after vaccination

PCV20/Saline
na (%)
1476 (97.5)
974 (64.3)
502 (33.2)

PCV13/PPSV23
na (%)
1456 (97.4)
972 (65.0)
484 (32.4)

Total
na (%)
2932 (97.4)
1946 (64.7)
986 (32.8)

38 (2.5)

39 (2.6)

77 (2.6)

7 (0.5)

5 (0.3)

12 (0.4)

38 (2.5)

39 (2.6)

77 (2.6)

Abbreviation: OPA = opsonophagocytic activity.
a
n = Number of subjects with the specified characteristic.
b
These values are the denominators for the percentage calculations.
c
Subjects may have been excluded for more than 1 reason.
d
Includes subjects who took prohibited concomitant medication or vaccine, who entered into study but did not meet eligibility
criterion, and who were administered investigational product after a temperature excursion (n=13 at 1 site)
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Tables 8, p 53-54.

Table 4. PCV20 Vaccination in Cohort 1 Subset (60-64 Years), Cohort 2 and Cohort 3, Evaluable-20
Immunogenicity Populations, Study B7471007
Cohort 1
Subset
PCV20/Saline
Group
Cohort 2
Cohort 3
(60-64 years)
PCV20 Group
PCV20 Group
Reason for Exclusion
an (%)
na (%)
na (%)
b
Randomized
996 (100.0)
334 (100.0)
336 (100.0)
Evaluable-20 immunogenicity population
946 (95.0)
321 (96.1)
317 (94.3)
Subjects excludedc from evaluable-20
50 (5.0)
13 (3.9)
19 (5.7)
immunogenicity population
Didn’t receive PCV20 vaccination as
3 (0.3)
0
1 (0.3)
Randomized
Wasn’t enrolled in appropriate cohort/stratum
0
0
1 (0.3)
based on age on the day of first vaccination
Did not have Visit 2 blood collection within
41 (4.1)
11 (3.3)
16 (4.8)
27 to 49 days after PCV20 vaccination
Didn’t have valid and determinate OPA
29 (2.9)
3 (0.9)
12 (3.6)
titer for any of the 20 serotypes for Visit 2
d
Had any other major protocol deviations
10 (1.0)
2 (0.6)
3 (0.9)
Abbreviation: OPA = opsonophagocytic activity.
a
n = Number of subjects with the specified characteristic.
b
These values are the denominators for the percentage calculations.
c
Subjects may have been excluded for more than 1 reason.
d
Includes subjects who took prohibited vaccine, who entered into the study but did not meet elig bility criterion, and who were
enrolled into the incorrect cohort.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Tables 9, p 54-55.

6.1.10.1.1 Demographics
Table 5 summarizes baseline demographic characteristics and smoking history by study cohort
and study group for the safety population (results were similar for each evaluable population;
data not shown, Supplemental Tables 14.4 through 14.6). The two study groups within each
cohort were similar with regard to baseline demographics and smoking history. Overall, the
safety population included 58%-69% females, 81%-90% White, 6%-14% Black and <6% from
other racial groups across all cohorts; 4%-11% were Hispanic/Latino; and 11%-20% were
current smokers. Overall in Cohort 1, 66.2% were 60-64 years of age, 20.8% were 65-69 years
of age, 10.6% were 70-79 years of age, and 2.3% were ≥80 years of age. The mean age of
subjects was 65 years in Cohort 1, 55 years in Cohort 2, and 34 years in Cohort 3.
38

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 5. Baseline Demographic Characteristics by Study Cohort and Study Group, Safety Population, Study B7471007
Cohort 1
Cohort 1
Cohort 2
Cohort 2
Cohort 3
Cohort 3
(≥60 Years)
(≥60 Years) (50-59 Years) (50-59 Years) (18-49 Years) (18-49 Years)
PCV20/Saline PCV13/PPSV23
PCV20
PCV13
PCV20
PCV13
Na=1507
Na=1490
Na=334
Na=111
Na=335
Na=112
Characteristic
nb (%)
nb (%)
nb (%)
na (%)
na (%)
na (%)
Sex
Male
610 (40.5)
611 (41.0)
139 (41.6)
42 (37.8)
121 (36.1)
35 (31.3)
Female
897 (59.5)
879 (59.0)
195 (58.4)
69 (62.2)
214 (63.9)
77 (68.8)
Race
White
1295 (85.9)
1237 (83.0)
278 (83.2)
90 (81.1)
274 (81.8)
101 (90.2)
Black or African American
177 (11.7)
212 (14.2)
35 (10.5)
15 (13.5)
34 (10.1)
7 (6.3)
Asian
19 (1.3)
15 (1.0)
10 (3.0)
2 (1.8)
11 (3.3)
1 (0.9)
American Indian or Alaska Native
6 (0.4)
9 (0.6)
0 (0.0)
3 (2.7)
1 (0.3)
1 (0.9)
Native Hawaiian or other Pacific Islander
1 (0.0)
1 (0.0)
0 (0.0)
0 (0.0)
3 (0.9)
1 (0.9)
Multiracial
7 (0.5)
9 (0.6)
6 (1.8)
1 (0.9)
8 (2.4)
1 (0.9)
Not Reported
2 (0.1)
7 (0.5)
5 (1.5)
0 (0.0)
4 (1.2)
0 (0.0)
Ethnicity
Hispanic/Latino
167 (11.1)
169 (11.3)
12 (3.6)
8 (7.2)
24 (7.2)
7 (6.3)
Non-Hispanic/non-Latino
1324 (87.9)
1308 (87.8)
319 (95.5))
101 (91.0)
300 (89.6)
102 (91.1)
Not reported
16 (1.1)
13 (0.9)
3 (0.9)
2 (1.8)
11 (3.3)
3 (2.7)
Age Group
60-64 years
993 (65.9)
992 (66.6)
N/A
N/A
N/A
N/A
65-69 years
319 (21.2)
305 (20.5)
N/A
N/A
N/A
N/A
70-79 years
160 (10.6)
159 (10.7)
N/A
N/A
N/A
N/A
≥80 years
35 (2.3)
34 (2.3)
N/A
N/A
N/A
N/A
Age at Vaccination 1 (Years)
Mean (SD)
64.6 (4.8)
64.6 (4.8)
54.9 (2.8)
55.0 (3.1)
34.0 (8.8)
33.9 (8.0)
Median (Min, Max)
63.0 (60, 91)
63.0 (60, 89) 55.0 (50, 59)
56.0 (48, 59) 34.0 (18, 60) 32.0 (19, 49)
Smoking History
Current Smoker
170 (11.3)
192 (12.9)
52 (15.6)
17 (15.3)
49 (14.6)
22 (19.6)
Mean (SD) # Years Smoking
38.4 (15.4)
37.4 (14.4)
31.6 (11.4)
28.7 (13.5)
14.8 (8.9)
13.5 (9.0)
Ex-smoker
446 (29.6)
472 (31.7)
67 (20.1)
22 (19.8)
47 (14.0)
22 (19.6)
Mean (SD) # Years Since Quitting
23.5 (14.6)
24.7 (14.8)
18.5 (11.6)
18.8 (13.3)
8.1 (6.9)
6.8 (5.9)
Never Smoked
891 (59.1)
826 (55.4)
215 (64.4)
72 (64.9)
239 (71.3)
68 (60.7)
Note: N/A = not applicable. Note: Subject (b) (6)
was incorrectly enrolled in Cohort 3 rather than in Cohort 1 and is included in the Cohort 3 data analysis. Subject (b) (6)
was incorrectly enrolled in Cohort 2, rather than in Cohort 3 and is included in the Cohort 2 data analysis.
N = number of subjects in the specified group or the total sample. This value is the denominator for the percentage calculations.
b
n = Number of subjects with the specified characteristic.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Tables 10-12, p 56-60.
a

39

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.1.10.1.2 Medical/Behavioral Characterization of the Enrolled Population
At enrollment, approximately one-third of subjects had risk factors for serious pneumococcal
disease, including smoking (12.9%), stable medical conditions of chronic cardiovascular disease
(5.5%), chronic pulmonary disease including asthma (8.7%), chronic liver disease (0.4%), and
diabetes mellitus (13.9%). (Data not shown. Integrated Summary of Safety Table 17 shows data
for Study B7471007 Cohorts Pooled).
Table 6 presents the proportions of study subjects with one or more risk factors6 for serious
pneumococcal infections in the primary immunogenicity analysis populations. The proportion of
subjects with underlying comorbidities were similar between the two Cohort 1 study groups and
were generally similar across the smaller study groups in Cohorts 2 and 3 (PCV20 groups
shown only in Table 6). The distributions of baseline comorbidities were consistent with those
observed in the primary immunogenicity analysis populations.
Table 6. Subjects with Stable Underlying Comorbidities Known to Increase the Risk for Serious
Pneumococcal Infection, Cohort 1, Evaluable 13-Matched Immunogenicity Population, and the
Evaluable-20 Immunogenicity Population for Cohorts 2 and 3, Study B7471007
Cohort 1
Cohort 1
(≥60 Years)
(≥60 Years)
Cohort 2
Cohort 3
PCV20/
PCV13/ (50-59 Years) (18-49 Years)
Saline
PPSV23
PCV20
PCV20
Na=1435
Na=1420
Na=321
Na=108
Comorbidity
nb (%)
nb (%)
nb (%)
nb (%)
c
Subjects with ≥1 risk factor(s)
465 (32.4)
516 (36.3)
104 (32.4)
79 (24.9)
Any selected medical historyd
354 (24.7)
404 (28.5)
65 (20.2)
39 (12.3)
Chronic cardiovascular disease
71 (4.9)
109 (7.7)
12 (3.7)
3 (0.9)
Chronic liver disease
5 (0.3)
7 (0.5)
2 (0.6)
0 (0.0)
Chronic pulmonary disease
130 (9.1)
117 (8.2)
22 (6.9)
30 (9.5)
Diabetes mellitus
209 (14.6)
243 (17.1)
39 (12.1)
9 (2.8)
Current smoking
163 (11.4)
179 (12.6)
50 (15.6)
46 (14.5)
Note: MedDRA (v22.1) coding dictionary applied.
a
N = Number of subjects in the specified group or the total sample. This value is in the denominator for the percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
Includes current smoking as a risk factor.
d
Includes medical condition risk factors based on 2010 MMWR;59(34):1102-1106. Does not include current smokers.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Tables 14.7 - 14.9 on pages 141-147.

Reviewer Comment: The at-risk conditions summarized in Table 6 above were based
on the Updated Recommendations for Prevention of Invasive Pneumococcal Disease
Among Adults Using the 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23)
(Nuorti and Whitney 2010). These include the following medical conditions in
immunocompetent adults:
• Chronic heart disease (excluding hypertension and arrhythmias and including
congestive heart failure and cardiomyopathies); this includes atherosclerotic
cardiovascular disease, angina, congestive heart failure, and Medical Dictionary
for Regulatory Activities (MedDRA) Preferred Terms relating to certain heart valve
conditions (i.e., mitral valve incompetence, aortic valve incompetence, mitral valve
disease and aortic valve disease). (Note: mitral valve prolapse was not included
because Wyeth noted that, although it can progress to mitral regurgitation and
heart failure, it can exist in a stable form without significant physiologic
consequences; in addition, pulmonary valve incompetence in retrospect should
have been added to this list, however the only study participant with pulmonary
40

Clinical Reviewer: Tina Mongeau
STN: 125731/0

valve incompetence was already included in Table 6 due to concomitant mitral
valve incompetence which was considered a risk condition).
• Chronic lung disease (including chronic obstructive pulmonary disease,
emphysema and asthma)
• Diabetes mellitus
• Cigarette smoking
There were no subjects with cerebrospinal fluid leaks and cochlear implants; there were
only a few subjects with alcoholism or chronic liver disease, as in most cases, such
subjects would not meet eligibility criteria.
Table 7 presents select baseline comorbidities noted in the medical history (ongoing at the time
of enrollment) for Cohort 1, 2, and 3 PCV20 group safety populations. Of note, pre-licensure
PCV20 studies excluded persons with serious chronic disorders (e.g., severe chronic
obstructive pulmonary disease, end-stage renal disease, clinically unstable cardiac disease)
and persons with known or suspected immunodeficiency or other conditions associated with
immunosuppression.

41

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Table 7. Select Medical History (Ongoing) of Cohorts 1, 2, and 3, Safety Population, Study B7471007
Cohort 1
Cohort 1
Cohort 2
Cohort 2
Cohort 3
Cohort 3
(≥60 Years)
(≥60 Years) (50-59 Years) (50-59 Years) (18-49 Years) (18-49 Years)
PCV20/Saline PCV13/PPSV23
PCV20
PCV13
PCV20
PCV13
Na=1507
Na=1490
Na=334
Na=111
Na=335
Na=112
Comorbidity
nb (%)
nb (%)
nb (%)
na (%)
na (%)
na (%)
Any medical history by MedDRA SOC/PT
1448 (96.1)
1438 (96.5)
310 (92.8)
105 (94.6)
261 (77.9)
93 (83.0)
Blood and lymphatic system disorders
41 (2.7)
41 (2.8)
7 (2.1)
2 (1.8)
8 (2.4)
1 (0.9)
Cardiac disordersc
134 (8.9)
147 (9.9)
16 (4.8)
1 (0.9)
6 (1.8)
2 (1.8)
Endocrine disorders
233 (15.5)
249 (16.7)
51 (15.3)
17 (15.3)
19 (5.7)
7 (6.3)
Gastrointestinal disorders
454 (30.1)
409 (27.4)
83 (24.9)
19 (17.1)
59 (17.6)
11 (9.8)
Hepatobiliary disorders
25 (1.7)
24 (1.6)
1 (0.3)
0 (0.0)
3 (0.9)
1 (0.9)
Immune system disordersd
621 (41.2)
593 (39.8)
130 (38.9)
46 (41.4)
107 (31.9)
46 (41.1)
Drug hypersensitivity
325 (21.6)
317 (21.3)
69 (20.7)
27 (24.3)
57 (17.0)
14 (12.5)
Infections and infestations
103 (6.8)
112 (7.5)
15 (4.5)
2 (1.8)
26 (7.8)
11 (9.8)
Metabolism and nutrition disorders
779 (51.7)
779 (52.3)
142 (42.5)
42 (37.8)
52 (15.5)
23 (20.5)
Hypercholesterolaemia
191 (12.7)
184 (12.3)
44 (13.2)
12 (10.8)
6 (1.8)
1 (0.9)
Hyperlipidemia
286 (19.0)
294 (19.7)
27 (8.1)
8 (7.2)
5 (1.5)
2 (1.8)
Obesity
147 (9.8)
148 (9.9)
22 (6.6)
8 (7.2)
22 (6.6)
12 (10.7)
Type 2 diabetes mellitus
214 (14.2)
243 (16.3)
38 (11.4)
12 (10.8)
9 (2.7)
3 (2.7)
Nervous system disorders
342 (22.7)
328 (22.0)
78 (23.4)
18 (16.2)
64 (19.1)
26 (23.2)
Renal and urinary disorders
138 (9.2)
120 (8.1)
19 (5.7)
5 (4.5)
9 (2.7)
4 (3.6)
Respiratory, thoracic and mediastinal
296 (19.6)
280 (18.8)
41 (12.3)
8 (7.2)
42 (12.5)
18 (16.1)
Disorders
Asthma
89 (5.9)
80 (5.4)
16 (4.8)
4 (3.6)
23 (6.9)
11 (9.8)
Chronic obstructive pulmonary disease
41 (2.7)
35 (2.3)
3 (0.9)
0 (0.0)
1 (0.3)
0 (0.0)
Sleep apnoea syndrome
109 (7.2)
107 (7.2)
14 (4.2)
2 (1.8)
7 (2.1)
3 (2.7)
Vascular disorders
705 (46.8)
754 (50.6)
110 (32.9)
39 (35.1)
29 (8.7)
8 (7.1)
Hypertension
671 (44.5)
727 (48.8)
105 (31.4)
35 (31.5)
25 (7.5)
5 (4.5)
Note: MedDRA (v22.1) coding dictionary applied. SOC: System Organ Class. PT: Preferred Term.
Note: Select clinically-relevant and frequently reported PTs are listed in this table.
a
N = Number of subjects in the specified group or the total sample. This value is in the denominator for the percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
This includes approximately 60 individual Preferred Terms encompassing valvular disease, arrhythmias, and other cardiac-related disease.
d
This consisted of allergies, sensitivities, and sarcoidosis.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report, Tables 14.12-14.14, pages 150-283.

42

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.1.10.1.3 Subject Disposition
The dispositions of all randomized subjects (as described in Section 6.1.10) are summarized in
Table 8. In Cohorts 1-3, subject disposition was similar in both study groups within each cohort
and the most common reason for withdrawal in both study groups was being lost to follow-up.
There was one death in a Cohort 1 subject due to a self-inflected gunshot wound in the
PCV20/saline group that was considered unrelated to study treatment.
Table 8. Disposition of All Randomized Subjects, by Age Cohort and Study Group, Study
B7471007
PCV20/Saline
PCV13/PPSV23
Total
Cohort 1 (≥60 Years)
na (%)
na (%)
na (%)
Randomizedb
1514 (100.0)
1495 (100.0)
3009 (100.0)
Not vaccinated
7 (0.5)
5 (0.3)
12 (0.4)
Vaccinated
Vaccination 1
1507 (99.5)
1490 (99.7)
2997 (99.6)
Vaccination 2c
1461 (96.5)
1446 (96.7)
2907 (96.6)
Completed visit 3d
1441 (95.2)
1428 (95.5)
2869 (95.3)
Completed study
1418 (93.7)
1417 (94.8)
2835 (94.2)
Withdrawn from study
96 (6.3)
78 (5.2)
174 (5.8)
Reason for withdrawal
Adverse event
11 (0.7)
8 (0.5)
19 (0.6)
Deathe
1 (0.0)
0 (0.0)
1 (0.0)
Lost to follow-up
41 (2.7)
28 (1.9)
69 (2.3)
No longer meets eligibility criteria
3 (0.2)
9 (0.6)
12 (0.4)
Protocol deviation
21 (1.4)
13 (0.9)
34 (1.1)
Withdrawal by subject
19 (1.3)
20 (1.3)
39 (1.3)
PCV20
PCV13
Total
Cohort 2 (50-59 Years)
na (%)
na (%)
na (%)
Randomizedb
334 (100.0)
111 (100.0)
445 (100.0)
Not vaccinated
0 (0.0)
0 (0.0)
0 (0.0)
Vaccinated
Completed visit 2f
330 (98.8)
110 (99.1)
440 (98.9)
Completed study
323 (96.7)
109 (98.2)
432 (97.1)
Withdrawn from study
11 (3.3)
2 (1.8)
13 (2.9)
Reason for withdrawal
Lost to follow-up
9 (2.7)
2 (1.8)
11 (2.5)
Protocol deviation
1 (0.3)
0 (0.0)
1 (0.2)
Withdrawal by subject
1 (0.3)
0 (0.0)
1 (0.2)
PCV20
PCV13
Total
Cohort 3 (18-49 Years)
na (%)
na (%)
na (%)
Randomizedb
336 (100.0)
112 (100.0)
448 (100.0)
Not vaccinated
1 (0.3)
0 (0.0)
1 (0.2)
Vaccinated
335 (99.7)
112 (100.0)
447 (99.8)
Completed visit 2f
325 (96.7)
109 (97.3)
434 (96.9)
Completed study
319 (94.9)
104 (92.9)
423 (94.4)
Withdrawn from study
17 (5.1)
8 (7.1)
25 (5.6)

43

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Reason for withdrawal
Lost to follow-up
No longer meets eligibility criteria
Protocol deviation
Withdrawal by subject

14 (4.2)
1 (0.3)
1 (0.3)
1 (0.3)

8 (7.1)
0 (0.0)
0 (0.0)
0 (0.0)

22 (4.9)
1 (0.2)
1 (0.2)
1 (0.2)

a

Number of subjects with the specified characteristics.
These values are the denominators for the percentage calculations.
c
Includes subject (b) (6)
erroneously injected with a non-protocol defined investigational product at Vaccination #2.
d
One-month after Vaccination #2.
e
One-month after Vaccination #1
f
One subject died of a self-inflicted gunshot wound (considered unrelated to study vaccination).
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Tables 5-7, p 48-50.
b

No concomitant vaccines were administered to any study subjects within the 14 days before or
after investigational product administration (Visit 1 or 2 for Cohort 1; Visit 1 for Cohorts 2 and 3)
(STN 125731.11).
6.1.11 Efficacy Analyses
The results from the unadjusted OPA GMT ratios and associated 95% CIs were consistent with
the linear regression model-based OPA GMT ratio results for each of the 20 vaccine serotypes.
6.1.11.1 Analyses of Primary Endpoint(s)
Cohort 1 Primary Non-inferiority Analysis
PCV20 met the primary immunogenicity objective for the 13-matched vaccine serotypes (Table
9). One month post-vaccination, the OPA GMTs to each of the 13-matched vaccine serotypes
induced by PCV20 were non-inferior to those induced by PCV13, as the lower bound of the 2sided 95% CI for the primary analysis of the evaluable 13-matched immunogenicity population
model-based OPA GMT ratios (PCV20/saline relative to PCV13/PPSV23) was >0.5 (2-fold noninferiority margin).
Table 9. Pneumococcal Opsonophagocytic Activity GMTs and GMT Ratio for the PCV13 Serotypes
at 1 Month Post-Vaccination 1, by Study Group, Cohort 1 (≥60 Years), Evaluable 13-Matched
Immunogenicity Population, Study B7471007
PCV20/
PCV13/
Saline
PCV20/
PPSV23
PCV13/
Comparison
Group
Saline Group
Group
PPSV23 Group
GMT Ratioc
a
b
b
a
b
b
Serotype
n
GMT (95% CI )
n
GMT (95% CI )
(95% CIc)
1
1430
123 (112, 136)
1419
154 (140, 169)
0.80 (0.71, 0.90)
3
1415
41 (38, 44)
1411
48 (45, 51)
0.85 (0.78, 0.93)
4
1415
509 (457, 567)
1409
627 (564, 697)
0.81 (0.71, 0.93)
5
1418
92 (83, 101)
1395
110 (100, 120)
0.83 (0.74, 0.94)
6A
1403
889 (795, 994)
1390
1165 (1043, 1301)
0.76 (0.66, 0.88)
6B
1413
1115 (1003, 1240)
1401
1341 (1209, 1489)
0.83 (0.73, 0.95)
7F
1409
969 (887, 1058)
1391
1129 (1035, 1232)
0.86 (0.77, 0.96)
9V
1399
1456 (1318, 1608)
1391
1568 (1421, 1731)
0.93 (0.82, 1.05)
14
1418
747 (679, 821)
1408
747 (680, 820)
1.00 (0.89, 1.13)
18C
1420
1253 (1123, 1397)
143
1482 (1331, 1652)
0.85 (0.74, 0.97)
19A
1420
518 (472, 568)
1398
645 (589, 707)
0.80 (0.71, 0.90)

44

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Serotype
19F
23F

PCV20/
Saline
Group
na
1421
1424

PCV20/
Saline Group
GMTb (95% CIb)
266 (240, 294)
277 (243, 315)

PCV13/
PPSV23
Group
na
1403
1409

PCV13/
PPSV23 Group
GMTb (95% CIb)
333 (302, 368)
335 (294, 381)

Comparison
GMT Ratioc
(95% CIc)
0.80 (0.70, 0.91)
0.83 (0.70, 0.97)

Note: The PCV20/saline group received PCV20 on study day 1 followed by Saline 1 month later. The PCV13/PPSV23 group
received 13PnC on study day 1 followed by PPSV23 1 month later.
Note: GMT = geometric mean titer; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.
a
n = Number of subjects with valid and determinate OPA titers for the specified serotype.
b
GMTs and 2-sided CIs were calculated by exponentiating the least squares means and the corresponding CIs based on analysis
of log-transformed OPA titers using a regression model with vaccine group, sex, smoking status, age at vaccination in years
(continuous), and baseline log transformed OPA titers.
c
GMT ratios (ratio of GMTs PCV20/saline to PCV13/PPSV23) and 2-sided CIs were calculated by exponentiating the difference of
least squares means and the corresponding CIs based on the same regression model as above.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Table 16, p 65-66.

Reviewer Comments:
• Although the pre-specified 2-fold non-inferiority criterion was met by each the 13
serotypes shared between PCV20 and PCV13, the GMT ratios (ratio of PCV20 to
PCV13) were numerically less than 1 for 12 of the 13 common serotypes. These
data suggest that there is some interference in OPA antibody response due to the 7
additional serotypes included in PCV20, resulting in lower OPA titers elicited by
PCV20 compared to PCV13 against 12 of the 13 common serotypes. This
phenomenon was also observed in PCV13 infant studies for the additional serotypes
relative to the 7-valent pneumococcal conjugate vaccine (see clinical review of STN
125324/0).
• A 2-fold non-inferiority margin was used in the evaluation of Prevnar, Prevnar 13 and
other bacterial polysaccharide conjugate vaccines. In the infant pneumococcal
conjugate vaccine programs, this margin was based on an IgG ELISA assay. Since
OPA is an assay with greater variability, setting a more stringent criterion (e.g., 1.5fold) would have been inconsistent and resulted in substantially larger sample sizes
to demonstrate non-inferiority for 20 primary outcomes.
• Based on the data in Table 9, Prevnar 20 would have met a 1.5-fold non-inferiority
criterion since the lower limit of the 95% CI for the GMT ratios was > 0.67 for each of
the PCV13 serotypes. This, in addition to the supportive secondary endpoints,
provides reassurance regarding PCV20 vaccine effectiveness.
PCV20 met the primary immunogenicity objective for 6 of the 7 additional vaccine serotypes
(Table 10). One month post-vaccination, the OPA GMTs for 6 of the 7 additional serotypes
induced by PCV20 were non-inferior to those induced by PPSV23, as the lower bound of the 2sided 95% CI for the model-based OPA GMT ratio (PCV20/saline relative to PCV13/PPSV23
group) exceeded CBER’s agreed upon pre-specified non-inferiority margin of 0.5 (2-fold noninferiority margin) for these six serotypes. The lower bound of the 95% CI for the model-based
GMT ratio for serotype 8 was 0.49, which was outside the pre-specified non-inferiority criterion
of 0.5.

45

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 10. Pneumococcal Opsonophagocytic Activity GMTs and GMT Ratios for the 7 Additional
Serotypes 1 Month Post-Vaccination, Cohort 1, Evaluable 7-Additional Immunogenicity
Population, Study B7471007
PCV20/
PCV13/
Saline
PCV20/Saline
PPSV23
PCV13/PPSV23
Comparison
Group
Group
Group
Group
GMT Ratioc (95%
Serotype
na
GMTb (95% CIb)
na
GMTb (95% CIb)
CIc)
8
1374
466 (423, 513)
1319
848 (769, 935)
0.55 (0.49, 0.62)
10A
1310
2008 (1808, 2229)
1263
1080 (972, 1200)
1.86 (1.63, 2.12)
11A
1198
4427 (3966, 4942)
1209d
2535 (2277, 2822)
1.75 (1.52, 2.01)
12F
1294
2539 (2255, 2858)
1222
1717 (1522, 1936)
1.48 (1.27, 1.72)
15B
1283
2398 (2091, 2751)
1249
769 (670, 882)
3.12 (2.62, 3.71)
22F
1274
3666 (3244, 4143)
1227
1846 (1637, 2083)
1.99 (1.70, 2.32)
33F
1157
5126 (4611, 5698)
1201
3721 (3356, 4125)
1.38 (1.21, 1.57)
Note: The PCV20/Saline group received PCV20 on study day 1 followed by Saline 1 month later. The PCV13/PPSV23 group
received 13PnC on study day 1 followed by PPSV23 1 month later.
Note: GMT = geometric mean titer; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.
a
n = Number of subjects with valid and determinate OPA titers for the specified serotype.
b
GMTs and 2-sided CIs were calculated by exponentiating the least squares means and the corresponding CIs based on analysis
of log-transformed OPA titers using a regression model with vaccine group, sex, smoking status, age at vaccination in years
(continuous), and baseline log transformed OPA titers.
c
GMT ratios (GMTs PCV20/saline to PCV13/PPSV23) and 2-sided CIs were calculated by exponentiating the difference of least
squares means and the corresponding CIs based on a regression model.
d
There were a total of 1102 evaluable subjects at 1 month after the PCV13 dose (Visit 2) versus 1209 evaluable subjects at 1
month after the PPSV23 dose (Visit 3). Wyeth explains that this difference is accounted for by a modestly higher rate of subjects
with indeterminate 11A assay results at Visit 2 (1 month after PCV13) compared to Visit 3 (1 month after the PPSV23 dose). The
OPA assay by nature has a small proportion of indeterminate results that occur across all serotypes due to various immunologic and
non-immunologic factors. This appears to be slightly more frequent with serotype 11A in unvaccinated persons. However, subjects
at Visit 2 in the PCV13/PPSV23 group are unvaccinated with respect to the serotype 11A antigen and do not contribute to the
primary analyses for serotype 11A. In addition, the majority of subjects with sera at Visit 2 in the PCV13/PPSV23 group (and thus
contributing to the analyses of serotype 11A) had a valid result. This was therefore found to be acceptable by the statistical
reviewers.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Table 17, p 68-69.

Reviewer Comment: Although the non-inferiority criterion for serotype 8 was not met
(Table 8) and the percentage of subjects who achieved a ≥4-fold increase in antiserotype 8 antibodies was lower in the PCV20 group compared to the PPSV23 active
control (Table 14), it is important to note that a specific protective OPA antibody titer has
not been established for any pneumococcal vaccine serotype. In addition, a substantial
proportion of subjects in Cohort 1 achieved a ≥4-fold increase in anti-serotype 8 OPA
antibody titers (77.8%), demonstrating that the vaccine elicits functional OPA antibody
responses. Thus, it is reasonable to include serotype 8 in the Indications for Prevnar 20,
because the vaccine elicits functional antibodies that will likely contribute to protection
against IPD and pneumococcal pneumonia.
6.1.11.2 Analyses of Secondary Endpoints
Cohort 2 Immunobridging Analyses
PCV20 met the secondary immunogenicity objective for each of the 20 vaccine serotypes based
on comparisons of the serotype-specific OPA GMTs in subjects 50-59 years of age (Cohort 2) to
those in subjects 60-64 years of age (Cohort 1 subset). The lower bound of the 2-sided 95% CI
for the ratio (PCV20 in Cohort 2 relative to PCV20 in Cohort 1 subset) of the model-based OPA
GMTs at 1 month post-vaccination exceeded 0.5 (the pre-specified 2-fold immune-bridging
success criterion) for each of the 20 vaccine serotypes (Table 11).

46

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 11. Comparisons of Pneumococcal Opsonophagocytic Activity GMTs 1 Month After PCV20
Vaccination in Cohort 2 (50-59 Years of Age) and Cohort 1 Subset (60-64 Years of Age), Evaluable20 Immunogenicity Population, Study B7471007
Cohort 1
Cohort 1
Cohort 2
Cohort 2
Subset
Subset
Comparison
50-59 Years
50-59 Years
60-64 Years
60-64 Years
Serotype
na
GMTb (95% CIb)
na
GMTb (95% CIb) GMT ratioc (95% CIc)
PCV13
1
320
136 (113, 163)
941
132 (117, 148)
1.03 (0.84, 1.26)
3
318
43 (38, 49)
935
41 (38, 45)
1.06 (0.92, 1.22)
4
318
633 (514, 780)
931
578 (506, 661)
1.10 (0.87, 1.38)
5
313
85 (70, 102)
935
97 (86, 109)
0.88 (0.72, 1.07)
6A
318
1204 (968, 1497)
921
997 (867, 1148)
1.21 (0.95, 1.53)
6B
318
1503 (1228, 1839)
933
1199 (1054, 1363)
1.25 (1.00, 1.56)
7F
313
1047 (884, 1240)
924
1173 (1053, 1307)
0.89 (0.74, 1.07)
9V
312
1726 (1424, 2091)
922
1688 (1494, 1907)
1.02 (0.83, 1.26)
14
313
926 (762, 1126)
933
742 (656, 840)
1.25 (1.01, 1.54)
18C
315
1805 (1460, 2232)
937
1355 (1184, 1551)
1.33 (1.06, 1.68)
19A
318
618 (520, 736)
932
600 (538, 671)
1.03 (0.85, 1.25)
19F
320
287 (236, 348)
937
290 (256, 329)
0.99 (0.80, 1.22)
23F
319
549 (425, 709)
937
328 (278, 385.6)
1.68 (1.27, 2.22)
Additional
8
314
487 (401, 592)
901
502 (443, 570)
0.97 (0.78, 1.20)
10A
296
2520 (2076, 3060)
857
2437 (2150, 2763)
1.03 (0.84, 1.28)
11A
271
6417 (5132, 8024)
796
5249 (4565, 6036)
1.22 (0.96, 1.56)
12F
292
3445 (2808, 4227)
855
3105 (2723, 3541)
1.11 (0.88, 1.39)
15B
284
3356 (2582, 4362)
830
2874 (2438, 3387)
1.17 (0.88, 1.56)
22F
284
3808 (2998, 4837)
835
4228 (3630, 4926)
0.90 (0.69, 1.17)
33F
266
5571 (4496, 6904)
765
5445 (4749, 6243)
1.02 (0.81, 1.30)
Note: GMT = geometric mean titer; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.
a
n = Number of subjects with a determinate OPA titer to the given serotype.
b
GMTs and 2-sided CIs were calculated by exponentiating the least squares means and the corresponding CIs based on analysis
of log-transformed OPA titers using a regression model with cohort, sex, smoking status, and baseline log transformed OPA titers.
c
GMT ratios (ratio of Cohort 2 to Cohort 1 subset) and 2-sided CIs were calculated by exponentiating the difference of least squares
means and the corresponding CIs based on the regression model described above.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Table 22, p 77.

Cohort 3 Immunobridging Analyses
PCV20 met the secondary immunogenicity objective for each of the 20 vaccine serotypes based
on comparisons of the serotype-specific OPA GMTs in subjects 18-49 years of age (Cohort 2) to
those in subjects 60-64 years of age (Cohort 1). The lower bound of the 2-sided 95% CI for the
ratio (PCV20 in Cohort 3 relative to PCV20 in Cohort 1) of the model-based OPA GMTs at 1
month post-vaccination exceeded the pre-specified non-inferiority margin of 0.5 (2-fold noninferiority margin) for each of the 20 vaccine serotypes (Table 12).

47

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 12. Comparisons of Pneumococcal Opsonophagocytic Activity GMTs 1 Month After PCV20
Vaccination in Cohort 3 (18-49 Years of Age) and Cohort 1 Subset (60-64 Years of Age), Evaluable20 Immunogenicity Population, Study B7471007
Cohort 1
Cohort 3
Cohort 3
Subset
Cohort 1 Subset
18-49 Years
60-64 Years
Comparison
18-49 Years
60-64 Years
Serotype
na
GMTb (95% CIb)
na
GMTb (95% CIb)
GMT Ratioc (95% CIc)
PCV13
1
316
163 (135, 196)
941
132 (118, 148)
1.23 (1.01, 1.50)
3
316
42 (37, 48)
935
42 (39, 46)
1.00 (0.87, 1.16)
4
315
1967 (1600, 2418)
931
595 (523, 676)
3.31 (2.65, 4.13)
5
317
108 (89, 130)
935
97 (86, 109)
1.11 (0.91, 1.36)
6A
315
3931 (3176, 4864)
921
1023 (896, 1167)
3.84 (3.06, 4.83)
6B
314
4260 (3461, 5243)
933
1250 (1102, 1418)
3.41 (2.73, 4.26)
7F
311
1873 (1564, 2242)
924
1187 (1064, 1324)
1.58 (1.30, 1.91)
9V
315
6041 (4963, 7355)
922
1727 (1529, 1950)
3.50 (2.83, 4.33)
14
316
1848 (1515, 2256)
933
773 (685, 872)
2.39 (1.93, 2.96)
18C
312
4461 (3585, 5550)
937
1395 (1221, 1595)
3.20 (2.53, 4.04)
19A
312
1415 (1182, 1694)
932
611 (548, 682)
2.31 (1.91, 2.81)
19F
315
655 (538, 797)
937
301 (267, 340)
2.17 (1.76, 2.68)
23F
315
1559 (1208, 2012)
937
325 (277, 380)
4.80 (3.65, 6.32)
Additional
8
306
867 (710, 1059)
901
508 (449, 575)
1.71 (1.38, 2.12)
10A
292
4157 (3411, 5067)
857
2570 (2274, 2904)
1.62 (1.31, 2.00)
11A
263
7169 (5736, 8961)
796
5420 (4738, 6200)
1.32 (1.04, 1.68)
12F
273
5875 (4720, 7314)
855
3075 (2698, 3504)
1.91 (1.51, 2.41)
15B
279
4601 (3488, 6069)
830
3019 (2563, 3556)
1.52 (1.13, 2.05)
22F
273
7568 (5927, 9663)
835
4483 (3863, 5202)
1.69 (1.30, 2.20)
33F
251
7977 (6342, 10034)
765
5693 (4970, 6522)
1.40 (1.10, 1.79)
Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.
a
n = Number of subjects with a determinate OPA titer to the given serotype.
b
GMTs and 2-sided CIs were calculated by exponentiating the least squares means and the corresponding CIs based on analysis
of log-transformed OPA titers using a regression model with cohort, sex, smoking status, and baseline log transformed OPA titers.
c
GMT ratios (ratio of Cohort 3 to Cohort 1 subset) and 2-sided CIs were calculated by exponentiating the difference of least squares
means and the corresponding CIs based on the regression model described above.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Table 25, p 84.

Reviewer Comment: For 19 of the 20 vaccine serotypes, adults 18-49 years of age
responded with numerically higher OPA GMTs (GMT ratios ranging from 1.1 to 4.8)
compared to adults 60-64 years of age. For serotype 3, the same OPA GMT point
estimate was achieved across the two age groups.
Descriptive Secondary Analyses (≥4-fold rise in OPA titers)
The following analyses were descriptive in nature with no hypothesis testing and no prespecified success criteria.
Cohort 1 (≥60 years of age) Descriptive Analyses
For the PCV13 serotypes, the proportion of subjects achieving a ≥4-fold rise in serotype-specific
OPA titers from pre- to 1 month after PCV20 was generally similar to or lower than the
corresponding proportion following PCV13 (Table 13). There was one exception (serotype 14),
as the proportion of subjects achieving ≥4-fold rise in anti-serotype 14 OPA antibodies was
numerically higher following PCV20 compared to PCV13.

48

Clinical Reviewer: Tina Mongeau
STN: 125731/0

For the 7 additional serotypes, the proportion of subjects achieving a ≥4-fold rise in OPA titers
from pre- to 1 month after PCV20 was generally higher than the corresponding proportion after
PPSV23, except for serotype 8 (Table 14). After PPSV23, 86.8% achieved a ≥ 4-fold rise in
OPA titers to serotype 8. After PCV20, 77.8% of subjects achieved a ≥4-fold rise in OPA titers to
serotype 8.
Cohort 2 (50-59 years of age) Descriptive Analyses
The proportions of subjects achieving a ≥4-fold rise in OPA titers from pre- to 1 month postvaccination with PCV20 were generally similar between Cohort 2 subjects (50-59 years of age)
and Cohort 1 subset subjects (60-64 years of age) (Data not shown, Table 24 of Study
B7471007 CSR).
Cohort 3 (18-49 years of age) Descriptive Analyses
The proportions of subjects achieving a ≥4-fold rise in OPA titers from pre- to 1 month postvaccination with PCV20 were generally similar between Cohort 3 subjects 18-49 years of age
and Cohort 1 subset subjects (60-64 years of age) (Data not shown, Table 27 of Study
B7471007 CSR).
Table 13. Proportion of Subjects Achieving a ≥4-Fold Rise in Opsonophagocytic Activity Titers for
the PCV13 Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1, Cohort 1,
Evaluable 13-Matched Immunogenicity Population, Study B7471007
PCV20/
PCV20/
PCV13/
PCV13/
Saline
Saline
PCV20/Saline
PPSV23
PPSV23
PCV13/PPSV23
Group
Group
Group
Group
Group
Group
Serotype
Na
nb
% (95% CIc)
Na
nb
% (95% CIc)
PCV13
1
1425
1027
72.1 (69.7, 74.4)
1418
1060
74.8 (72.4, 77.0)
3
1404
787
56.1 (53.4, 58.7)
1401
864
61.7 (59.1, 64.2)
4
1370
1035
75.5 (73.2, 77.8)
1374
1094
79.6 (77.4, 81.7)
5
1411
784
55.6 (52.9, 58.2)
1394
845
60.6 (58.0, 63.2)
6A
1382
1112
80.5 (78.3, 82.5)
1371
1152
84.0 (82.0, 85.9)
6B
1360
1029
75.7 (73.3, 77.9)
1360
1055
77.6 (75.3, 79.8)
7F
1367
981
71.8 (69.3, 74.1)
1355
979
72.3 (69.8, 74.6)
9V
1317
892
67.7 (65.1, 70.3)
1294
897
69.3 (66.7, 71.8)
14
1370
797
58.2 (55.5, 60.8)
1366
737
54.0 (51.3, 56.6)
18C
1407
1093
77.7 (75.4, 79.8)
1396
1111
79.6 (77.4, 81.7)
19A
1400
1031
73.6 (71.3, 75.9)
1379
1069
77.5 (75.2, 79.7)
19F
1405
894
63.6 (61.1, 66.2)
1397
935
66.9 (64.4, 69.4)
23F
1409
995
70.6 (68.2, 73.0)
1402
1043
74.4 (72.0, 76.7)
Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.
Note: The PCV20/saline group received PCV20 on study day 1 followed by saline 1 month later. The PCV13/PPSV23 group
received PCV13 on study 1 followed by PPSV23 1 month later.
a
n = Number of subjects with a valid and determinate assay result to the specified serotype from both before and 1 month after
vaccination blood sample collections. These values are the denominators for the percentage calculations.
b
n = Number of subjects with a ≥4-fold rise in titers from before Vaccination 1 to 1 month after Vaccination 1 for the specified
serotype.
c
Exact 2-sided CI based on the Clopper and Pearson method.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Table 20, p 73.

49

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 14. Proportion of Subjects Achieving a ≥4-Fold Rise in Opsonophagocytic Activity Titers for
the 7 Additional Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1, Cohort 1,
Evaluable 7-Additional Immunogenicity Population, Study B7471007
PCV20/ PCV20/
PCV13/
PCV13/
Saline
Saline
PCV20/ Saline
PPSV23
PPSV23 PCV13/ PPSV23
Group
Group
Group
Group
Group
Group
Serotype
Na
nb
% (95% CIc)
Na
nb
% (95% CIc)
8
1353
1053
77.8 (75.5, 80.0)
1293
1122
86.8 (84.8, 88.6)
10A
1208
912
75.5 (73.0, 77.9)
1164
764
65.6 (62.8, 68.4)
11A
973
576
59.2 (56.0, 62.3)
993
515
51.9 (48.7, 55.0)
12F
1226
1072
87.4 (85.5, 89.2)
1147
924
80.6 (78.1, 82.8)
15B
1228
955
77.8 (75.3, 80.1)
1178
752
63.8 (61.0, 66.6)
22F
1178
974
82.7 (80.4, 84.8)
1156
888
76.8 (74.3, 79.2)
33F
1020
613
60.1 (57.0, 63.1)
1080
599
55.5 (52.4, 58.5)
Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.
Note: For the PCV20/saline group, fold rise is calculated using assay results from before Vaccination 1 to 1 month after Vaccination
1; for subjects in the PCV13/PPSV23 group, fold rise is calculated using assay results from before Vaccination 1 to 1 month after
Vaccination 2.
Note: The PCV20/saline group received PCV20 on study day 1 followed by saline 1 month later. The PCV13/PPSV23 group
received PCV13 on study 1 followed by PPSV23 1 month later.
a
N = number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after
vaccination blood sample collections. These values are the denominators for the percentage calculations.
b
n = Number of subjects with a ≥4-fold rise in titers from before Vaccination 1 to 1 month after vaccination for the specified
serotype.
c
Exact 2-sided CI based on the Clopper and Pearson method.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007 Clinical Study Report. Table 21, p 74.

Reviewer Comment: While serotype-specific OPA titers < LLOQ were replaced with
0.5xLLOQ for determination of the 4-fold rise calculations, CBER conducted additional
analyses using LLOQ to replace titers < LLOQ in the calculation of 4-fold rise (i.e.,
4xLLOQ). The results of these additional analyses were generally consistent with the
original analyses.
The proportions of participants achieving a ≥4-fold rise in OPA titers from before vaccination to
1 month after PCV20 were generally similar between Cohort 2 and Cohort 1 subset subjects
(60-64 years of age) (Data not shown, CSR Table 24).
The proportions of participants achieving a ≥4-fold rise in OPA titers from before vaccination to
1 month after PCV20 were generally higher in Cohort 3 than in Cohort 1 for the 13 original
serotypes (ranging from 56.7% for serotype 3 to 91.4% for serotype 4 in Cohort 3 participants)
(Data not shown, CSR Table 27). For 6 of the 7 new serotypes, the proportions of subjects
achieving a ≥4-fold rise in OPA titers from before vaccination to 1 month after PCV20 in Cohort
3 were similar to those in Cohort 1. For serotype 11A, the proportion was higher among Cohort
3 subjects (60.4%) than among Cohort 1 subjects (47.3%) (Data not shown, CSR Table 27).
Reviewer Comment: Among all study cohorts, ≥72% of subjects in both study groups
achieved OPA titers ≥ LLOQ for each of the vaccine serotypes assessed, supporting the
acceptability of the serotype-specific OPA assays. These data were provided in the
following tables within the CSR: 14.25 (p366), 14.26 (p368), 14.38 (p387), 14.43 (p398),
14.52 (p419), 14.53 (p422), 14.58 (p432).

50

Clinical Reviewer: Tina Mongeau
STN: 125731/0

The CBER statistical reviewer determined that the differences in the proportions of
Cohort 1 subjects who achieved OPA titers ≥ LLOQ one month after PCV20 relative to
one month after the active control (PCV13 for the 13 original serotypes and PPSV23 for
the 7 new serotypes) would be expected to be greater than -10% (a commonly accepted
margin of noninferiority).
6.1.11.3 Subpopulation Analyses
Descriptive subgroup analyses of the primary immunogenicity endpoint (OPA GMTs) for the
primary and secondary objective were provided based on age, sex, race, and country
subgroups. Since <6% of the study population comprised the “All Others” racial group (i.e.,
Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiracial
or not reported), this review focuses on results pertaining to White and Black subjects.
Subpopulation Analyses by Age
In subgroup analyses of Cohort 1 by age (60-64, 65-69 70-79, ≥80 years), OPA GMTs generally
decreased with increasing age in each of the immunogenicity analysis populations (evaluable13, evaluable-7, and evaluable-20 populations) (Data not shown, CSR Tables 14.72, 14.76).
Among PCV20 recipients, the OPA GMTs of subjects 70-79 years of age and ≥80 years of age
were generally lower than those of younger subjects (18-49, 50-59 and 60-64 years) for all
pneumococcal serotypes.
OPA GMTs also decreased with increasing age among PCV20 recipients across the age-based
cohorts of subjects 18-49 years, 50-59 years and ≥60 years (see Tables 11 and 12).
Subpopulation Analyses by Sex
In Cohorts 1 and 2, serotype-specific OPA GMTs for the 20 vaccine serotypes were generally
higher among females compared to males in each of the immunogenicity analysis populations
(evaluable-13, evaluable-7, and evaluabe-20 populations) (Data not shown, CSR Tables 14.70,
14.74, and 14.109). In Cohort 3 (18-49 years), OPA GMTs appeared similar with between
females and males (evaluable-20 population) (Data not shown, CSR Table 14.113).
Reviewer Comment: The statistical reviewer confirmed that his analysis of OPA GMT
ratios by sex would not result in different outcomes in males versus females with regards
to the primary or secondary study objectives.
Although the biologic basis for numerically higher immune responses post-vaccination
among females compared to males in Cohorts 1 and 2 is unclear, hormonal and genetic
differences between the sexes are possible contributing factors (Fathi et al. 2021;
Fischinger et al. 2019).
In the adult PCV13 immunogenicity trials supporting accelerated approval, females
generally achieved higher serotype-specific OPA GMTs compared to males in one
Phase 3 study. However, in the subsequent confirmatory study, vaccine efficacy by sex
was not consistent across the primary and secondary study objectives. Vaccine efficacy
against vaccine-type IPD (secondary endpoint) was statistically significant among
women but not men in study 6115A1-3006. However, vaccine efficacy against VT-CAP
(primary endpoint) was similar between males and females, and vaccine efficacy against
vaccine-type non-bacteremic CAP (a secondary endpoint) was statistically significant
among males but not females.

51

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Subpopulation Analyses by Race (White, Black and “All Others”)
In Cohort 1, serotype-specific OPA GMTs for the 20 vaccine serotypes generally appeared
similar between White and Black racial subgroups in Cohort 1 (evaluable-13 and evaluable 7
immunogenicity populations) (Data not shown, CSR, Tables 14.71, 14.75). No clear trends were
observed in these Cohort 1 racial subgroups. In Cohorts 2 and 3, serotype-specific OPA GMTs
for the 20 vaccine serotypes were generally lower among Black subjects compared to White
subjects (evaluable-20 population) (Data not shown, CSR Tables 14.110 and 14.114).
Subpopulation Analyses by Country
Serotype-specific OPA GMTs for the 20 vaccine serotypes were generally similar between
country subgroups, although lower GMTs were achieved in Sweden compared to the U.S. for
several serotypes (Data not shown, CSR Tables 14.73, 14.77). The sample size of subjects
enrolled in Sweden was small relative to the number of subjects enrolled in the U.S. (<5% of the
total study population), which resulted in wider confidence intervals. This subgroup analysis was
limited to adults ≥65 years of age in Cohort 1, because only subjects in this age group were
enrolled in Sweden.
6.1.11.4 Dropouts and/or Discontinuations
Please see Section 6.1.10.1.3 for information on subject disposition, including withdrawals.
Missing values were not imputed for subject who had missing blood draws.
6.1.11.5 Exploratory and Post Hoc Analyses
In exploratory analyses conducted in random subsets of subjects, PCV20 elicited functional
OPA antibody responses to serotype 15C in each study cohort based on OPA GMTs and the
proportion of subjects achieving a ≥4-fold rise in OPA titers (Data not shown, CSR Tables 32,
34, and 29-31).
•

•

The serotype 15C OPA GMT at 1 month after PCV13 was 40.6 11 (95% CI 38.2,
43.2) in Cohort 1 (N=211) and at 1 month after PCV20 was:
− 118 (95% CI 96, 146), in Cohort 1 (N=205);
− 104 (95% CI (82, 130) in Cohort 2 (N=153); and
− 139 (95% CI 107, 180) in Cohort 3 (N=144).
The proportion of subjects achieving a ≥4-fold rise in 15C OPA titers from pre- to
1 month post-PCV13 was 1.9% (95% CI 0.5, 4.8) and from pre-to 1 month postPCV20 was:
− 34.8% (95% CI 28.3, 41.8) in Cohort 1 (N=204);
− 33.3% (95% CI 25.9, 41.5) in Cohort 2 (N=150); and
− 37.3% (95% CI 29.4, 45.8) in Cohort 3 (N=142).

Reviewer Comment: Although PCV20 vaccine elicits functional antibodies to nonvaccine serotype 15C, results from this exploratory analysis are not adequate to support
definitive conclusions about effectiveness of PCV20 to prevent serotype 15C IPD or
pneumonia due to cross-protection.

11

This is below the 15C assay LLOQ.

52

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.1.12 Safety Analyses
6.1.12.1 Methods
Safety analyses were descriptive. Please see Section 6.1.7 for details regarding safety
surveillance/monitoring, Section 6.1.1 for a listing of safety endpoints, and Section 6.1.9 for
details regarding the safety analysis population.
For solicited local and systemic adverse reactions, if any data were reported for local reactions
within 10 days after vaccination or systemic reactions within 7 days after vaccination, then the ediary was considered transmitted. Daily transmission of e-diary data during the entire e-diary
collection period was ≥91.5% for each day in Cohort 1, ≥88.3% for each day in Cohort 2, and
≥85.1% for each day in Cohort 3 (Data not shown, CSR Tables 13-15). These daily e-diary
transmission rates in Cohorts 1, 2 and 3 were similar in the PCV20 and PCV13 study groups
each day. However, in Cohort 3, transmission rates on days 5, 7, 8 and 9 were lower in the
PCV20 group (86.0%-89.3%) compared to the PCV13 group (92.0%-93.8%). Transmission
rates for all 10 days was 71%-72% in Cohort 1 and 70%-72% in Cohort 2; these rates were
similar in the two study groups. The transmission rate for all 10 days was lower in the PCV20
group (49.0%) than the PCV13 group (65.2%).
Reviewer Comment: Although there was a lower transmission rate for all 10 days postvaccination among PCV20 recipients in Cohort 3, the daily transmission rates were
generally similar between the PCV20 and PCV13 study groups. Therefore, e-diary data
were considered adequate to assess reactogenicity in each study cohort.
6.1.12.2 Overview of Adverse Events
Solicited Local Injection Site Adverse Reactions
The proportions of subjects within each study cohort reporting solicited local injection site
reactions within 10 days after Vaccination 1 by maximum severity were similar between the two
study groups (Tables 15-17). The most frequently reported local adverse reaction was injection
site pain (55.4%, 72.5%, 81.2% among PCV20 recipients in Cohorts 1, 2, and 3 respectively).
Most local reactions were mild or moderate in severity. Rates of solicited local injection site
reactions were highest in the oldest cohort (Cohort 1) and lowest in the youngest cohort (Cohort
3).
Within each study cohort, the mean day of onset and mean duration of solicited local reactions
were also similar across the two study groups after Vaccination 1 (Data not shown, CSR Tables
14.121-14.126). The mean day of onset of these local reactions across study cohorts was
between Days 1-2 (SD ~1 day) to Days 2.5-3.5 (SD ~1-2 days) (Day 1 = day of vaccination).
The mean duration of these local reactions across study cohorts was between 2 days (SD ~2
days) to 3 days (SD ~1.5-2.5 days).

53

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 15. Local Reactions, by Maximum Severity, Within 10 Days After
Vaccination 1, Cohort 1 (≥60 years), Safety Population, Study B7471007
PCV20/Saline Group
PCV13/PPSV23 Group
Na=1505
Na=1483
Local Reaction
nb (%)
nb (%)
Any local reactionc
864 (57.4)
830 (56.0)
Pain at injection sited
Any
834 (55.4)
803 (54.1)
Mild
682 (45.3)
662 (44.6)
Moderate
149 (9.9)
136 (9.2)
Severe
3 (0.2)
5 (0.3)
Swellinge
Any (>2.0 cm)
113 (7.5)
118 (8.0)
Mild
72 (4.8)
72 (4.9)
Moderate
36 (2.4)
42 (2.8)
Severe
5 (0.3)
4 (0.3)
Rednesse
Any (>2.0 cm)
110 (7.3)
92 (6.2)
Mild
56 (3.7)
56 (3.8)
Moderate
42 (2.8)
33 (2.2)
Severe
12 (0.8)
3 (0.2)
a
N = number of subjects with any e-diary data reported after Vaccination 1. This value is the
denominator for the percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
Any local reaction = any pain at injection site, any swelling >2.0 cm, or any redness >2.0 cm during
Day 1 to Day 10 after Vaccination 1.
d
Absent: none; Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents
daily activity. Prevention of daily activity may include missed days of work or school or other
incapacitation and includes use of narcotics for analgesia. Any = mild, moderate or severe.
e
Absent: 0 to ≤2.0; Mild: >2.0 to 5.0 cm; Moderate: >5.0 to 10.0 cm; Severe: >10.0 cm. Any = mild,
moderate or severe.
Note: There were no Grade 4 injection site reactions reported in this study. Grade 4 erythema and
Grade 4 edema were defined as necrosis or exfoliative dermatitis. Grade 4 injection site pain was
defined as an ER visit or hospitalization.
Source: STN 125731/0.1 module 5.3.5.1, B7471007 Clinical Study Report. Table 35, p 104.

Table 16. Local Reactions, by Maximum Severity, Within 10 Days After
Vaccination, Cohort 2 (50-59 Years), Safety Population, Study B7471007
PCV20 Group
PCV13 Group
Na=331
Na=111
b
Local Reaction
n (%)
nb (%)
c
Any local reaction
241 (72.8)
78 (70.3)
Pain at injection sited
Any
240 (72.5)
77 (69.4)
Mild
177 (53.5)
58 (52.3)
Moderate
59 (17.8)
18 (16.2)
Severe
4 (1.2)
1 (0.9)
Swellinge
Any (>2.0 cm)
29 (8.8)
12 (10.8)
Mild
19 (5.7)
8 (7.2)
Moderate
10 (3.0)
4 (3.6)
Severe
0 (0.0)
0 (0.0)

54

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Local Reaction
Rednesse
Any (>2.0 cm)
Mild
Moderate
Severe

PCV20 Group
Na=331
nb (%)

PCV13 Group
Na=111
nb (%)

27 (8.2)
17 (5.1)
9 (2.7)
1 (0.3)

6 (5.4)
3 (2.7)
3 (2.7)
0 (0.0)

a
N = number of subjects with any e-diary data reported after Vaccination. This value is the
denominator for the percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
Any local reaction = any pain at injection site, any swelling >2.0 cm, or any redness >2.0 cm during
Day 1 to Day 10 after Vaccination 1.
d
Absent: none; Mild: does not interfere with activity; Moderate: interferes with activity; Severe:
prevents daily activity. Prevention of daily activity may include missed days of work or school or other
incapacitation and includes use of narcotics for analgesia. Any = mild, moderate or severe.
e
Absent: 0 to ≤2.0; Mild: >2.0 to 5.0 cm; Moderate: >5.0 to 10.0 cm; Severe: >10.0 cm. Any = mild,
moderate or severe.
Note: There were no Grade 4 injection site reactions reported in this study. Grade 4 erythema and
Grade 4 edema were defined as necrosis or exfoliative dermatitis. Grade 4 injection site pain was
defined as an ER visit or hospitalization.
Source: STN 125731/0.1 module 5.3.5.1, B7471007 Clinical Study Report. Table 36, p 105.

Table 17. Local Reactions, by Maximum Severity, Within 10 Days After
Vaccination, Cohort 3 (18-49 Years), Safety Population, Study B7471007
PCV20 Group
PCV13 Group
Na=335
Na=112
b
Local Reaction
n (%)
nb (%)
c
Any local reaction
272 (81.2)
92 (82.1)
Pain at Injection Sited
Any
272 (81.2)
92 (82.1)
Mild
143 (42.7)
59 (52.7)
Moderate
128 (38.2)
32 (28.6)
Severe
1 (0.3)
1 (0.9)
Swellinge
Any (>2.0 cm)
39 (11.6)
14 (12.5)
Mild
24 (7.2)
10 (8.9)
Moderate
15 (4.5)
4 (3.6)
Severe
0 (0.0)
0 (0.0)
Rednesse
Any (>2.0 cm)
30 (9.0)
11 (9.8)
Mild
10 (3.0)
6 (5.4)
Moderate
18 (5.4)
5 (4.5)
Severe
2 (0.6)
0 (0.0)
a
N = number of subjects with any e-diary data reported after Vaccination. This value is the
denominator for the percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
Any local reaction = any pain at injection site, any swelling >2.0 cm, or any redness >2.0 cm during
Day 1 to Day 10 after Vaccination 1.
d
Absent: none; Mild: does not interfere with activity; Moderate: interferes with activity; Severe:
prevents daily activity. Prevention of daily activity may include missed days of work or school or other
incapacitation and includes use of narcotics for analgesia. Any = mild, moderate or severe.
e
Absent: 0 to ≤2.0; Mild: >2.0 to 5.0 cm; Moderate: >5.0 to 10.0 cm; Severe: >10.0 cm. Any = mild,
moderate or severe.
Note: There were no Grade 4 injection site reactions reported in this study. Grade 4 erythema and
Grade 4 edema were defined as necrosis or exfoliative dermatitis. Grade 4 injection site pain was
defined as an ER visit or hospitalization.
Source: STN 125731/0.1 module 5.3.5.1, B7471007 Clinical Study Report. Table 37, p 106-107.

55

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Solicited Systemic Adverse Reactions
The proportions of subjects within each study cohort reporting solicited systemic adverse
reactions within 10 days after Vaccination 1 by maximum severity were similar between the two
study groups (Tables 18-20). The most frequently reported systemic adverse reaction was
muscle pain (39.1%, 49.8%, and 66.6% among PCV20 recipients in Cohorts 1, 2, and 3
respectively). Most systemic adverse reactions were mild or moderate in severity. Rates of
solicited systemic reactions were highest among the older cohort (Cohort 1) and lowest in the
youngest cohort (Cohort 3).
Within each study cohort, the mean day of onset and mean duration of solicited systemic
adverse reactions were also similar across the two study groups after Vaccination 1 (Data not
shown, CSR Tables 14.34 - 14.35 and 14.37 - 14.40). The mean day of onset of these systemic
reactions across study cohorts was between Day 1.5 (SD ~1 day) and Days 3-4 (SD ~2 days)
(Day 1 = day of vaccination). The mean duration of these reactions across study cohorts was
between 1-2 days (SD ~0-2 days) and 3.5-4.0 days (SD ~3-6 days).
Table 18. Systemic Adverse Reactions, by Maximum Severity, Within 7 Days After
Vaccination 1, Cohort 1 (≥60 Years), Safety Population, Study B7471007
PCV20/Saline Group
PCV13/PPSV23 Group
Na=1505
Na=1483
b
Local Reaction
n (%)
nb (%)
c
Any Systemic Adverse Reaction
831 (55.2)
822 (55.4)
Muscle Paind
Any
588 (39.1)
533 (37.3)
Mild
435 (28.9)
398 (26.8)
Moderate
147 (9.8)
148 (10.0)
Severe
6 (0.4)
7 (0.5)
Fatigued
Any
454 (30.2)
455 (30.7)
Mild
243 (16.1)
260 (17.5)
Moderate
193 (12.8)
177 (11.9)
Severe
18 (1.2)
18 (1.2)
Headached
Any
324 (21.5)
345 (23.3)
Mild
233 (15.5)
252 (17.0)
Moderate
81 (5.4)
88 (5.9)
Severe
10 (0.7)
5 (0.3)
Joint Paind
Any
190 (12.6)
203 (13.7)
Mild
104 (6.9)
106 (7.1)
Moderate
81 (5.4)
94 (6.3)
Severe
5 (0.3)
3 (0.2)

56

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Local Reaction
Fever
≥38.0°C
≥38.0°C to 38.4°C
>38.4°C to 38.9°C
>38.9°C to 40.0°C
>40.0°C
Use of antipyretic or pain medicatione

PCV20/Saline Group
Na=1505
nb (%)

PCV13/PPSV23 Group
Na=1483
nb (%)

14 (0.9)
4 (0.3)
4 (0.3)
1 (0.0)
5 (0.3)
278 (18.5)

12 (0.8)
6 (0.4)
3 (0.2)
0 (0.0)
3 (0.2)
303 (20.4)

a
N = number of subjects with any e-diary data reported after Vaccination 1. This value is the denominator for the
percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
Any systemic event = any fever ≥38.0°C, any fatigue, any headache, any joint pain, or any muscle pain during Day 1 to
Day 7 after vaccination.
d
Mild = does not interfere with activity, moderate = interferes with activity, severe = prevents daily activity. Prevention of
daily activity may include missed days of work or school or other incapacitation and includes use of narcotics for
analgesia. Any = mild, moderate or severe.
e
Use of antipyretic or pain medication was recorded as “yes” or “no.”
Note: There were no Grade 4 solicited reactions reported in this cohort other than fever. Grade 4 reactions were defined
as an ER visit or hospitalization. Grade 4 fever was defined as a temperature >40.0oC.
Note: Twelve subjects in Cohort 1 (5 in the PCV20/saline group and 7 in the PCV13/PPSV23 group) were confirmed by
the study site to have entered Grade 4 fever in error and were excluded from Table 18. These subjects confirmed that
they experienced no reaction or fever of any severity at the specified timepoints.
Source: STN 125731/0.1 module 5.3.5.1, B7471007 Clinical Study Report. Table 38, p 108-109.

Table 19. Systemic Adverse Reactions, by Maximum Severity, Within 7 Days After
Vaccination 1, Cohort 2 (50-59 Years), Safety Population, Study B7471007
PCV20/Saline Group
PCV13/PPSV23 Group
Na=331
Na=111
b
Local Reaction
n (%)
nb (%)
c
Any Systemic Adverse Reaction
230 (69.5)
75 (67.6)
Muscle Paind
Any
165 (49.8)
55 (49.5)
Mild
112 (33.8)
35 (31.5)
Moderate
51 (15.4)
19 (17.1)
Severe
2 (0.6)
1 (0.9)
Fatigued
Any
130 (39.3)
40 (36.0)
Mild
70 (21.1)
20 (18.0)
Moderate
57 (17.2)
17 (15.3)
Severe
3 (0.9)
3 (2.7)
Headached
Any
107 (32.3)
40 (36.0)
Mild
68 (20.5)
24 (21.6)
Moderate
36 (10.9)
15 (13.5)
Severe
3 (0.9)
1 (0.9)
Joint Paind
Any
51 (15.4)
23 (20.7)
Mild
35 (10.6)
14 (12.6)
Moderate
16 (4.8)
8 (7.2)
Severe
0 (0.0)
1 (0.9)
Fever
≥38.0°C
5 (1.5)
1 (0.9)
≥38.0°C to 38.4°C
2 (0.6)
1 (0.9)
>38.4°C to 38.9°C
1 (0.3)
0 (0.0)
>38.9°C to 40.0°C
1 (0.3)
0 (0.0)
>40.0°C
1 (0.3)
0 (0.0)

57

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Local Reaction
Use of antipyretic or pain medicatione

PCV20/Saline Group
Na=331
nb (%)
81 (24.5)

PCV13/PPSV23 Group
Na=111
nb (%)
31 (27.9)

a
N = number of subjects with any e-diary data reported after Vaccination 1. This value is the denominator for the
percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
Any systemic event = any fever ≥38.0°C, any fatigue, any headache, any joint pain, or any muscle pain during Day 1 to
Day 7 after vaccination.
d
Mild = does not interfere with activity, moderate = interferes with activity, severe = prevents daily activity. Prevention of
daily activity may include missed days of work or school or other incapacitation and includes use of narcotics for
analgesia. Any = mild, moderate or severe.
e
Use of antipyretic or pain medication was recorded as “yes” or “no.”
Note: There were no Grade 4 solicited reactions reported in this cohort other than fever. Grade 4 reactions were defined
as an ER visit or hospitalization. Grade 4 fever was defined as a temperature >40.0°C.
Source: STN 125731/0.1 module 5.3.5.1, B7471007 Clinical Study Report. Table 39, p 110.

Table 20. Systemic Adverse Reactions, by Maximum Severity, Within 7 Days After
Vaccination 1, Cohort 3 (18-49 Years), Safety Population, Study B7471007
PCV20/Saline Group
PCV13/PPSV23 Group
Na =335
Na=112
b
Local Reaction
n (%)
nb (%)
c
Any Systemic Adverse Reaction
266 (79.4)
93 (83.0)
Muscle Paind
Any
223 (66.6)
83 (74.1)
Mild
122 (36.4)
47 (42.0)
Moderate
97 (29.0)
35 (31.3)
Severe
4 (1.2)
1 (0.9)
Fatigued
Any
143 (42.7)
49 (43.8)
Mild
63 (18.8)
23 (20.5)
Moderate
74 (22.1)
22 (19.6)
Severe
6 (1.8)
4 (3.6)
Headached
Any
130 (38.8)
38 (33.9)
Mild
72 (21.5)
18 (16.1)
Moderate
49 (14.6)
19 (17.0)
Severe
9 (2.7)
1 (0.9)
Joint Paind
Any
45 (13.4)
20 (17.9)
Mild
21 (6.3)
10 (8.9)
Moderate
24 (7.2)
9 (8.0)
Severe
0 (0.0)
1 (0.9)
Fever
≥38.0°C
4 (1.2)
2 (1.8)
≥38.0°C to 38.4°C
2 (0.6)
0 (0.0)
>38.4°C to 38.9°C
1 (0.3)
0 (0.0)
>38.9°C to 40.0°C
1 (0.3)
2 (1.8)
>40.0°C
0 (0.0)
0 (0.0)

58

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Local Reaction
Use of antipyretic or pain medicatione

PCV20/Saline Group
Na =335
nb (%)
86 (25.7)

PCV13/PPSV23 Group
Na=112
nb (%)
26 (23.2)

a
N = number of subjects with any e-diary data reported after Vaccination 1. This value is the denominator for the
percentage calculations.
b
n = Number of subjects with the specified characteristic.
c
Any systemic event = any fever ≥38.0°C, any fatigue, any headache, any joint pain, or any muscle pain during Day 1 to
Day 7 after vaccination.
d
Mild = does not interfere with activity, moderate = interferes with activity, severe = prevents daily activity. Prevention of
daily activity may include missed days of work or school or other incapacitation and includes use of narcotics for
analgesia. Any = mild, moderate or severe.
e
Use of antipyretic or pain medication was recorded as “yes” or “no.”
Note: There were no Grade 4 solicited reactions reported in this cohort. Grade 4 reactions were defined as an ER visit or
hospitalization. Grade 4 fever was defined as a temperature >40.0oC.
Note: Two subjects in Cohort 3 (both in the PCV20/saline group) were confirmed by the study site to have entered Grade
4 fever in error and were excluded from Table 20. These subjects confirmed that they experienced no reaction or fever of
any severity at the specified timepoints.
Source: STN 125731/0.1 module 5.3.5.1, B7471007 Clinical Study Report. Table 40, p 112.

Unsolicited Adverse Events (AEs) Reported Through 30 Days Post-Vaccination
Cohort 1 Safety Population
In the Cohort 1 safety population, a similar and low proportion of subjects in the PCV20/saline
group (9.8%) and the PCV13/PPSV23 group (11.1%) reported at least one unsolicited AE within
1 month after Vaccination 1 (Data not shown, Table 14.149). Most unsolicited AEs were mild or
moderate in severity. Severe AEs were reported by 12 subjects (0.8%) in each of the two study
groups within the Cohort 1 safety population (Data not shown, CSR Table 14.159). Among
Cohort 1 subjects, the most frequently reported unsolicited AEs after Vaccination 1 occurring in
a higher proportion of PCV20 recipients compared to PCV13 recipients are as follows:
•
•
•
•

upper respiratory tract infection (0.8% after PCV20, 0.5% after PCV13);
arthralgia (0.4% after PCV20, 0.1% after PCV13);
bronchitis (0.3% after PCV20, 0.2% after PCV13); and
viral infection (0.3% after PCV20, 0% after PCV13).

There was a minor imbalance in the rates of subjects reporting Preferred Terms within the
System Organ Class (SOC) of Cardiac disorders through 1 month after Vaccination 1, with 7
subjects (0.46%) in the PCV20/saline group and 2 subjects (0.13%) in the PCV13/PPSV23
group reporting AEs including coronary artery disease, atrial fibrillation, bradycardia,
palpitations, and myocardial infarction. In the PCV20/saline group, 7 subjects reported one or
more of the following cardiac events: atrial fibrillation (n=2), bradycardia (n=1), coronary artery
disease (n=3), myocardial infarction (n=1), and palpitations (n=1). In the PCV13/PPSV23, the
following cardiac events were reported by one subject each: palpitations and silent myocardial
infarction.
Cohort 2 Safety Population
In the Cohort 2 safety population, a similar and low proportion of subjects in the PCV20 group
(10.2%) and PCV13 group (8.1%) reported at least 1 unsolicited AE within 1 month after
Vaccination (Data not shown, CSR, Table 14.152). Severe AEs were reported by 2 subjects
(0.6%) in the PCV20 group and 1 subject (0.9%) in the PCV13 group (Data not shown, CSR
Table 14.161). Unsolicited AEs reported most frequently after vaccination in a higher proportion
of PCV20 recipients compared to PCV13 recipients in Cohort 2 are as follows:
•
•

fall (1.2% after PCV20, 0% after PCV13);
bronchitis (0.9% after PCV20, 0% after PCV13);
59

Clinical Reviewer: Tina Mongeau
STN: 125731/0

•
•
•

nasopharyngitis (0.6% after PCV20, 0% after PCV13);
arthralgia (0.6% after PCV20, 0% after PCV13); and
nephrolithiasis (0.6% after PCV20, 0% after PCV13).

There were no Preferred Terms reported for the SOC Cardiac disorders in Cohort 2.
Cohort 3 Safety Population
In the Cohort 3 safety population, a similar proportion of subjects in the PCV20 group (15.2%)
and PCV13 group (11.6%) reported at least 1 unsolicited AE within 1 month after vaccination
(Data not shown, CSR, Table 14.153). Severe AEs were reported by 5 subjects (1.5%) in the
PCV20 group and 2 subjects (1.8%) in the PCV13 group (Data not shown, CSR Table 14.162).
The unsolicited AEs reported most frequently after vaccination in a higher proportion of PCV20
recipients compared to PCV13 recipients in Cohort 3 are as follows:
•
•
•
•
•
•
•

upper respiratory tract infection (2.1% after PCV20, 0.9% after PCV13);
influenza (2.1% after PCV20, 0.9% after PCV13);
pharyngitis streptococcal (0.6% after PCV20, 0% after PCV13);
cough (0.6% after PCV20, 0% after PCV13);
nasal congestion (0.6% after PCV20, 0% after PCV13);
respiratory disorder (0.6% after PCV20, 0% after PCV13); and
pain in extremity (0.6% after PCV20, 0% after PCV13).

One subject (0.3%) in the PCV20 group was reported to have an acute myocardial infarction
and coronary artery disease.
Newly Diagnosed Chronic Medical Conditions (Section 12.5.4 page 128)
Within Cohort 1, a similar proportion of subjects in the PCV20/saline group (2.3%) and the
PCV13/PPSV23 group (2.3%) reported a newly diagnosed chronic medical condition (NDCMC)
within 6 months post-vaccination (Data not shown, CSR Table 14.176). Overall, NDCMCs were
most frequently reported within the SOC Musculoskeletal and connective tissue disorders.
Three subjects (0.2%) in the PCV20/saline group and 1 subject in the PCV13/PPSV23 group
reported NDCMCs within the SOC Cardiac disorders.
Within Cohort 2, 5 subjects (1.5%) in the PCV20 group and 1 subject (0.9%) in the PCV13
reported a NDCMC (Data not shown, CSR Table 14.178). NDCMCs in the PCV20 group were
classified as type 2 diabetes mellitus (n=2), hypertension (n=2), and peripheral venous disease
(n=1). NDCMCs in the PCV13 group were classified as type 2 diabetes mellitus (n=1).
Within Cohort 3, 5 subjects (1.5%) in the PCV20 group and 2 subjects (1.8%) in the PCV13
group reported a NDCMC (Data not shown, CSR Table 14.180). NDCMCs in the PCV20 group
were classified as coronary artery disease, type 2 diabetes mellitus, rheumatoid arthritis, breast
cancer, and migraine; in the PCV13 group, NDCMCs were classified as diabetic retinopathy,
type 2 diabetes mellitus, and headache.
Immediate Adverse Reactions (Data not shown, Tables 14.155, 14.157, 14.158)
Within 30 minutes after Vaccination 1, three Cohort 1 subjects (0.2%) in each study group
reported adverse reactions. These included injection site pain and swelling, joint swelling,
musculoskeletal stiffness, and somnolence. In the Cohort 2 and Cohort 3 safety populations, 1
subject in each cohort experienced an adverse reaction (headache and dizziness, respectively)
in the 30 minutes immediately following vaccination.
60

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Other Significant Adverse Events
Two Cohort 3 participants (18-49 years of age) who had documented negative urine pregnancy
tests at enrollment became pregnant during the study. The pregnancies were reported 71 and
116 days after vaccination with PCV20. Both participants gave birth to healthy male infants at
39 weeks of gestation with no reported pregnancy complications.
Safety Analyses by Subgroups
Since <6% of the study population were included in “All Others” racial groups (i.e., Asian,
American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, Multiracial or not
reported), this review focuses on results pertaining to White and Black subjects.
Subgroup Analyses by Age (Cohort 1 Only)
There was a general trend toward decreased rates of injection site reactions with age (Data not
shown, CSR Table 14.129). With the exception of fever, rates of systemic adverse reactions
(including use of antipyretic or pain medication) decreased with increasing age; the fever rate
was highest in adults ≥80 years) (Data not shown, CSR Table 14.144).
Subgroup Analyses by Sex
•

Local reactions: In Cohort 1, prompted local injection site reactions within 7 days
after Vaccination 1 (Data not shown, CSR Table 14.127) were generally reported
by a higher proportion of females in Cohort 1 compared to males. In Cohorts 2
and 3, the proportions of females and males reporting prompted local injection
site reactions after Vaccination 1 were generally similar (Data not shown, CSR,
Tables 14.130 and 14.132).

•

Systemic reactions: In Cohort 1, prompted systemic reactions and antipyretic or
pain medication use within 10 days after Vaccination 1 were generally reported by
a higher proportion of females compared to males (Data not shown, CSR Table
14.142) In Cohorts 2 and 3, a higher proportion of females generally reported
fatigue, headache, muscle pain (cohort 2 only) and use of antipyretic or pain
medication after Vaccination 1, whereas the proportions of females and males
reporting other prompted systemic events (muscle pain (Cohort 3 only), joint pain
and fever) were generally similar (Data not shown, CSR Tables 14.145 and
14.147).

Reviewer Comment: Although the biologic basis for the noted higher rates of
reactogenicity among females compared to males is unclear, these findings are
consistent with the literature on differences between males and females with respect to
reactogenicity following preventive vaccines (Klein and Pekosz 2014).
Subgroup Analyses by Race (White, Black, and “All Others”)
•

In Cohort 1, a numerically lower proportion of Black subjects reported injection
site redness and pain compared to White subjects (rates of swelling were similar)
(Data not shown, CSR Table 14.128). In Cohort 2, a numerically lower proportion
of Black subjects reported injection site pain compared to White subjects (Data
not shown, CSR Table 14.131). In Cohort 3, a numerically lower proportion of
Black reported prompted local injection site reactions compared to White subjects
(Data not shown, CSR Table 14.133).

61

Clinical Reviewer: Tina Mongeau
STN: 125731/0

•

There were no clear trends in the rates of solicited adverse reactions reported
among subjects by race (Data not shown, CSR Tables 14.143, 14.146, 14.148).

Similar trends as described above were generally observed in analyses of unsolicited AEs by
age, sex and race.
Reviewer Comment: This study was conducted in the U.S. and Sweden. Subgroup
analyses were not provided by country. Since less than 0.5% of the total study
population was enrolled in Sweden (172/3902), CBER did not consider such subgroup
analyses by country would have been helpful.
6.1.12.3 Deaths
There was one death in this study in a Cohort 1 PCV20/saline recipient aged 60 years with a
medical history of suicide attempts resulting in hospitalization (1974, 1985, and 2006) and
depression since 2006. The subject’s death was due to a self-inflicted gunshot wound to the
head 48 days after receipt of Vaccination 2 (saline). This death was not considered related to
the investigational product.
6.1.12.4 Nonfatal Serious Adverse Events
Overall, there were no serious adverse events (SAEs) that were considered by the investigator
to be related to the study vaccine.
The proportions of subjects in the Cohort 1 safety population reporting at least 1 serious
adverse event (SAE) within 6 months post-Vaccination 1 were similar in the PCV20/saline group
(2.4% (36/1507)) and in the PCV13/PPSV23 group (1.9% (29/1490)) (Data not shown, CSR
Table 46). There were no meaningful imbalances in rates of SAEs based on reported preferred
terms (PTs) or systemic organ classes (SOCs), including no imbalance overall in cardiovascular
serious adverse events. No SAEs were considered by the study investigator to be related to the
study vaccination.
Within 1 month after Vaccination 1, 0.5% of subjects in each of the study group of the Cohort 1
safety population reported at least 1 SAE (Data not shown, CSR Table 14.170). No consistent
imbalances were noted in the rates of subjects reporting individual Preferred Terms within the
SOC Cardiac disorders or in the overall rates of all reported PTs within Cardiac disorders at 1
month post-Vaccination 1 (Data not shown, CSR Table 14.149).
In the Cohort 2 safety population, the proportions of subjects reporting at least 1 SAE within 6
months post-vaccination were low and similar in the PCV20 group (0.3%) and the PCV13 group
(0.9%) (Data not shown, CSR Table 47). One subject in the PCV20 group reported two SAEs
(nephrolithiasis and ureteric obstruction) and 1 subject in the PCV13 group reported one SAE
(skin bacterial infection). Each of these SAEs occurred within 1 month post-vaccination. None of
the reported SAEs in Cohort 2 were considered by the investigator to be related to the study
vaccination.
In the Cohort 3 safety population, the proportions of subjects reporting at least 1 SAE within 6
months post-vaccination were low and similar in the PCV20 group (0.6%) and the PCV13
(0.9%) (Data not shown, CSR Table 48). Within the PCV20 group, 1 subject reported an acute
myocardial infarction within 1 month post-vaccination, and one subject reported a pulmonary
embolism within 6 months post-vaccination. In the PCV13 group, 1 subject reported herpes

62

Clinical Reviewer: Tina Mongeau
STN: 125731/0

simplex meningitis within 6 months post-vaccination. None of the SAEs reported in Cohort 3
were considered by the investigator to be related to study vaccination.
Serious Adverse Event Narratives
Narratives were provided for 2 subjects (both in Cohort 1) who reported SAEs and were
discontinued for safety-related reasons.
•

Subject (b) (6) : A 65-year-old black female from the U.S. with pertinent
medical history of hypertension (since 2007) presented to the Emergency Room
on Day 14 after receipt of PCV20 with chest pain and was subsequently
hospitalized. On Day 15, the subject underwent a cardiac catheterization to treat
severe 3-vessel coronary artery disease. On Day 17, the subject underwent a
triple bypass surgery. The subject was withdrawn from further vaccination on
Study Day 50 because of ongoing coronary artery disease and completed safety
follow-up on Day 169. The investigator considered that there was no reasonable
possibility that the CAD was related to the study vaccine, but rather was related to
underlying cardiac disease.

•

Subject (b) (6) : An 84-year-old while male from the U.S. with a pertinent
medical history of left knee meniscus damage (in 2002) and arthroscopy
(unreported date), left knee meniscus injury and repair (2010), arthritis (since
2010), left knee sprain (2019), and left knee pain (since April 2019), received
Vaccination 1 (PCV13). Twenty days post-vaccination, the subject was diagnosed
with a severe muscle rupture (torn left quadricep muscle). The subject’s ongoing
history of left knee pain since April 2019 worsened to the point that he sought
medical attention. The subject refused to continue in the safety follow-up phase
and subsequently withdrew on Day 169 due to the muscle rupture. The
investigator considered that there was no reasonable possibility that the torn left
quadricep muscle was related to the study vaccine but rather to the prior noted
injury.

6.1.12.7 Dropouts and/or Discontinuations
A total of 20 subjects in Cohort 1 (12 subjects in the PCV20/saline group (including 1 death) and
8 subjects in the PCV13/PPSV23 group) were withdrawn prior from further vaccination due to
an AE or SAE (Table 8), and narratives were provided for these subjects (CSR, pages 822916). No subjects in Cohort 2 or Cohort 3 were withdrawn due to an adverse event. The
narratives for the 17 subjects withdrawn early due to an AE are described below, and the
narratives for the remaining 3 subjects withdrawn early due to a SAE or death are summarized
above in Sections 6.1.12.3 and 6.1.12.4.
•

Subject (b) (6) : On study Day 8 after receipt of PCV20, an 80-year-old White
U.S. female subject with a history of coronary artery disease and
hypercholesterolemia (treated with lovastatin) developed mild angioedema. Wyeth
did not have details regarding the body location(s) affected in the clinical
presentation upon request. On Day 24, lovastatin was discontinued and on the
same day, the angioedema resolved. The subject was discontinued from further
vaccination per her request due to the adverse event. The angioedema was
considered by the investigator to be related to concomitant drug treatment
(lovastatin).

63

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Reviewer Comment: Angioedema was temporally associated with PCV20
administration. However, this reviewer agrees that this event is more likely
related to concomitant administration of lovastatin based on the persistent
nature of the event (lasting 22 days) and the resolution of the mild
angioedema following lovastatin discontinuation. Angioedema is listed as a
known adverse reaction reported during post-approval use of lovastatin.
Although PCV20 cannot be ruled out as a cause of this event (i.e., non-IgE
mediated mast cell degranulation resulting from an inflammatory response
to PCV20 [delayed angioedema]), this reviewer agrees that PCV20 is a less
likely cause of the noted adverse event.
•

Subject (b) (6) : On study Day 22 after receipt of PCV13, a 79-year-old White
U.S. female with a history of hypertonic bladder developed moderate cystitis. On
Day 29, the cystitis resolved. This AE was considered related to the pre-existing
hypertonic bladder.

•

Subject (b) (6) : On study Day 1 within 5 hours after receipt of PCV13, a 64year-old White U.S. female subject experienced mild injection site pain and mild
myalgia which resolved on Days 2 and 3, respectively. The subject also reported
mild fatigue (Day 2 only) and mild myalgia (Day 1 only). The reported injection site
pain and myalgia were considered related to the study vaccine.

•

Subject (b) (6) : On Day 1, ~12 hours after receipt of PCV20, a 64-year-old
White U.S. female with a medical history of hypothyroidism, Raynaud’s disease
and taking concomitant levothyroxine (0.1 mg) reported moderate anxiety and
palpitations which resolved on Days 7 and 3, respectively. The investigator
considered there was a reasonable possibility that the anxiety and palpitations
were possibly related to the study vaccine.

•

Subject (b) (6) : On Day 1 ~9 hours after receipt of PCV20, a 62-year-old
White U.S. female subject with a medical history of rosacea, paresthesia,
hypertension (taking lisinopril), and tension headaches and on hormonal therapy
for menopausal symptoms reported moderate injection site pruritis and swelling
which resolved on Days 6 and 8, respectively. The investigator considered there
was a reasonable possibility that these AEs were related to study vaccination.

•

Subject (b) (6) : On Day 31 after receipt of PCV20, a 65-year-old White U.S.
male subject with no pertinent medical history reported severe presyncope at the
time of blood sample collection for Visit 2. The investigator considered the AE to
be related to a vasovagal reflex-vasomotor reaction after blood was drawn by
venipuncture.

•

Subject (b) (6) : On Day 2 after receipt of PCV20, a 72-year-old multiracial
U.S. male subject with a medical history pertinent for drug hypersensitivity
(penicillin) and food allergy (chocolate) reported moderate pruritis and mild
abnormal feeling in the head which resolved on Day 17 and Day 8, respectively.
The subject also reported moderate rash on Day 6 through Day 9. The
investigator considered there to be a reasonable possibility that the AEs on Day 2
were related to the study product.

64

Clinical Reviewer: Tina Mongeau
STN: 125731/0

•

Subject (b) (6) : On day 2 after receipt of PCV13, a 62-year-old White U.S.
male subject with a history of hypertension reported a moderate headache which
resolved on Day 17. The subject also reported moderate fatigue on Days 2
through 17, moderate myalgia from Days 1-2, and moderate arthralgia on days
2017. The subject used an antipyretic/pain medication on Days 2, 4, 5, 6, and 7.
The subject was withdrawn on Day 99 due to the headache, and the investigator
considered headache to be related to study vaccination.

•

Subject (b) (6) : On Day 5 after receipt of PCV20, a 64-year-old black U.S.
male subject with no pertinent medical history reported severe injection site
swelling which resolved on Day 6. The subject also reported moderate injection
site redness on Day 2 only and mild injection site pain on Days 1-4. The subject
was withdrawn due to the injection site swelling on Day 64. The investigator
considered there was a reasonable possibility that the injection site swelling was
related to the study product.

•

Subject (b) (6) : On Day 16 after receipt of PCV20, a 63-year-old White U.S.
female subject with a history of atopic dermatitis reported moderate worsening of
atopic dermatitis which resolved on Day 49. The investigator considered there no
reasonable possibility that the worsening atopic dermatitis was related to the
study product but rather to the pre-existing condition.

•

Subject (b) (6) : On Day 26 after receipt of PCV13, a 63-year old White U.S
male subject with no pertinent medical history reported a mild lower respiratory
tract infection. The subject withdrew consent and safety follow-up on Day 42 due
to this AE. The investigator considered there was no reasonable possibility that
the AE was related to the study product but rather to community exposure.

•

Subject (b) (6) : On Day 2 after receipt of PCV13, a 67-year-old White U.S.
male subject with no pertinent medical history reported mild injection site pain
from Days 2-4, severe injection site redness on Days 2-6, and mild fever on Day 2
only. The subject used an antipyretic/pain medication on day 2 only. The
investigator considered there was a reasonable possibility that the injection site
pain and redness were related to the study product.

•

Subject (b) (6) : On Day 37 after receipt of PCV20, a 61-year-old black male
U.S. subject with a medical history of ongoing seasonal allergies (receiving allergy
shots) reported mild hypersensitivity due to seasonal allergens and received a
steroid injection the same day. The investigator considered there to be no
reasonable possibility that hypersensitivity occurring 36 days post-vaccination
was related to the study product but rather to seasonal allergies.

•

Subject (b) (6) : On Day 1 ~5 hours before receipt of PCV20, an 83-year-old
male U.S. subject with a history of osteoarthritis of the right should and right hand
(on methotrexate) reported arthritis. The subject started treatment with prednisone
on Day 2. The investigator considered the AE related to the underlying medical
history.

•

Subject (b) (6) : On Day 6 after receipt of PCV13, a 65-year-old White male
U.S. subject with a BMI of 41.1 and a medical history of being a former cigarette
smoker (1975-2004), dyslipidemia, deep vein thrombosis, peripheral venous
65

Clinical Reviewer: Tina Mongeau
STN: 125731/0

disease and hypertension reported severe bronchial hyperreactivity which
resolved on Day 33. The subject’s concomitant medications included simvastatin,
warfarin, lisinopril, omega-3 fatty acids and ibuprofen. The event was not
considered serious. The investigator considered there was a reasonable
possibility that the AE was related to the study product.
•

Subject (b) (6) : On day 2 after receipt of PCV13, a 73-year-old White U.S.
female subject with a history of chronic obstructive pulmonary disease (COPD)
reported severe exacerbation of COPD. The investigator considered that the AE
was related to the medical history of COPD.

•

Subject (b) (6) : On day 2 after receipt of PCV20, a 63-year old White U.S.
female with no pertinent medical history reported severe injection site erythema
which resolved on Day 10. The subject also reported moderate injection site
swelling from Days 6-8 and mild injection site pain on Days 2-6. Mild fever was
recorded on Day 2 only. The subject was withdrawn due to the injection site
erythema, which the investigator considered related to the study product.

Reviewer Comment: Of the 20 AEs/SAEs that led to withdrawal, 10 were viewed by the
study investigator to be attributed to an alternative etiology. The investigator considered
the remaining 10 AEs/SAEs to be possibly related to the study vaccine; these included
injection site reactions (pain, pruritis, erythema and swelling), myalgia, moderate anxiety,
palpitations, pruritis, feeling abnormal, headache and bronchial hyperreactivity. The
clinical reviewer agrees with the assessments of the investigators as noted above.
6.1.13 Study Summary and Conclusions
The effectiveness of Prevnar 20 (PCV20) was demonstrated in persons 60 years of age and
older by demonstrating immunologic noninferiority of the serotype-specific OPA antibody
responses induced by PCV20 compared to the corresponding serotypes-specific OPA antibody
responses induced by a licensed pneumococcal conjugate vaccine. For the original 13
serotypes, the OPA antibody responses induced by PCV20 were compared to those induced by
Prevnar 13. For the 7 new serotypes, OPA antibody responses induced by PCV20 were
compared to those induced by Pneumovax 23. The pre-specified 2-fold non-inferiority criterion
(a lower limit of the 95% CI for the GMT ratio (GMTPCV20/GMTactive control) >0.5) was met for each
serotype, except for serotype 8 (LL =0.49). In supportive secondary analyses, 77.8% of subjects
≥60 years of age achieved a ≥4-fold increase in anti-serotype 8 OPA titers.
The effectiveness of Prevnar 20 in younger adults 18-49 years of age and 50-59 years of age
was demonstrated by immunobridging to the established effectiveness in the 60-64-year-old
adult age group (Cohort 1 Subset).
Overall, the safety profile of Prevnar 20 in adults was generally consistent with the known safety
profile of U.S.-licensed Prevnar 13 (the active control for safety). No safety concerns were
identified.
6.2 Study B7471008
Study B7471008 was designed to provide clinical data supporting manufacturing consistency.
This study was conducted between February 14, 2019 and April 6, 2020 and enrolled a total of
1,708 subjects across all vaccine groups. The clinical study report was dated June 30, 2020.

66

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.2.1 Objectives
Primary Safety Objective: To demonstrate the safety profile of PCV20.
•

Primary safety endpoints:
Reported prompted local reactions (redness, swelling, and pain at the injection site)
within 10 days after vaccination.
− Reported prompted systemic events (fever, headache, fatigue, muscle pain, and
joint pain) within 7 days after vaccination.
− Reported AEs within 1 month after vaccination.
− Reported SAEs and NDCMCs within 6 months after vaccination.
−

Primary Immunogenicity Objective: To demonstrate that the immune responses to 20
serotypes induced by PCV20 were equivalent across 3 lots.
•
•

Primary endpoint: serotype-specific OPA titers 1 month after vaccination
Equivalence criterion: The serotype-specific OPA GMT ratio and 2-sided 95% CI
for each pair of lot comparisons (Lot 1/Lot 2, Lot 1/Lot 3, Lot 2/Lot 3) were
calculated. Using a 2-fold equivalence margin, lot consistency was declared for a
given serotype if each of the 3 pairwise CIs for that serotype was contained in the
interval (0.5, 2.0). Overall lot consistency was declared if the 3 lots met the criteria
for all 20 serotypes. Note: this requires a total of 60 comparisons (3 pairwise
between-lot comparisons for each of the 20 serotypes).

Secondary Immunogenicity Objective: To describe the immune response to PCV20
•

−
−
−

Secondary endpoints:
Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.
≥4-fold rise in serotype-specific OPA titers from before to 1 month after vaccination.
Serotype-specific OPA titers ≥ LLOQ 1 month after vaccination.

Reviewer Comment: This review focuses on the primary endpoint only, as the primary
objective was met for each vaccine serotype, and the supportive secondary endpoints
are less informative for the purposes of lot-to-lot consistency.
Exploratory Immunogenicity Objective: To further describe the immune response induced by
PCV20
•

Exploratory endpoints:
≥4-fold rise in pneumococcal serotype 15C OPA titer from before to 1 month after
vaccination.
− Pneumococcal serotype 15C OPA titer ≥ LLOQ 1 month after vaccination.
− Pneumococcal serotype 15C OPA titer 1 month after vaccination.
− Fold rise in pneumococcal serotype 15C OPA titer from before to 1 month after
vaccination.
−

6.2.2 Design Overview
Study B7471008 was a Phase 3, randomized, double-blind, multicenter study with a 4-arm
parallel design conducted in the U.S. A total of ~1,610 adults 18-49 years of age with no history
of pneumococcal vaccination were planned to be enrolled and randomized (via site-based
randomization) into 1 of 4 groups in a 2:2:2:1 ratio to receive one of three lots of PCV20 or
PCV13 (Table 21). The PCV13 group was a control for safety only, but sera were assayed to
67

Clinical Reviewer: Tina Mongeau
STN: 125731/0

maintain blinding and for descriptive purposes. Adults 18-49 years of age with no history of
pneumococcal vaccination were selected as the study population because they have lower
variability in immune response than potentially previously vaccinated older populations, thus
facilitating interpretation of immunogenicity results for lot consistency.
Investigational product was administered in a double-blind fashion as the appearance of PCV20
and PCV13 were identical pre-filled syringes packaged in blinded cartons. Laboratory personnel
performing immunogenicity assays were blinded throughout clinical testing. Wyeth personnel
directly involved with evaluating participant data and investigator site staff were blinded until the
database was locked and unblinded for the final analyses of all safety and immunogenicity data.
The duration of subject participation was approximately 6 months post-vaccination and included
the 2 study visits and 1 telephone contact listed below. Please see Section 6.2.7 for details
regarding safety and immunogenicity monitoring.
•
•
•

Visit 1 (Day 1): Informed consent, Vaccination 1, Blood draw for immunogenicity
Visit 2 (Day 28 to 42 post-vaccination): Blood draw for immunogenicity and
collection of safety data
6-Month Safety Telephone Contact (168 to 196 days post-vaccination)

Table 21. Enrollment and Vaccination, Study B7471008
Vaccine Group
Planned # of Participants
PCV20 Lot 1
460
PCV20 Lot 2
460
PCV20 Lot 3
460
PCV13
230
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007, Clinical Study
Report, Table 3, p20.

6.2.3 Population
Individuals were eligible for enrollment if they met all study inclusion criteria and none of the
exclusion criteria. With one exception (age), inclusion criteria and exclusion criteria for study
B7471008 were identical to those described for study B7471007 (see Section 6.1.3). The one
exception was that study B7471008 inclusion criteria required subject age to be ≥18 years and
<50 years at the time of enrollment. Criteria for temporarily delaying vaccination at visit 1 or
delaying the immunogenicity blood draw at visits 1 and 2 were also identical to those described
for study B7471007 (see Section 6.1.3).
6.2.4 Study Treatments or Agents Mandated by the Protocol
A 0.5 mL dose of 3 lots of PCV20 vaccine or PCV13 vaccine was administered intramuscularly
in the deltoid muscle of the non-dominant arm at Visit 1 based on randomization. The study
vaccines were identical in appearance and supplied as single-use prefilled syringes. Please see
Section 6.1.4 for detailed descriptions of the PCV20 and PCV13 vaccines’ composition. The
PCV20 lot numbers used in this study included the following: W73014 (lot 1), X29529 (lot 2),
X29567-1 (lot 3). The PCV13 lot number used in this study was T82473.
Non-study Vaccines
The name and date of administration of any permitted non-study vaccinations were recorded in
the CRF. Licensed inactivated influenza vaccine was permitted >14 days prior to or >14 days
after study product injection. Receipt of any other licensed non-study vaccine (except
pneumococcal vaccine which was prohibited in this study) was permitted after Visit 2.
68

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Prophylactic antipyretics were permitted but not recommended on the day prior to or the day of
investigational product administration.
6.2.6 Sites and Centers
Study B7471008 was conducted at 21 sites in the U.S.
6.2.7 Surveillance/Monitoring
Safety Monitoring
Safety monitoring, adverse reaction grading, and procedures for unscheduled visits in study
B7471008 were identical to those specified for study B7471007. Please see Section 6.1.7 for
details. MedDRA version 22.1 coding dictionary was applied in study B7471008.
Immunogenicity Monitoring
Blood samples for immunogenicity were collected from all subjects prior to and 1 month after
vaccination. OPA titers for all serotypes present in PCV20 were determined on all sera
collected. In addition, OPA titers were tested for non-vaccine serotype 15C in a random subset
of patients.
6.2.8 Endpoints and Criteria for Study Success
Please see Section 6.2.1 of the clinical review.
6.2.9 Statistical Considerations & Statistical Analysis Plan
Sample Size Calculations
•
•
•

A total of 1,610 subjects (460 in each of the three PCV20 lot groups and 230 in
the PCV13 control group) was planned to ensure 1,449 evaluable subjects (414 in
each of the three PCV20 lot groups and 207 in the PCV13 group).
A δ 12 of 0.2 was used in the power calculation, corresponding to an assumption
that the true GMT ratio of any lot to another lot is between 0.82 and 1.22.
Based on the stated assumptions, the planned sample size provided the study
with an overall power of 89.8% for declaring overall equivalence of the 3 lots of
PCV20 vaccine.

Statistical Considerations
•

•
•

12

For each serotype, a linear regression model that included terms for age,
corresponding baseline OPA titer, sex, smoking status, and PCV20 lot was used
as the primary approach to calculate serotype-specific OPA GMT ratio and CI for
each pair of lot comparisons. The unadjusted serotype-specific OPA GMT ratio
and CI were also calculated for each of the serotypes.
Missing assay results will not be replaced or imputed.
Serotype-specific OPA titers below the corresponding serotype-specific assay
LLOQ were set to 0.5 x LLOQ for analysis.

δ is the true maximum difference in the serotype-specific OPA titers between any 2 lots.

69

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Analysis Timing
One analysis was performed after the complete study data were available and the database
was locked.
Safety Analysis
The safety objective was evaluated by descriptive summary statistics for each primary safety
endpoint for each study group.
Analysis Populations
•

The safety population included all subjects who received at least 1 dose of any
PCV20 lot or PCV13 and had safety follow-up after vaccination. Subjects were
included in the vaccine group corresponding to the vaccine actually received.

•

The evaluable immunogenicity population was the primary analysis population for
the immunogenicity results. Participants were included in the vaccine group as
randomized in the analysis. Criteria for inclusion in this population are as follows:
−
−
−
−

Received randomized vaccine,
Had Visit 2 blood draw within 27 to 49 days after study vaccination,
Had ≥1 valid and determinate OPA titer for any serotype at Visit 2, and
Had no other major protocol deviations as determined by the clinician.

•

The all-available immunogenicity population was the secondary analysis
population for immunogenicity results. Participants were included in the vaccine
group as randomized in the analysis. The criteria for inclusion in this population
were receipt of PCV20 (from any lot) or PCV13 and at least 1 valid and
determinate OPA titer after vaccination.

•

Analysis of immunogenicity data based on the all‑available immunogenicity
population was to be performed only if there was 10% or more difference in
sample size between the evaluable immunogenicity population and the
all‑available immunogenicity population.

6.2.10 Study Population and Disposition
Of the 1,710 randomized subjects, 1,708 were vaccinated with either PCV20 (lot 1, 2 or 3) or
PCV13, and 1,635 (95.6%) completed the study.
6.2.10.1 Populations Enrolled/Analyzed
Section 6.2.9 defines this study’s populations enrolled and analyzed.
The proportion of subjects included in the evaluable immunogenicity population and all-available
immunogenicity population were similar across all study groups. The most common reason for
exclusion from the evaluable immunogenicity population was not having a blood draw within the
pre-specified time window.
No analysis was performed on the all-available immunogenicity population because the
difference between the evaluable and all-available populations was <10%.

70

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 22. Evaluable and All-Available Immunogenicity Populations, Study B7471008
PCV20
PCV20
PCV20
Lot 1
Lot 2
Lot 3
Pooled
Disposition
nb (%)
nb (%)
nb (%)
nb (%)
Randomized
489 (100.0)
490 (100.0)
486 (100.0) 1465 (100.0)
Evaluable immunogenicity
463 (94.7)
473 (96.5)
456 (93.8)
1392 (95.0)
population
Subjects excluded from
evaluable immunogenicity
26 (5.3)
17 (3.5)
30 (6.2)
73 (5.0)
population
Didn’t receive the vaccine
1 (0.2)
1 (0.2)
0 (0.0)
2 (0.1)
as randomized
Didn’t have Visit 2 blood
sample collected within 27
24 (4.9)
15 (3.1)
27 (5.6)
66 (4.5)
to 49 days after
vaccination
No valid and determinate
15 (3.1)
9 (1.8)
16 (3.3)
40 (2.7)
OPA titer after vaccination
Had any other major
1 (0.2)
3 (0.6)
3 (0.6)
7 (0.5)
protocol deviationsd
All-available
474 (96.9)
481 (98.2)
470 (96.7)
1425 (97.3)
immunogenicity population
Subjects excluded from allavailable immunogenicity
15 (3.1)
9 (1.8)
16 (3.3)
40 (2.7)
population
Did not receive ≥1 dose of
1 (0.2)
1 (0.2)
0 (0.0)
2 (0.1)
investigational product
No valid and determinate
15 (3.1)
9 (1.8)
16 (3.3)
40 (2.7)
OPA titer after vaccination

PCV13
nb (%)
245 (100.0)
232 (94.7)
13 (5.3)
0 (0.0)

10 (4.1)

7 (2.9)
2 (0.8)
238 (97.1)
7 (2.9)
0 (0.0)
7 (2.9)

a

n = Number of subjects with the specified characteristic.
These values are the denominators for the percentage calculations.
c
Subjects may have been excluded for more than 1 reason.
d
Four subject received vaccines within a prohibited time frame (i.e., 1 subject received Tdap within 14 days before vaccination and
3 participants received tetanus, human papillomavirus vaccine, Tdap vaccines (1 each) between vaccination and 1 month postvaccination. Five subjects were enrolled but later found to have not met elig bility criteria (2 previously received pneumococcal
vaccine, 1 had a medical history of asplenia, 1 had an ongoing history of leukopenia, and 1 met 3 criteria (unwilling to comply with
visits and study procedures and had multiple suspected chronic medical conditions including rheumatoid arthritis, which required the
use of systemic steroids).
Source: STN 125731/0.1 module 5.3.5.1, Study B7471007, Clinical Study Report, Table 6, p28.
b

6.2.10.1.1 Demographics
Table 23 summarizes baseline demographic characteristics and smoking history for the safety
population. The four study groups were similar with regard to baseline demographics and
smoking history. Overall, the safety population included 65.3% females, 72.7% White, 18.5%
Black, 3.5% Asian, 2.2% multiracial, 1.3% American Indian or Alaska Native, 1.5% not reported
and 0.4% Native Hawaiian or other Pacific Islander; 11.2% were Hispanic/Latino; 20.8% were
current smokers, 17.2% were ex-smokers, and 62% never smoked. Overall, the mean age was
35.3 years (standard deviation 9.0 years).
Demographic characteristics and smoking history for the evaluable immunogenicity population
were similar to those for the safety population.

71

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Table 23. Demographic Characteristics and Smoking History, Safety Population, Study B7471008
PCV20 Lot 1
PCV20 Lot 2
PCV20 Lot 3
Pooled
Na=488
Na=489
Na=486
Na=1463
Characteristic
nb (%)
nb (%)
nb (%)
nb (%)
Sex
Male
157 (32.2)
173 (35.4)
162 (33.3)
492 (33.6)
Female
331 (67.8)
316 (64.6)
324 (66.7)
971 (66.4)
Race
White
367 (75.2)
351 (71.8)
350 (72.0)
1068 (73.0)
Black or African American
87 (17.8)
88 (18.0)
97 (20.0)
272 (18.6)
Asian
13 (2.7)
17 (3.5)
17 (3.5)
47 (3.2)
American Indian or Alaska Native
5 (1.0)
9 (1.8)
5 (1.0)
19 (1.3)
Native Hawaiian or other Pacific Islander
2 (0.4)
1 (0.2)
1 (0.2)
4 (0.3)
Multiracial
6 (1.2)
13 (2.7)
13 (2.7)
32 (2.2)
Not Reported
8 (1.6)
10 (2.0)
3 (0.6)
21 (1.4))
Ethnicity
Hispanic/Latino
48 (9.8)
58 (11.9)
56 (11.5)
162 (11.1)
Non-Hispanic/non-Latino
434 (88.9)
427 (87.3)
427 (87.9)
1288 (88.0)
Not reported
6 (1.2)
4 (0.8)
3 (0.6)
13 (0.9)
Age at Vaccination (Years)
Mean (SD)
35.6 (9.17)
35.7 (9.03)
34.9 (9.05)
35.4 (9.08)
Median (Min, Max)
37.0 (18, 49)
36.0 (18, 49)
35.0 (18, 49)
36.0 (18, 49)
Smoking History
Current Smoker
100 (20.5)
101 (20.7)
102 (21.0)
303 (20.7)
Mean (SD) # Years Smoking
16.6 (9.88)
14.6 (9.07)
15.1 (8.97)
15.4 (9.32)
Ex-smoker
Mean (SD) # Years Since Quitting
7.5 (8.36)
8.6 (7.53)
7.5 (7.31)
7.8 (7.71)
Never Smoked
308 (63.1)
307 (62.8))
295 (60.7
910 (62.2)

PCV13
Na=245
nb (%)

Total
Na=1708
nb (%)

101 (41.2)
144 (58.8)

593 (34.7)
1115 (65.3)

173 (70.6)
44 (18.0)
12 (4.9)
4 (1.6)
2 (0.8)
5 (2.0)
5 (2.0

1241 (72.7)
316 (18.5)
59 (3.5)
23 (1.3)
6 (0.4)
37 (2.2)
26 (1.5)

29 (11.8)
215 (87.8)
1 (0.4)

191 (11.2)
1503 (88.0)
14 (0.8)

35.0 (8.70)
35.0 (18, 49)

35.3 (9.03)
36.0 (18, 49)

53 (21.6)
16.2 (9.30)

356 (20.8)
15.6 (9.31)

6.6 (7.12)
149 (60.8)

7.7 (7.63)
1059 (62.0)

a

N = number of subjects in the specified group or the total sample. This value is the denominator for the percentage calculations.
n = Number of subjects with the specified characteristic.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471008. Clinical Study Report, Table 7, p30-31.
b

72

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.2.10.1.2 Medical/Behavioral Characterization of the Enrolled Population
Table 24 presents select baseline comorbidities noted in the medical history in the safety
population. The proportion of subjects with any medical history was similar across study groups
(overall 83.6%). A numerically higher proportion of PCV13 recipients reported a medical history
within the SOC Cardiac disorders (4.1%) compared to the pooled PCV20 group (1.7%).
However, the proportion of subjects with a cardiac medical condition was low across all study
groups.
Table 24. Medical History, Safety Population, Study B7471008
PCV20
PCV20
PCV20
Pooled
Lot 1
Lot 2
Lot 3
PCV20
Na=488
Na=489
Na=486
Na=1463
Comorbidity
nb (%)
nb (%)
nb (%)
nb (%)
Any medical history by
419 (85.9) 408 (83.4) 402 (82.7) 1229 (84.0)
MedDRA SOC/PT
Blood and lymphatic system
12 (2.5)
18 (3.7)
18 (3.7)
48 (3.3)
disorders
Cardiac disorders
8 (1.6)
8 (1.6)
9 (1.9)
25 (1.7)
Endocrine disorders
22 (4.5)
23 (4.7)
31 (6.4)
76 (5.2)
Gastrointestinal disorders
73 (15.0)
74 (15.1)
80 (16.5) 227 (15.5)
Hepatobiliary disorders
23 (4.7)
18 (3.7)
31 (6.4)
72 (4.9)
Immune system disorders
182 (37.3) 168 (34.4) 177 (36.4) 527 (36.0)
Drug hypersensitivity
91 (18.6)
90 (18.4)
80 (16.5) 261 (17.8)
Infections and infestations
64 (13.1)
54 (11.0)
56 (11.5) 174 (11.9)
Metabolism and nutrition
92 (18.9)
85 (17.4) 103 (21.2) 280 (19.1)
disorders
Hypercholesterolaemia
10 (2.0)
9 (1.8)
13 (2.7)
32 (2.2)
Hyperlipidemia
10 (2.0)
6 (1.2)
10 (2.1)
26 (1.8)
Obesity
41 (8.4)
48 (9.8)
61 (12.6) 150 (10.3)
Type 2 diabetes mellitus
11 (2.3)
12 (2.5)
8 (1.6)
31 (2.1)
Nervous system disorders
115 (23.6)
97 (19.8) 101 (20.8) 313 (21.4)
Renal and urinary disorders
16 (3.3)
15 (3.1)
18 (3.7)
49 (3.3)
Respiratory, thoracic and
71 (14.5)
74 (15.1)
55 (11.3) 200 (13.7)
mediastinal disorders
Asthma
39 (8.0)
40 (8.2)
32 (6.6)
111 (7.6)
Sleep apnoea syndrome
8 (1.6)
8 (1.6)
9 (1.9)
25 (1.7)
Vascular disorders
43 (8.8)
52 (10.6)
47 (9.7)
142 (9.7)
Hypertension
36 (7.4)
48 (9.8)
36 (7.4)
120 (8.2)

PCV13
Total
Na=245
Na=1708
nb (%)
nb (%)
199 (81.2) 1428 (83.6)
6 (2.4)

54 (3.2)

10 (4.1)
10 (4.1)
28 (11.4)
10 (4.1)
79 (32.2)
41 (16.7)
27 (11.0)
54 (22.0)

35 (2.0)
86 (5.0)
255 (14.9)
82 (4.8)
606 (35.5)
302 (17.7)
201 (11.8)
334 (19.6)

5 (2.0)
37 (2.2)
5 (2.0)
31 (1.8)
30 (12.2) 180 (10.5)
3 (1.2)
34 (2.0)
51 (20.8) 364 (21.3)
8 (3.3)
57 (3.3)
26 (10.6) 226 (13.2)
14 (5.7)
4 (1.6)
19 (7.8)
16 (6.5)

125 (7.3)
29 (1.7)
161 (9.4)
136 (8.0)

Note: MedDRA (v22.1) coding dictionary applied.
a
N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b
n = Number of subjects with the specified characteristic.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471008. Clinical Study Report, Table 14.2, p70-107.

6.2.10.1.3 Subject Disposition
The disposition of all randomized subjects (as described in Section 6.2.10) are summarized in
Table 25. Subject disposition was similar across the 4 study groups; the most common reason
for withdrawal in all study groups was being lost to follow-up (overall 3.7%).

73

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 25. Disposition of All Randomized Subjects, Study B7471008
PCV20
PCV20
PCV20
Lot 1
Lot 2
Lot 3
Pooled
Na=488
Na=489
Na=486
Na=1463
Disposition
nb (%)
nb (%)
nb (%)
nb (%)
Randomizedb
489
490
486
1465
(100.0)
(100.0)
(100.0)
(100.0)
Not vaccinated
1 (0.2)
1 (0.2)
0 (0.0)
2 (0.1)
Vaccinated
488
489
486
1463
(99.8)
(99.8)
(100.0)
(99.9)
Completed 1-month follow477
483
472
1432
up after Vaccination 2
(97.5)
(98.6)
(97.1)
(97.7)
Completed Study
465
475
460
1400
(95.1)
(96.9)
(94.7)
(95.6)
Withdrawn from study
24 (4.9)
15 (3.1)
26 (5.3)
65 (4.4)
Reason for withdrawal
Lost to follow-up
22 (4.5)
12 (2.4)
23 (4.7)
57 (3.9)
No longer meets
0 (0.0)
1 (0.2)
1 (0.2)
2 (0.1)
eligibility criteria
Protocol deviation
0 (0.0)
2 (0.4)
0 (0.0)
2 (0.1)
Withdrawal by subject
2 (0.4)
0 (0.0)
2 (0.4)
4 (0.3)

PCV13
Na=245
nb (%)
245
(100.0)
0 (0.0)
245
(100.0)
241
(98.4)
235
(95.9)
10 (4.1)

Total
Na=1708
nb (%)
1710
(100.0)
2 (0.1)
1708
(99.9)
1673
(97.8)
1635
(95.6)
75 (4.4)

7 (2.9)
3 (1.2)

64 (3.7)
5 (0.3)

0 (0.0)
0 (0.0)

2 (0.1)
4 (0.2)

a

n = Number of subjects with the specified characteristic.
These values are the denominators for the percentage calculations.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471008. Clinical Study Report, Table 5, p26.
b

6.2.11 Efficacy Analyses
The results from the unadjusted OPA GMT ratios and associated 95% CIs were consistent with
the model-based OPA GMT ratio results for each of the 20 vaccine serotypes.
6.2.11.1 Analyses of Primary Endpoint(s)
Lot Equivalence – Pneumococcal OPA GMTs and GMT Ratios
The study’s primary objective was met, demonstrating that the serotype-specific OPA GMTs for
the 20 vaccine serotypes in PCV20 induced by each of three manufacturing scale lots of PCV20
were equivalent based on a 2-fold equivalence margin. The 2-sided 95% CI for the model-based
estimate of serotype-specific OPA GMT ratios at 1 month post-vaccination for each pair of lot
comparisons were contained in the pre-specified interval (0.5, 2.0) for each of the 20 serotypes
in PCV20 (Table 26).

74

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Table 26. Pneumococcal Opsonophagocytic Activity GMTs and GMT Ratios 1 Month After Vaccination, Linear Regression Model,
Evaluable Immunogenicity Population, Study B7471008
PCV20
PCV20
PCV20
Lot 1 to 2
Lot 1 to 2
Lot 1 to 2
PCV20
Lot 1
PCV20
Lot 2
PCV20
Lot 3 Comparison
Comparison Comparison
Lot 1
Lot 2
Lot 3
GMT
GMT Ratio
GMT Ratio
GMT Ratio
GMT
GMT
Serotype
na
(95% CI)b
na
(95% CI)b
na
(95% CI)b
(95% CI)c
(95% CI)c
(95% CI)c
PCV13
Serotypes
200
175
165
1.14
1.21
1.06
1
462
470
454
(174, 230)
(153, 201)
(143, 189)
(0.95, 1.37)
(1.01, 1.46)
(0.89, 1.28)
47
47
43
1.01
1.10
1.09
3
458
469
451
(43, 52)
(42, 52)
(39, 48)
(0.88, 1.16)
(0.96, 1.26)
(0.95, 1.24)
1500
1568
1506
0.96
1.00
1.04
4
455
468
451
(1288, 1746)
(1350, 1821)
(1294, 1751)
(0.78, 1.17)
(0.82, 1.22)
(0.85, 1.27)
126
136
117
0.93
1.08
1.16
5
457
466
450
(109, 146)
(117, 157)
(101, 135)
(0.77, 1.12)
(0.89, 1.31)
(0.96, 1.41)
4654
3748
3330
1.24
1.40
1.13
6A
454
468
446
(4033, 5371)
(3256, 4315)
(2885, 3845)
(1.03, 1.50)
(1.16, 1.69)
(0.93, 1.36)
4403
4350
3907
1.01
1.13
1.11
6B
458
469
453
(3833, 5059)
(3796, 4984)
(3401, 4488)
(0.85, 1.21)
(0.94, 1.35)
(0.93, 1.33)
1821
1866
1876
0.98
0.97
0.99
7F
452
464
441
(1589, 2087)
(1630, 2136)
(1633, 2155)
(0.82, 1.17)
(0.81, 1.16)
(0.83, 1.19)
5120
4604
4922
1.11
1.04
0.94
9V
454
467
446
(4465, 5873)
(4024, 5268)
(4292, 5643)
(0.93, 1.33)
(0.87, 1.25)
(0.78, 1.12)
2240
2091
2002
1.07
1.12
1.04
14
455
467
450
(1965, 554)
(1840, 2377)
(1760, 2277)
(0.90, 1.27)
(0.94, 1.33)
(0.88, 1.24)
3904
4451
4222
0.88
0.92
1.05
18C
455
465
449
(3340, 4563)
(3818, 5188)
(3616, 4929)
(0.72, 1.07)
(0.75, 1.13)
(0.86, 1.29)
1458
1528
1434
0.95
1.02
1.07
19A
451
465
450
(1288, 1651)
(1353, 1726)
(1268, 1623)
(0.81, 1.12)
(0.86, 1.20)
(0.91, 1.25)
525
529
549
0.99
0.96
0.96
19F
455
466
452
(451, 610)
(456, 615)
(472, 638)
(0.81, 1.21)
(0.78, 1.17)
(0.79, 1.17)
1416
1548
1435
0.92
0.99
1.08
23F
459
471
454
(1182, 1696)
(1295, 1849)
(1198, 1718)
(0.72, 1.16)
(0.78, 1.25)
(0.85, 1.37)

75

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Serotype
New
Serotypes

PCV20
Lot 1
na

8

435

10A

399

11A

394

12F

418

15B

392

22F

367

33F

391

PCV20
Lot 1
GMT
(95% CI)b

1595
(1403, 1814)
6328
(5408, 7405)
8656
(7308, 10253)
8563
(7322, 10015)
7343
(6108, 8827)
12508
(10318, 15161)
10746
(9042, 12771)

PCV20
Lot 2
na

448
418
399
418
426
392
401

PCV20
Lot 2
GMT
(95% CI)b

1346
(1186, 1528)
5693
(4890, 6627)
6729
(5693, 7952)
7908
(6765, 9243)
6357
(5325, 7589)
11213
(9337, 13467)
10328
(8737, 12209)

PCV20
Lot 3
GMT
(95% CI)b

Lot 1 to 2
Comparison
GMT Ratio
(95% CI)c

Lot 1 to 2
Comparison
GMT Ratio
(95% CI)c

Lot 1 to 2
Comparison
GMT Ratio
(95% CI)c

1624
(1430, 1845)
5962
410
(5121, 6941)
8720
399
(7409, 10264)
7412
411
(6332, 8677)
7019
402
(5854, 8416)
12729
384
(10572, 15326)
10418
409
(8815, 12313)

1.19
(1.00, 1.40)
1.11
(0.91, 1.36)
1.29
(1.03, 1.60)
1.08
(0.88, 1.33)
1.16
(0.91, 1.46)
1.12
(0.87, 1.43)
1.04
(0.83, 1.30)

0.98
(0.83, 1.16)
1.06
(0.87, 1.30)
0.99
(0.80, 1.24)
1.16
(0.94, 1.42)
1.05
(0.82, 1.33)
0.98
(0.77, 1.26)
1.03
(0.82, 1.29)

0.83
(0.70, 0.98)
0.95
(0.78, 1.17)
0.77
(0.62, 0.96)
1.07
(0.87, 1.31)
0.91
(0.71, 1.15)
0.88
(0.69, 1.12)
0.99
(0.79, 1.24)

PCV20
Lot 3
na

436

Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; CIs: confidence intervals; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.
a
n = Number of subjects with valid and determinate OPA titers for the specified serotype.
b
GMTs and 2-sided CIs were calculated by exponentiating the least squares means and the corresponding CIs based on the same regression model as above.
c
GMT ratios for each pair of lot comparisons and 2-sided CIs were calculated by exponentiating the difference in least squares means and the corresponding CIs based on the
analysis of log-transformed OPA titers using a regression model with PCV20 lot, sex, smoking status, age at vaccination in years (continuous), and baseline log-transformed OPA
titers.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471008. Clinical Study Report, Table 9, p36-38.

76

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.2.11.2 Analyses of Secondary Endpoints
This review focuses on the primary endpoint only, as the primary objective was met for each
vaccine serotype, and the supportive secondary endpoints are less informative for the purposes
of lot-to-lot consistency.
6.2.11.3 Subpopulation Analyses
Subgroup analyses of the primary immunogenicity endpoint (OPA GMTs) were provided based
on sex and race.
Subpopulation Analyses by Sex
Serotype-specific OPA GMTs were generally similar between males and females for the 20
vaccine serotypes (Data not shown, CSR Table 14.9).
Subpopulation Analyses by Race
No clear trend in serotype-specific OPA GMTs were identified among White, Black or other
racial groups combined for the 20 vaccine serotypes
6.2.11.4 Dropouts and/or Discontinuations
Please see Section 6.2.10.1.3 for information on subject disposition, including withdrawals.
Missing values were not imputed for subjects who had missing blood draws.
6.2.11.5 Exploratory and Post Hoc Analyses
In exploratory analyses, PCV20 elicited functional OPA titers to serotype 15C (Data not shown,
CSR Tables 10 and 11). In a random subset of subjects for whom serotype 15C OPA was
measured, 44.4% (2-sided 95% CI of 35.9% to 53.2%, n=60) achieved a ≥4-fold rise in 15C
OPA titers from before vaccination to 1 month after vaccination with PCV20. The OPA GMT
achieved by PCV20 recipients (pooled) at 1 month post-vaccination was 150.5 (95% CI 117.6,
192.5, n=138). The proportion of participants with 15C OPA titers ≥ LLOQ 1 month after
vaccination with PCV20 was 55.1% (2-sided 95% CI of 46.4% to 63.5%, n=76). The serotype
(b) (4)
15C LLOQ is . There was no response to serotype 15C after vaccination with PCV13, which
does not contain 15B conjugate.
6.2.12 Safety Analyses
6.2.12.1 Methods
Safety analyses were descriptive. Please see Section 6.2.7 for details regarding safety
surveillance/monitoring, Section 6.2.1 for a listing of safety endpoints, and Section 6.2.9 for
details regarding the safety analysis population.
E-diary transmission rates were similar across all study groups for each day for the entire 10day period (Data not shown, CSR Table 8). Daily e-diary transmission rates ranged from 83.8%
to 86.9%; transmission rates during the 10-day reporting period ranged from 49.2% to 53.5%.

77

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.2.12.2 Overview of Adverse Events
Solicited Local Injection Site Adverse Events
The proportions of subjects reporting local injection site reactions were generally similar,
although reactogenicity rates were generally highest among PCV20 lot 1 recipients followed by
PCV20 lot 2 recipients and generally lowest among PCV20 lot 3 recipients. A similar trend
across the PCV20 lot groups was not evident in the immunogenicity data presented in Table 26,
which is reassuring. Injection site reaction rates in the pooled PCV20 group and the 13vPnC
group were generally similar.
Most local adverse reactions were mild or moderate in severity. The mean onset day and mean
duration of injection site reactions were similar across PCV20 lots. When PCV20 data were
pooled, the mean onset day was 2.5 days for redness, 2.0 days for swelling and 1.0 day for
pain. The mean duration of injection site reactions for the PCV20 groups when pooled was 2.8
days for redness, 2.1 days for swelling and 2.5 for pain (Data not shown, CSR Tables 14.19 and
14.20).
Table 27. Local Reactions, by Maximum Severity, Within 10 Days After Vaccination, Safety
Population, Study B7471008
PCV20
PCV20
PCV20
Pooled
Pooled PCV20
Lot 1
Lot 2
Lot 3
PCV20
PCV13
vs PCV13
Na=486
Na=489
Na=481
N =1456
Na=243
Difference
Local Reaction
nb (%)
nb (%)
nb (%)
nb (%)
nb (%)
(95% CI)c
Any local
403 (82.9) 386 (78.9) 364 (75.7) 1153 (79.2) 184 (75.7)
3.5 (-2.0, 9.6)
reactiond
Pain at
injection sitef
Any
402 (82.7) 386 (78.9) 358 (74.4) 1146 (78.7) 184 (75.7)
3.0 (-2.4, 9.1)
Mild
262 (53.9) 253 (51.7) 213 (44.3) 728 (50.0) 113 (46.5) 3.5 (-3.3, 10.2)
Moderate
135 (27.8) 128 (26.2) 138 (28.7) 401 (27.5)
67 (27.6)
-0.0 (-6.4, 5.7)
Severe
5 (1.0)
5 (1.0)
7 (1.5)
17 (1.2)
4 (1.6)
-0.5 (-3.0, 0.8)
Swellingg
Any (>2.0 cm)
52 (10.7)
39 (8.0)
33 (6.9)
124 (8.5)
21 (8.6)
-0.1 (-4.5, 3.2)
Mild
35 (7.2)
26 (5.3)
18 (3.7)
79 (5.4)
13 (5.3)
0.1 (-3.6, 2.6)
Moderate
16 (3.3)
12 (2.5)
14 (2.9)
42 (2.9)
8 (3.3)
-0.4 (-3.6, 1.5)
Severe
1 (0.2)
1 (0.2)
1 (0.2)
3 (0.2)
0 (0.0) 0.2 (-1.4, 0.6)
Rednessg
Any (>2.0 cm)
30 (6.2)
39 (8.0)
33 (6.9)
102 (7.0)
15 (6.2)
0.8 (-3.1, 3.7)
Mild
18 (3.7)
19 (3.9)
20 (4.2)
57 (3.9)
8 (3.3)
0.6 (-2.6, 2.6)
Moderate
11 (2.3)
17 (3.5)
10 (2.1)
38 (2.6)
7 (2.9)
-0.3 (-3.3, 1.5)
Severe
1 (0.2)
3 (0.6)
3 (0.6)
7 (0.5)
0 (0.0)
0.5 (-1.1, 1.0)
a
N = number of subjects with any e-diary data reported after vaccination. This value is the denominator for the percentage
calculations.
b
n = Number of subjects with the specified characteristic.
c
2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions (pooled PCV20 – PCV13)
expressed as a percentage.
d
Any local reaction = any injection site pain, any swelling >2.0 cm, or any redness >2.0 cm during Days 1 to 10 postvaccination.
f
Mild = does not interfere with activity, moderate = interferes with activity, severe = prevents daily activity. Any = mild,
moderate or severe.
g
Mild is >2.0 to 5.0 cm, moderate is >5.0 to 10.0 cm, severe is >10.0 cm. Any = mild, moderate or severe.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471008. Clinical Study Report, Table 12, p47-48.

Solicited Systemic Adverse Reactions
The proportions of subjects reporting systemic reactions overall and by maximum severity were
similar across each of the PCV20 lots and between the pooled group of PCV20 recipients
78

Clinical Reviewer: Tina Mongeau
STN: 125731/0

compared to the PCV13 control group (Table 28). The most frequently reported systemic
reaction across all vaccine groups was muscle pain. Most systemic reactions across all study
groups were mild or moderate in severity. The proportions of subjects reporting antipyretic or
pain medication was similar across all vaccine groups.
The mean onset day and mean duration of systemic reactions were similar across PCV20 lots
and between the pooled PCV20 group and the PCV13 control group. When PCV20 data were
pooled, the mean onset day was Day 1.5 (muscle pain), Day 2.1 (fatigue), Day 2.6 (headache
and joint pain) and Day 3.3 (fever). The mean duration of systemic reactions for the PCV20
groups when pooled was 3.3 days for fatigue, 2.7 days for headache, 2.5 days for muscle pain
and joint pain and 1.2 days for fever (Data not shown, CSR Tables 14.21 and 14.22).
Table 28. Systemic Reactions, by Maximum Severity, Within 7 Days After Vaccination, Safety
Population, Study B7471008
PCV20
PCV20
PCV20
Pooled
Pooled PCV20
Lot 1
Lot 2
Lot 3
PCV20
PCV13
vs PCV13
Na=486
Na=489
Na=481
Na=1456
Na=243
Difference
Local Reaction
nb (%)
nb (%)
nb (%)
nb (%)
nb (%)
(95% CI)c
Any Systemic
370 (76.1) 366 (74.8) 375 (78.0) 1111 (76.3) 176 (72.4) 3.9 (-1.8, 10.2)
Adverse Reactiond
e
Muscle Pain
Any
301 (61.9) 299 (61.1) 304 (63.2)
904 (62.1) 147 (60.5)
1.6 (-4.9, 8.3)
Mild
189 (38.9) 193 (39.5) 178 (37.0)
560 (38.5)
94 (38.7)
-0.2 (-6.9, 6.2)
Moderate
109 (22.4)
98 (20.0) 121 (25.2)
328 (22.5)
48 (19.8)
2.8 (-3.1, 7.8)
Severe
3 (0.6)
8 (1.6)
5 (1.0)
16 (1.1)
5 (2.1)
-1.0 (-3.7, 0.4)
Fatiguee
Any
229 (47.1) 222 (45.4) 242 (50.3)
693 (47.6) 106 (43.6) 4.0 (-2.8, 10.6)
Mild
108 (22.2) 127 (26.0) 124 (25.8)
359 (24.7)
59 (24.3)
0.4 (-5.8, 5.9)
Moderate
111 (22.8)
88 (18.0) 110 (22.9)
309 (21.2)
43 (17.7)
3.5 (-2.1, 8.4)
Severe
10 (2.1)
7 (1.4)
8 (1.7)
25 (1.7)
4 (1.6)
0.1 (-2.5, 1.4)
Headachee
Any
179 (36.8) 169 (34.6) 179 (37.2)
527 (36.2)
92 (37.9)
-1.7 (-8.4, 4.7)
Mild
118 (24.3) 112 (22.9)
99 (20.6)
329 (22.6)
66 (27.2) -4.6 (-10.8, 1.1)
Moderate
55 (11.3)
52 (10.6)
68 (14.1)
175 (12.0)
24 (9.9)
2.1 (-2.5, 5.8)
Severe
6 (1.2)
5 (1.0)
12 (2.5)
23 (1.6)
2 (0.8)
0.8 (-1.4, 1.8)
Joint Paine
Any
90 (18.5)
78 (16.0)
77 (16.0)
245 (16.8)
34 (14.0)
2.8 (-2.4, 7.2)
Mild
52 (10.7)
44 (9.0)
49 (10.2)
19 (7.8)
19 (7.8)
2.1 (-2.2, 5.4)
Moderate
36 (7.4)
30 (6.1)
28 (5.8)
94 (6.5)
13 (5.3)
1.1 (-2.6, 3.7)
Severe
2 (0.4)
4 (0.8)
0 (0.0)
6 (0.4)
2 (0.8)
0.4 (-2.6, 0.4)
Fever
≥38.0°C
8 (1.6)
4 (0.8)
6 (1.2)
18 (1.2)
2 (0.8)
0.4 (-1.7, 1.4)
≥38.0°C to 38.4°C
4 (0.8)
2 (0.4)
5 (1.0)
11 (0.8)
1 (0.4)
0.3 (-1.6, 1.1)
>38.4°C to 38.9°C
2 (0.4)
1 (0.2)
1 (0.2)
4 (0.3)
1 (0.4)
-0.1 (-2.0, 0.4)
>38.9°C to 40.0°C
2 (0.4)
1 (0.2)
0 (0.0)
3 (0.2)
0 (0.0) 0.2 (-1.4, 0.6)
>40.0°C
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0) 0.0 (-1.6, 0.3)

79

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Local Reaction
Use of antipyretic
or pain medicationf

PCV20
Lot 1
Na=486
nb (%)

PCV20
Lot 2
Na=489
nb (%)

PCV20
Lot 3
Na=481
nb (%)

Pooled
PCV20
Na=1456
nb (%)

PCV13
Na=243
nb (%)

Pooled PCV20
vs PCV13
Difference
(95% CI)c

109 (22.4)

96 (19.6)

115 (23.9)

320 (22.0)

44 (18.1)

3.9 (-1.8, 8.8)

a

N = number of subjects with any e-diary data reported after vaccination. This value is the denominator for the percentage
calculations.
b
n = Number of subjects with the specified characteristic.
c
2-Sided CI based on the Miettinen and Nurminen method for the difference in proportions (pooled PCV20 – PCV13) expressed as
a percentage.
d
Any systemic event = any fever ≥38.0℃, any fatigue, any headache, any joint pain, or any muscle pain during Day 1 to Day 7 after
vaccination.
e
Mild = does not interfere with activity, moderate = some interference with activity, severe = prevents daily activity. Any = mild,
moderate or severe.
f
Severity was not collected for use of antipyretic or pain medication. The numbers in the table reflect yes responses (i.e., number of
events reported).
Note: One participant entered a fever of 41.1oC that was confirmed by the investigator site to be in error (no fever occurred). This
has been corrected in Table 28.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471008. Clinical Study Report, Table 13, p50-52.

Unsolicited Adverse Events (AEs) Reported Through 30 Days Post-Vaccination
Similar and low proportions of subjects across each of the 3 manufacturing scale lots of PCV20
(5.9%-7.4%) and in the pooled PCV20 (6.8%) and PCV13 (5.3%) groups reported at least 1
unsolicited AE within 1 month after vaccination (Data not shown, CSR Table 14.24). Most
unsolicited AEs were mild or moderate in severity. Severe AEs were reported by 7 subjects in
the PCV20 pooled group and 2 subjects (0.8%) in the PCV13 group (Data not shown, CSR
Table 14.26). There were no clear imbalances in rates of adverse reactions by the reported
MedDRA Preferred Terms. The most frequently reported unsolicited AEs after vaccination that
were reported by a numerically higher proportion of PCV20 recipients in the pooled PCV20
group versus the PCV13 group were within the SOC Infections and infestations (3.1% in the
pooled PCV20 group and 1.6% in the PCV13 group).
At least one unsolicited AE that was considered related to the study product was reported by
0.3% (5 subjects) in the pooled PCV20 group and 0.8% (2 subjects) in the PCV13 group. These
included reports of nausea, chills, injection site bruising, discoloration, induration or pain,
musculoskeletal pain, neck pain, pain in extremity, migraine, anxiety and pruritis (Data not
shown, CSR Table 14).
Newly Diagnosed Chronic Medical Conditions
Two percent or less of subjects in any vaccine group reported at least 1 NDCMC within 6
months after vaccination. None of the NDCMCs reported were considered by the investigator to
be related to the study vaccine (Data not shown, CSR Tables 16 and 14.36).

80

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Reviewer Comment: One PCV20 lot 1 recipient was noted in the CSR to have been
newly diagnosed with supraventricular extrasystoles. This subject (subject (b) (6) )
was a 33-year old, White, non-Hispanic, non-smoking female with a history of
palpitations occurring throughout her life. The subject, who was also noted to be
pregnant at about 11 weeks post-vaccination, reported that the palpitations started
occurring more frequently prior to her pregnancy. A heart monitor was used to evaluate
the palpitations, and the monitor showed only occasional premature atrial contractions.
The subject was diagnosed with an NDCMC of premature atrial contractions 10 weeks
after receipt of PCV20. The event was reported as mild in severity, ongoing, not serious
and not related to investigational product; the investigator noted that event represents an
early heartbeat seen in 99% of adult heart monitors. The subject gave birth to a full-term
male infant approximately one year post-vaccination (5.69 lb, 41.5 cm, head
circumference 31 cm, Apgar score within 1 min was 8, within 5 min was 9); the
estimated gestational age was 39 weeks, 2 days. The infant was considered small for
gestational age. No other AEs or SAEs were reported for this participant. The subject
confirmed that the reported palpitations decreased in frequency after her pregnancy.
This reviewer agrees that the premature atrial contractions reported in this subject are
more likely related to pregnancy rather than the study vaccination.
Immediate Adverse Reactions
Two subjects (0.1%) in the pooled PCV20 group and no subjects in the PCV13 group reported
an immediate adverse reaction within 30 minutes after vaccination. These subjects each
reported nausea and vomiting due to residual anxiety from the blood draws.
Other Significant AEs
Six subjects who had documented negative urine pregnancy tests at enrollment became
pregnant during the study (5 PCV20 recipients and 1 PCV13 recipient). Four events had an
outcome of full-term live birth, 1 event had an unknown outcome, and 1 event had an outcome
of spontaneous abortion (the latter involved a PCV13 recipient).
Two of these subjects (both PCV20 recipients) had estimated conception dates before
vaccination (Day 4 and Day 19) and were reported at Visit 2 (1 month after vaccination). The
subject with the estimated conception date 4 days prior to vaccination gave live birth to a fullterm male infant at an estimated 39 weeks gestation. The pregnancy outcome of the subject
with an estimated conception date 19 days prior to vaccination could not be determined, as the
site informed Wyeth that the subject’s telephone number was disconnected (subject (b) (6) ).
Of the remaining 4 pregnancies, the estimated conception dates were after vaccination (Day 41,
78, 80 and 126); 2 were reported at the 6-month safety telephone call and 2 had unknown
report dates. Three of these subjects (each PCV20) gave live birth to full term infants. The
fourth subject was the PCV13 recipient with the pregnancy outcome of spontaneous abortion;
the estimated conception date was ~4 months after vaccination). This subject reported being in
a motor vehicle accident 187 days after vaccination; the reported spontaneous abortion
occurred 196 days after vaccination (subject (b) (6) . The investigator considered there was
not a reasonable possibility that the event was related to the study treatment, but rather to have
more likely been triggered by the motor vehicle accident and associated fetal genetic anomaly,
likely due to trisomy 21 (based on post-fetal demise screening).

81

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Safety Analyses by Subgroups
Subgroup Analyses by Sex
A numerically higher proportion of females reported prompted local injection site reactions (pain,
redness and swelling) within 10 days after vaccination compared to males (Data not shown,
CSR Table 14.27). A numerically higher proportion of females reported fatigue, headache,
muscle pain and use of antipyretic or pain medication within 7 days after vaccination compared
to males (Data not shown, CSR 14.29). Rates of joint pain were similar between males and
females. Rates of fever were too low to identify clear trends.
Subgroup Analyses by Race
A numerically lower proportion of Black subjects reported prompted local injection site reactions
(pain, redness and swelling) within 10 days after vaccination compared to White and all other
racial groups combined (subjects in the following racial groups were combined in one “All
others” group due to low numbers: Asian, American Indian or Alaska Native, Native Hawaiian or
other Pacific Islander, multiracial or not reported) (Data not shown, CSR Table 14.28). Subjects
in the combined racial groups reported similar rates of redness and swelling and numerically
lower rates of injection site pain compared to White subjects. A numerically lower proportion of
Black subjects reported fatigue, headache, muscle pain and use of antipyretic or pain
medication within 7 days after vaccination compared to White subjects (Data not shown, CSR
Table 14.30). Rates of joint pain were similar with clear trend across racial groups evaluated. No
clear trend was observed among subjects in the combined racial groups.
Similar trends as described above were generally observed in analyses of unsolicited AEs by
sex and race.
6.2.12.3 Deaths
No deaths were reported during study B7471008.
6.2.12.4 Nonfatal Serious Adverse Events
A total of 10 subjects (0.7%) in the PCV20 groups reported a serious adverse event within 6
months after vaccination (0.4% each in the lot 1 and lot 2 groups and 1.2% in the lot 3 group).
No SAEs were reported by subjects in the PCV13 group in the same time period. No reported
SAEs were considered by the investigator to be related to the study vaccine.
6.2.12.7 Dropouts and/or Discontinuations
No subjects were withdrawn during this study for safety-related reasons.
6.2.13 Study Summary and Conclusions
Study B7471008 was designed to provide clinical data supporting manufacturing consistency
and additional safety data in the U.S. Pneumococcal vaccine-naïve adults 18-49 years of age
received 1 of 3 manufacturing scale lots of PCV20 or PCV13 control. The primary objective was
met, demonstrating that the immune responses induced by PCV20 at 1 month post-vaccination
to the 20 serotypes in the vaccine were equivalent across 3 manufacturing scale lots. The safety
profile of PCV20 among participants who received each manufacturing scale lot was
comparable to the safety profile of U.S.-licensed Prevnar 13 (the active control in this study),
and there were no important differences observed in safety outcomes among the three different
manufacturing scale lots.
82

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.3 Study B7471006
Study B7471006 was an open-label Phase 3 study designed to describe the safety and
immunogenicity of PCV20 administered to adults ≥65 years of age who have been previously
vaccinated with PPSV23 (Cohort A), PCV13 (Cohort B), or PCV13 followed by PPSV23 (Cohort
C). Cohort A and B participants were randomized 2:1 to receive PCV20 or a licensed
pneumococcal vaccine that they had not previously received (PCV13 in Cohort A and PPSV23
in Cohort B) that served as active controls for safety assessments. All Cohort C participants
received PCV20. The study was conducted between February 12, 2019 and May 29, 2020 and
enrolled a total of 875 subjects. The clinical study report was dated July 25, 2020.
Reviewer Comment: Although Wyeth considered this study to be Phase 3, the analyses
were descriptive only and there were no pre-specified success criteria for OPA
assessments. Wyeth’s intention with this study was to generate descriptive data that
would help inform efforts to immunize individuals who have previously received PPSV23
and/or to inform efforts to immunize against the 7 additional serotypes in those
previously vaccinated with PCV13.
Pneumococcal vaccination recommendations have evolved over the years, and current
recommendations differ across countries. In the U.S., from August 2014 through May
2019, the ACIP recommended vaccination of immunocompetent adults ≥65 years of age
with PCV13 followed by PPSV23 a year later (see Section 2.3 and 2.6 for more
information on ACIP recommendations on pneumococcal vaccination of adults).
6.3.1 Objectives
Primary Safety Objective: To describe the safety profile of PCV20.
•

Primary safety endpoints:
− Reported prompted local reactions (redness, swelling, and pain at the injection site)
within 10 days after vaccination.
− Reported prompted systemic events (fever, headache, fatigue, muscle pain, and
joint pain) within 7 days after vaccination.
− Reported AEs within 1 month after vaccination.
− Reported SAEs and NDCMCs within 6 months after vaccination.

Primary Immunogenicity Objective: To describe the immune responses to PCV20 in adults
previously vaccinated with PPSV23, previously vaccinated with PCV13, or previously
vaccinated with both PCV13 and PPSV23.
•

Primary immunogenicity endpoint: pneumococcal serotype-specific OPA titers 1
month after vaccination

Secondary Immunogenicity Objective: To further describe the immune responses to PCV20 in
adults previously vaccinated with PPSV23, previously vaccinated with PCV13, or previously
vaccinated with both PCV13 and PPSV23.
•

Secondary endpoints:
Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.
≥4-Fold rise in serotype-specific OPA titers from before to 1 month after
vaccination.
− Serotype-specific OPA titers ≥ LLOQ 1 month after vaccination.
−
−

83

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Exploratory Immunogenicity Objective: To further describe the immune responses induced by
PCV20.
•

Exploratory endpoints:
≥4-Fold rise in pneumococcal serotype 15C OPA titers from before to 1 month after
vaccination.
− Pneumococcal serotype 15C OPA titer ≥ LLOQ 1 month after vaccination.
− Pneumococcal serotype 15C OPA titer 1 month after vaccination.
− Fold rise in pneumococcal serotype 15C OPA titer from before to 1 month after
vaccination.
−

6.3.2 Design Overview
Study B7471006 was a Phase 3, randomized, open-label, multicenter descriptive safety and
immunogenicity study conducted in the U.S. and Sweden (Table 29). Approximately 875 adults
≥65 years of age were targeted to be enrolled into 3 different cohorts based on their prior
pneumococcal vaccination history.
Table 29. Vaccine Assignment, Study B7471006
Prior
Cohort Vaccination History
Received PPSV23 ≥1 to ≤5 years previously, but had
A
not been vaccinated with PCV13
Received PCV13 ≥6 months previouslya, but had not
been vaccinated with PPSV23

B

Previously received PCV13 followed by PPSV23
(PPSV23 must have been given ≥1 year prior to study
enrollment)

C

Vaccine
Assignment
Randomized 2:1 to
receive PCV20 or
PCV13
Randomized 2:1 to
receive PCV20 or
PPSV23
PCV20

Sample Size
PCV20: 250
PCV13: 125
PCV20: 250
PPSV23: 125
PCV20: 125

a
Although the upper limit on the interval for prior PCV13 vaccination was not specified, the U.S. ACIP recommendation for PCV13
in all adults ≥65 years of age was issued in September 2014 (5 years before enrollment into study B7471006). Therefore, the
PCV13 dose was likely to have been given no more than 5 years prior to study start.
Source: STN 125731/0.1 module 5.3.5.1, Study B7471006 Protocol Table 1, p22.

Participants in Cohort A were enrolled at both U.S. and Swedish sites, while participants in
Cohorts B and C were enrolled only at U.S. sites, where a routine recommendation for
administration of PCV13 followed by PPSV23 one (1) year later for all adults ≥65 years of age
was in place between June 2014 and June 2019.
The PCV13 arm in Cohort A and the PPSV23 arm in Cohort B served as control groups for
safety assessments of PCV20 in those cohorts. Blood was collected from all groups 13; however,
OPA titers were determined for the PCV20 groups only.
The duration of subject participation was approximately 6 months after vaccination and included
the 2 study visits and 1 telephone contact listed below. Please see Section 6.3.7 for details
regarding safety and immunogenicity monitoring.
•
•

13

Visit 1 (Day 1): Informed consent and vaccination with either PCV20 or a control
vaccine (PCV13 control in Cohort A and PPSV23 control in Cohort B)
Visit 2 (Day 28 to 42 post-vaccination): Blood draw for immunogenicity and
collection of safety data

In the control groups, blood was collected for future vaccine research.

84

Clinical Reviewer: Tina Mongeau
STN: 125731/0

•

6-Month Safety Telephone Contact (168 to 196 days post-vaccination)

6.3.3 Population
Individuals were eligible for enrollment if they met all study inclusion criteria and none of the
exclusion criteria. With two exceptions (age and prior pneumococcal vaccination history),
inclusion criteria and exclusion criteria for study B7471006 were identical to those described for
study B7471007 (see Section 6.1.3). The one exception was that study B7471006 inclusion
criteria required subjects to be ≥65 years at the time of enrollment and meet one of the following
criteria:
•
•
•

Vaccination with PPSV23 ≥1 year and ≤5 years prior to vaccination in the study,
and no prior PCV13 vaccination (Cohort A).
Vaccination with PCV13 ≥6 months prior to vaccination in the study, and no prior
PPSV23 vaccination (Cohort B).
Vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior
to vaccination in the study) (Cohort C).

Criteria for temporarily delaying vaccination at visit 1 or delaying the immunogenicity blood draw
at visits 1 and 2 were also identical to those described for study B7471007 (see Section 6.1.3).
6.3.4 Study Treatments or Agents Mandated by the Protocol
A 0.5 mL dose of PCV20, PCV13 or PPSV23 vaccines were administered intramuscularly in the
deltoid muscle of the non-dominant arm at Visit 1 based on cohort and randomization. Please
refer to Section 6.1.4 for detailed descriptions of each vaccine’s composition. The vaccine lot
numbers are as follows: PCV20 lot number X29567-2; PCV13 lot number T82473; PPSV23 lot
number R012501.
Non-study Vaccines
The name and date of administration of any permitted non-study vaccinations were recorded in
the CRF. Licensed inactivated influenza vaccine was permitted >14 days prior to or >14 days
after study product injection. Receipt of any other licensed non-study vaccine (except
pneumococcal vaccine which was prohibited in this study) was permitted after Visit 2.
6.3.6 Sites and Centers
Study B7471006 was conducted at 33 sites in the U.S. and 8 sites in Sweden. A total of 133
subjects were randomized/enrolled in Sweden and 742 subjects were randomized/enrolled in
the U.S.
6.3.7 Surveillance/Monitoring
Safety Monitoring
Safety monitoring, adverse reaction grading, and procedures for unscheduled visits in study
B7471008 were identical to those specified for study B7471007. Please see Section 6.1.7 for
details. MedDRA version 22.1 coding dictionary was also applied in study B7471006.
Immunogenicity Monitoring
Blood samples were collected from all subjects prior to and 1 month after vaccination. However,
OPA titers (for all serotypes present in PCV20 in addition to non-vaccine serotype 15C) were
only determined for sera collected from subjects in the PCV20 study groups. The PCV13 arm in
85

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Cohort A and the PPSV23 arm in Cohort B served as control groups only for safety
assessments.
6.3.8 Endpoints and Criteria for Study Success
See Section 6.3.1 of this clinical review.
6.3.9 Statistical Considerations & Statistical Analysis Plan
No hypothesis testing between vaccine groups was performed, and no formal statistical decision
rules were applied in this study. For immunogenicity results of serotype-specific OPA titers,
GMTs and GMFRs were computed along with associated 95% CIs. Missing assay results were
not imputed. OPA titers < LLOQ were set to 0.5 × LLOQ for analysis.
Analysis Populations
•

The safety population included all subjects who received at least 1 dose of PCV20
or PCV13 and had safety follow-up after vaccination. Subjects were included in
the vaccine group corresponding to the vaccine actually received.

•

The evaluable immunogenicity population was the primary analysis population for
the immunogenicity results. Participants were included in the vaccine group as
randomized in the analysis. Criteria for inclusion in this population are as follows:
−
−
−
−
−

Received PCV20,
Was enrolled in appropriate cohort based on prior pneumococcal vaccination
history,
Had Visit 2 blood draw within 27 to 49 days after study vaccination,
Had ≥1 valid and determinate OPA titer for any serotype at Visit 2, and
Had no other major protocol deviations as determined by the clinician.

•

The all-available immunogenicity population was the secondary analysis
population for immunogenicity results. Participants were included in the vaccine
group as randomized in the analysis. The criterion for inclusion in this population
was that the participant had to have received PCV20 and had at least 1 valid and
determinate OPA titer 1 month after vaccination.

•

Analysis of immunogenicity data based on the all‑available immunogenicity
population was to be performed only if there was 10% or more difference in
sample size between the evaluable immunogenicity population and the
all‑available immunogenicity population.

6.3.10 Study Population and Disposition
A total of 873 subjects were vaccinated in study B7471006; 375 subjects in Cohort A (prior
PPSV23 only), 373 in Cohort B, and 125 in Cohort C (prior PCV13 and PPSV23). Two subjects
enrolled and randomized to Cohort B were not vaccinated. Of all randomized subjects, 98.4%,
99.2% and 100% in Cohorts A, B, and C, respectively, completed the study.
6.3.10.1 Populations Enrolled/Analyzed
Section 6.3.9 of this clinical review defines this study’s populations enrolled and analyzed.

86

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Among subjects randomized to receive PCV20 in Cohorts A and B and among subjects in
Cohort C, a similar proportion were included in the evaluable and all-available immunogenicity
populations across the study cohorts (Table 30). Approximately 3% or less of subjects were
excluded from the evaluable immunogenicity population and ≤1.6% of subjects were excluded
from the all-available population. The most common reasons for exclusion from these
immunogenicity analysis populations were not having a blood sample collected within the prespecified time frame and not having a valid and determinate OPA titer after vaccination.
No immunogenicity analyses were performed using the all-available immunogenicity population,
as there was <10% difference in sample sizes between the evaluable and all-available
immunogenicity populations for each cohort.
Table 30. Evaluable and All-Available Immunogenicity Populations, Study B7471006
Cohort A
Cohort B
Cohort C
PCV20
PCV20
PCV20
Study Cohortsa
nb (%)
nb (%)
nb (%)
Randomizedc
253 (100.0) 248 (100.0) 125 (100.0)
Evaluable Immunogenicity Population
247 (97.6) 243 (98.0) 121 (96.8)
Subjects excluded from evaluable immunogenicity populationd
6 (2.4)
5 (2.0)
4 (3.2)
Reason for exclusion
Did not receive PCV20 as randomized
0 (0.0)
2 (0.8)
0 (0.0)
Did not have Visit 2 blood sample collection within 27 to 49
days after vaccination
5 (2.0)
5 (2.0)
1 (0.8)
Did not have valid and determinate OPA titer after
vaccination
4 (1.6)
4 (1.6)
1 (0.8)
Had any other major protocol deviationse
1 (0.4)
1 (0.4)
2 (1.6)
All-Available Immunogenicity Population
249 (98.4) 244 (98.4) 124 (99.2)
Subjects excluded from all-available immunogenicity
populationd
4 (1.6)
4 (1.6)
1 (0.8)
Reason for exclusion
Did not receive at least 1 dose of investigational product
0 (0.0)
2 (0.8)
0 (0.0)
Did not have valid and determinate OPA titer after any
vaccination
4 (1.6)
4 (1.6)
1 (0.8)
Abbreviation: OPA = opsonophagocytic activity.
Note: There are no immunogenicity results for the control groups PCV13 (Cohort A) and PPSV23 (Cohort B). Cohort C was a single
arm cohort.
a
Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination
Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and no prior PPSV23 vaccination
Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
b
n = Number of subjects with the specified characteristic.
c
These values are the denominators for the percentage calculations.
d
Subjects may have been excluded for more than 1 reason.
e
One Cohort A subject who was vaccinated with PCV20 was later determined to have received PPSV23 >5 years prior to
randomization. One Cohort B subject who was vaccinated with PCV20 was later determined to have received PPSV23 followed by
PCV13 prior to randomization. Two Cohort C subjects who were vaccinated with PCV20 were later determined to have received
PPSV23 <1 year prior to being enrolled in the study.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 5, p30.

6.3.10.1.1 Demographics
Study groups across cohorts were similar with respect to baseline demographics and smoking
history (Table 31). Overall, approximately 44%-48% were males, 90%-94% were White, 3%-7%
were Black, and 0.8%-3.3% were among one of the other racial groups (Asian, American Indian
or Alaskan Native, Native Hawaiian or other Pacific Islander, Multiracial or not reported). In
Cohort A, 35.5% of the participants were enrolled in Sweden. The mean or median number of
years since the prior pneumococcal vaccination was not summarized in the clinical study report.

87

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 31. Demographic Characteristics and Smoking History, Safety Population, Study B7471006
Cohort A
Cohort A
Cohort A
Cohort B
Cohort B
Cohort B
Cohort C
PCV20
PCV13
Total
PCV20
PPSV23
Total
PCV20
Nb=253
Nb=122
Nb=375
Nb=246
Nb=127
Nb=373
Nb=125
Study Groupa
nc (%)
nc (%)
nc (%)
nc (%)
nc (%)
nc (%)
nc (%)
Sex
Male
113 (44.7)
58 (47.5)
171 (45.6)
108 (43.9)
59 (46.5)
167 (44.8)
60 (48.0)
Female
140 (55.3)
64 (52.5)
204 (54.4)
138 (56.1)
68 (53.5)
206 (55.2)
65 (52.0)
Race
White
236 (93.3)
110 (90.2)
346 (92.3)
226 (91.9)
118 (92.9)
344 (92.2)
117 (93.6)
Black or African American
15 (5.9)
8 (6.6)
23 (6.1)
14 (5.7)
6 (4.7)
20 (5.4)
4 (3.2)
Asian
1 (0.4)
2 (1.6)
3 (0.8)
0 (0.0)
2 (1.6)
2 (0.5)
0 (0.0)
American Indian or Alaska Native
1 (0.4)
0 (0.0)
1 (0.3)
1 (0.4)
0 (0.0)
1 (0.3)
0 (0.0)
Native Hawaiian or other Pacific Islander
0 1 (0.8)
0 (0.0)
1 (0.3)
1 (0.4)
1 (0.8)
2 (0.5)
0 (0.0)
Multiracial
0 (0.0)
0 (0.0)
0 (0.0)
1 (0.4)
0 (0.0)
1 (0.3)
3 (2.4)
Not reported
0 (0.0)
1 (0.8)
1 (0.3)
3 (1.2)
0 (0.0)
3 (0.8)
1 (0.8)
Ethnicity
Hispanic/Latino
4 (1.6)
3 (2.5)
7 (1.9)
6 (2.4)
1 (0.8)
7 (1.9)
2 (1.6)
Non-Hispanic/non-Latino
247 (97.6)
117 (95.9)
364 (97.1)
231 (93.9)
122 (96.1)
353 (94.6)
113 (90.4)
Not reported
2 (0.8)
2 (1.6)
4 (1.1)
9 (3.7)
4 (3.1)
13 (3.5)
10 (8.0)
Country
U.S.
163 (64.4)
79 (64.8)
242 (64.5) 246 (100.0) 127 (100.0) 373 (100.0) 125 (100.0)
Sweden
90 (35.6)
43 (35.2)
133 (35.5)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
Age group
65-69 years
143 (56.5)
63 (51.6)
206 (54.9)
136 (55.3)
72 (56.7)
208 (55.8)
70 (56.0)
70-79 years
105 (41.5)
57 (46.7)
162 (43.2)
86 (35.0)
43 (33.9)
129 (34.6)
47 (37.6)
≥80 years
5 (2.0)
2 (1.6)
7 (1.9)
24 (9.8)
12 (9.4)
36 (9.7)
8 (6.4)
Age at vaccination (Years)
Mean (SD)
69.6 (3.88)
70.2 (4.09)
69.8 (3.96)
70.7 (5.71)
70.6 (5.73)
70.7 (5.71)
70.8 (4.26)
Median (min, max)
69.0 (65, 84 69.0 (65, 80) 69.0 (65, 84) 68.0 (65, 92) 68.0 (65, 92) 68.0 (65, 81) 69.0 (65, 90)
Smoking history
Current smoker
24 (9.5)
7 (5.7)
31 (8.3)
13 (5.3)
6 (4.7)
19 (5.1)
5 (4.0)
Mean (SD) # years smoking
46.2 (13.68) 39.6 (18.13) 44.7 (14.74) 37.5 (16.86)
47.5 (6.23) 40.6 (14.94)
50.9 (7.02)
Ex-smoker
94 (37.2)
43 (35.2)
137 (36.5)
95 (38.6)
36 (28.3)
131 (35.1)
43 (34.4)
Mean (SD) # years since quitting
24.7 (14.31) 26.0 (14.93) 25.1 (14.46) 27.8 (15.58) 30.8 (14.70) 28.6 (15.35) 33.4 (15.44)
Never smoked
135 (53.4)
72 (59.0)
207 (55.2)
138 (56.1)
85 (66.9)
223 (59.8)
77 (61.6)
Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination; Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and
no prior PPSV23 vaccination; Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
b
N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
c
n = Number of subjects with the specified characteristic.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 6, p31-32.
a

88

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.3.10.1.2 Medical/Behavioral Characterization of the Enrolled Population
Table 32 presents select baseline comorbidities noted in the medical history in the safety
population. The proportion of subjects with any medical history was similar across study groups
(overall 93%-100%). The proportion of subjects reporting a medical history in each System
Organ Class was generally highest in Cohort C (prior PCV13 and PPSV23).
Table 32. Medical History by Study Cohortsa, Safety Population, Study B7471006
Cohort A
Cohort A
Cohort B
Cohort B
PCV20
PCV13
PCV20
PPSV23
Nb=253
Nb=122
Nb=246
Nb=127
c
c
c
Comorbidity
n (%)
n (%)
n (%)
nc (%)
Any medical history by MedDRA
241 (95.3) 114 (93.4) 246 (100.0) 127 (100.0)
SOC/PT
Blood and lymphatic system
7 (2.8)
4 (3.3)
6 (2.4)
5 (3.9)
disorders
Cardiac disorders
56 (22.1)
24 (19.7)
40 (16.3)
27 (21.3)
Endocrine disorders
43 (17.0)
21 (17.2)
68 (27.6)
29 (22.8)
Gastrointestinal disorders
76 (30.0)
46 (37.7)
90 (36.6)
61 (48.0)
Hepatobiliary disorders
16 (6.3)
7 (5.7)
22 (8.9)
15 (11.8)
Immune system disorders
65 (25.7)
34 (27.9)
110 (44.7)
49 (38.6)
Drug hypersensitivity
40 (15.8)
16 (13.1)
59 (24.0)
35 (27.6)
Infections and infestations
37 (14.6)
22 (18.0)
51 (20.7)
30 (23.6)
Metabolism and nutrition disorders
146 (57.7)
70 (57.4)
169 (68.7)
72 (56.7)
Hypercholesterolaemia
49 (19.4)
18 (14.8)
59 (24.0)
27 (21.3)
Hyperlipidemia
58 (22.9)
27 (22.1)
79 (32.1)
34 (26.8)
Obesity
22 (8.7)
10 (8.2)
27 (11.0)
11 (8.7)
Type 2 diabetes mellitus
39 (15.4)
17 (13.9)
37 (15.0)
20 (15.7)
Nervous system disorders
61 (24.1)
26 (21.3)
66 (26.8)
25 (19.7)
Renal and urinary disorders
23 (9.1)
16 (13.1)
39 (15.9)
15 (11.8)
Respiratory, thoracic and
78 (30.8)
35 (28.7)
52 (21.1)
27 (21.3)
mediastinal disorders
Asthma
24 (9.5)
10 (8.2)
15 (6.1)
8 (6.3)
Chronic obstructive pulmonary
23 (9.1)
9 (7.4)
8 (3.3)
6 (4.7)
disease
Sleep apnoea syndrome
24 (9.5)
8 (6.6)
15 (6.1)
6 (4.7)
Vascular disorders
151 (59.7)
72 (59.0)
141 (57.3)
76 (59.8)
Hypertension
131 (51.8)
58 (47.5)
132 (53.7)
66 (52.0)

Cohort C
PCV20
Nb=125
nc (%)
125 (100.0)
9 (7.2)
32 (25.6)
25 (20.0)
67 (53.6)
8 (6.4)
48 (38.4)
33 (26.4)
19 (15.2)
96 (76.8)
33 (26.4)
41 (32.8)
21 (16.8)
23 (18.4)
34 (27.2)
27 (21.6)
41 (32.8)
10 (8.0)
7 (5.6)
16 (12.8)
76 (60.8)
64 (51.2)

Note: MedDRA (v22.1) coding dictionary applied.
a
Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination
Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and no prior PPSV23 vaccination
Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
b
N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
c
n = Number of subjects with the specified characteristic.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 14.1, p65-95.

6.3.10.1.3 Subject Disposition
The disposition of all randomized subjects (as described in Section 6.3.10) are summarized in
Table 33. Overall, 98%-100% of subjects completed the study.

89

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 33. Disposition, All Randomized Subjects, Study B7471006
Cohort Cohort Cohort Cohort Cohort
A
A
A
B
B
PCV20 PCV13
Total PCV20 PPSV23
Disposition
na (%)
na (%)
na (%)
na (%)
na (%)
253
122
375
248
127
Randomized
(100.0) (100.0) (100.0) (100.0) (100.0)
Not Vaccinated
0 (0.0)
0 (0.0)
0 (0.0)
2 (0.8)
0 (0.0)
253
122
375
246
127
Vaccinated
(100.0) (100.0) (100.0)
(99.2) (100.0)
Completed 1month
251
120
371
245
127
follow-up after
(99.2)
(98.4)
(98.9)
(98.8) (100.0)
vaccination
250
119
369
245
126
Completed study
(98.8)
(97.5)
(98.4)
(98.8)
(99.2)
Withdrawn from study
3 (1.2)
3 (2.5)
6 (1.6)
3 (1.2)
1 (0.8)
Reason for withdrawal
Lost to follow-up
1 (0.4)
1 (0.8)
2 (0.5)
0 (0.0)
0 (0.0)
No longer meets
0 (0.0)
1 (0.8)
1 (0.3)
0 (0.0)
0 (0.0)
eligibility criteria
Protocol deviation
1 (0.4)
1 (0.8)
2 (0.5)
2 (0.8)
0 (0.0)
Withdrawal by
1 (0.4)
0 (0.0)
1 (0.3)
1 (0.4)
1 (0.8)
subject

Cohort
B
Total
na (%)
375
(100.0)
2 (0.5)
373
(99.5)

Cohort
C
PCV20
na (%)
125
(100.0)
0 (0.0)
125
(100.0)

372
(99.2)

125
(100.0)

371
(98.9)
4 (1.1)

125
(100.0)
0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

2 (0.5)

0 (0.0)

2 (0.5)

0 (0.0)

Note: Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination
Note: Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and no prior PPSV23 vaccination
Note: Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
a
n = Number of subjects with the specified characteristic.
b
These values are the denominators for the percentage calculations.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 4, p27-28.

6.3.11 Efficacy Analyses
6.3.11.1 Analyses of Primary Endpoint(s)
Immune responses to all 20 vaccine serotypes were observed 1 month after PCV20 based on
OPA GMTs in all 3 cohorts, regardless of prior pneumococcal vaccination (Table 34).
At baseline (prior to study vaccination), OPA GMTs for the PCV13 serotypes were generally
highest in Cohort C (prior PCV13 and PPSV23), followed by Cohort B (prior PCV13 only) (Data
not shown, CSR, Table 8). Baseline GMTs were lowest in Cohort A (prior PPSV23 only).
At baseline, OPA GMTs for the 7 additional serotypes were generally highest in participants with
prior PCV13 and PPSV23, followed by participants with prior PPSV23 only (Data not shown,
CSR Table 8). Baseline GMTs were lowest in participants with prior PCV13 only.
Reviewer Comment: The baseline OPA GMTs for the 7 new serotypes were generally
highest among participants with prior PCV13 and PPSV23. Given that PCV13 does not
contain these 7 new serotypes, participants with prior PCV13 and PPSV23 may have
had higher baseline OPA GMTs compared to participants with prior PPSV23 alone due
to timing of the prior PPSV23 dose. Participants with prior PCV13 and PPSV23 (who
had to have their PPSV23 dose at least 1 year prior to vaccination) may have had a
shorter interval between their PPSV23 dose and PCV20 study vaccination compared to
participants with prior PPSV23 only (who had to have their PPSV23 dose 1 to 5 years
prior to study enrollment).

90

Clinical Reviewer: Tina Mongeau
STN: 125731/0

At 1 month after PCV20 vaccination, OPA GMTs for most of the PCV13 serotypes were
generally higher in participants with prior PCV13 only or prior PCV13 and PPSV23 (ranging
from 54 (serotype 3) to 4157 (serotype 22F) among participants with prior PCV13 only and
ranging from 39 (serotype 3) to 2718 (serotype 22F) among participants with prior PCV13 and
PPSV23) (Table 34). At 1-month post-PCV20, OPA GMTs for the PCV13 serotypes were lowest
in participants with prior PPSV23 only, ranging from 31 (serotype 3) to 2026 (serotype 33F).
At 1 month after PCV20 vaccination, OPA GMTs for the 7 new serotypes were generally highest
in participants with prior PCV13 only. The OPA GMTs for the 7 new serotypes were the lowest
in participants with prior PPSV23 only. OPA GMTs in participants with prior PCV13 and
PPSV23 fell in between the OPA GMTs achieved by the other two study cohorts (Table 34).

91

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Table 34. Pneumococcal Opsonophagocytic Activity GMTs, Evaluable Immunogenicity Population, Study B7471006
Cohort Aa
Cohort Aa
Cohort Ba
Cohort Ba
Cohort Ca
Cohort Cs
(prior
(prior
(prior
(prior
(prior PCV13
(prior PCV13
PPSV23)
PPSV23)
PCV13)
PCV13)
and PPSV23)
and PPSV23)
PCV20
PCV20
PCV20
PCV20
PCV20
PCV20
Serotype
nb
GMT (95% CI)c
nb
GMT (95% CI)c
nb
GMT (95% CI)c
PCV13 Serotypes
1
246
51 (42, 62)
243
115 (96, 138)
120
82 (61, 110)
3
243
31 (27, 36)
242
54 (47, 63)
119
39 (32, 48)
4
236
150 (118, 190)
241
335 (274, 410)
116
194 (143, 262)
5
244
63 (53, 75)
243
87 (73, 104)
120
84 (65, 108)
6A
242
749 (577, 972)
241
1081 (880, 1327)
121
1085 (797, 1478)
6B
243
727 (574, 922)
241
1159 (951, 1414)
121
1033 (755, 1415)
7F
240
378 (316, 452)
243
555 (467, 661)
120
346 (277, 432)
9V
241
550 (454, 667)
237
1085 (894, 1318)
117
723 (558, 938)
14
240
391 (315, 486)
242
665 (554, 798)
119
581 (434, 777)
18C
245
552 (445, 684)
240
846 (693, 1033)
120
621 (470, 821)
19A
242
239 (198, 288)
242
365 (303, 440)
120
341 (264, 440)
19F
244
159 (131, 192)
242
242 (199, 294)
118
218 (168, 282)
23F
245
152 (115, 199)
243
450 (358, 566)
120
293 (204, 421)
New Serotypes
8
230
212 (172, 261)
226
603 (483, 753)
109
294 (220, 392)
10A
219
1012 (807, 1270)
210
2005 (1586, 2536)
110
1580 (1176, 2124)
11A
216
1473 (1192, 1820)
206
1908 (1542, 2362)
102
1567 (1141, 2151)
12F
224
1055 (822, 1353)
214
1763 (1372, 2267)
110
1401 (1002, 1960)
15B
225
647 (491, 853)
201
1480 (1093, 2003)
110
1067 (721, 1578)
22F
218
1773 (1355, 2320)
206
4157 (3244, 5326)
108
2718 (1978, 3733)
33F
216
2026 (1684, 2437)
208
3175 (2579, 3908)
103
2183 (1639, 2908)
Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.
Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.
a
Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination
Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and no prior PPSV23 vaccination
Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
b
n = Number of subjects with valid and determinate assay results for the given serotype at the specified time point.
c
GMTs and 2-sided CIs calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distr bution).
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 8, p35-36.

92

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.3.11.2 Analyses of Secondary Endpoints
Proportion of Participants Achieving a ≥4-Fold Rise in Pneumococcal OPA
For most of the PCV13 serotypes, the proportions of participants who achieved a ≥4-fold rise in
OPA titers from before to 1 month after PCV20 were generally similar in Cohort B (prior PCV13
only) and Cohort A (prior PPSV23 only). The proportions of participants who achieved a ≥4-fold
rise in OPA titers from before to 1 month after PCV20 were lowest in Cohort C (prior PCV13 and
PPSV23) (Table 35).
For the 7 additional serotypes, the proportions of participants with a ≥4-fold rise in OPA titers
from before to 1 month after PCV20 were highest in Cohort B (prior PCV13 only); Cohort B
participants were naïve to these vaccine serotypes prior to receiving PCV20 (Table 35). The
proportions of participants with a ≥4-fold rise in OPA titers from before to 1 month after PCV20
were similar in Cohorts A (prior PPSV23 only) and C (prior PCV13 and PPSC23).

93

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Table 35. Proportion of Subjects Achieving a ≥4-Fold Rise in Pneumococcal OPA Titers From Before Vaccination to 1 Month After
Vaccination, Evaluable Immunogenicity Population, Study B7471006
Cohort Ca
Cohort Ca
a
a
a
a
Cohort A
Cohort A
Cohort B Cohort B
(prior
(prior
Cohort Ca
a
a
(prior
Cohort A
(prior
(prior
Cohort B
(prior
PCV13 and PCV13 and (prior PCV13
(prior PCV13)
PPSV23) (prior PPSV23) PCV13)
PCV13)
and PPSV23)
PPSV23)
PPSV23)
PPSV23)

Serotype
PCV13 Serotypes
1
3
4
5
6A
6B
7F
9V
14
18C
19A
19F
23F
New Serotypes
8
10A
11A
12F
15B
22F
33F

PCV20
Nb

PCV20
nc

PCV20
% (95% CI)d

PCV20
Nb

PCV20
nc

PCV20
% (95% CI)d

PCV20
Nb

PCV20
nc

PCV20
% (95% CI)d

245
243
231
241
239
238
233
226
236
245
239
243
242

56
72
95
62
147
127
61
64
37
72
71
71
120

22.9 (17.8, 28.6)
29.6 (24.0, 35.8)
41.1 (34.7, 47.8)
25.7 (20.3, 31.7)
61.5 (55.0, 67.7)
53.4 (46.8, 59.8)
26.2 (20.7, 32.3)
28.3 (22.5, 34.7)
15.7 (11.3, 21.0)
29.4 (23.8, 35.5)
29.7 (24.0, 35.9)
29.2 (23.6, 35.4)
49.6 (43.1, 56.1)

243
240
235
243
234
238
241
228
237
240
239
241
242

98
99
97
66
132
131
73
82
59
92
70
79
142

40.3 (34.1, 46.8)
41.3 (35.0, 47.8)
41.3 (34.9, 47.9)
27.2 (21.7, 33.2)
56.4 (49.8, 62.9)
55.0 (48.5, 61.5)
30.3 (24.6, 36.5)
36.0 (29.7, 42.6)
24.9 (19.5, 30.9)
38.3 (32.2, 44.8)
29.3 (23.6, 35.5)
32.8 (26.9, 39.1)
58.7 (52.2, 64.9)

120
119
115
120
118
119
119
114
119
119
117
118
119

25
22
29
19
53
42
17
23
19
21
18
20
51

20.8 (14.0, 29.2)
18.5 (12.0, 26.6)
25.2 (17.6, 34.2)
15.8 (9.8, 23.6)
44.9 (35.7, 54.3)
35.3 (26.8, 44.6)
14.3 (8.5, 21.9)
20.2 (13.2, 28.7)
16.0 (9.9, 23.8)
17.6 (11.3, 25.7)
15.4 (9.4, 23.2)
16.9 (10.7, 25.0)
42.9 (33.8, 52.3)

223
198
184
208
211
207
203

89
90
56
107
79
118
38

39.9 (33.4, 46.7)
45.5 (38.4, 52.7)
30.4 (23.9, 37.6)
51.4 (44.4, 58.4)
37.4 (30.9, 44.3)
57.0 (50.0, 63.8)
18.7 (13.6, 24.8)

219
199
183
200
184
191
196

159
141
100
153
122
159
105

72.6 (66.2, 78.4)
70.9 (64.0, 77.1)
54.6 (47.1, 62.0)
76.5 (70.0, 82.2)
66.3 (59.0, 73.1)
83.2 (77.2, 88.2)
53.6 (46.3, 60.7)

101
109
91
103
99
104
99

31
48
32
42
38
57
19

30.7 (21.9, 40.7)
44.0 (34.5, 53.9)
35.2 (25.4, 45.9)
40.8 (31.2, 50.9)
38.4 (28.8, 48.7)
54.8 (44.7, 64.6)
19.2 (12.0, 28.3)

Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.
a
Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination; Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and
no prior PPSV23 vaccination; Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
b
N = number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after vaccination blood sample collections. These values are
the denominators for the percentage calculations. c n = Number of subjects with a ≥4-fold rise in titers from before vaccination to 1 month after vaccination for the specified serotype.
d
Exact 2-sided CI based on the Clopper and Pearson method. Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 10, p40-41.

94

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.3.11.3 Subpopulation Analyses
OPA GMTs before and 1 month after PCV20 by sex were presented in the study CSR (Data not
shown, CSR Table 14.4). Serotype-specific OPA GMTs measured 1 month after PCV20 were
generally higher among females compared to males in the evaluable immunogenicity
populations for each study cohort.
6.3.11.4 Dropouts and/or Discontinuations
See Section 6.3.10.1.3 for information on subject disposition, including withdrawals. Missing
values were not imputed for subjects who had missing blood draws.
6.3.11.5 Exploratory and Post Hoc Analyses
In exploratory analyses, the proportion of subjects achieving a ≥4-fold rise in serotype 15C OPA
titers from before to 1 month after vaccination was 9.0% (95% CI 5.6, 13.5) in Cohort A, 19.5%
(95% CI 14.4, 25.5) in Cohort B, and 11.7% (95% CI 6.2, 19.5) in Cohort C.
However, due to the substantial proportion of subjects with OPA titers < LLOQ, exploratory
analyses of serotype 15C OPA responses in this study are not considered interpretable. The
proportion of subjects achieving OPA titers ≥ LLOQ was 21.8% (95% CI 17, 28) in Cohort A
(N=223); 31.3% (95% CI 25, 38) in Cohort B (N=210); and 28.6% (95% CI 20, 38) in Cohort C
(N=103). In addition, the OPA GMTs in each study cohort were consistently lower than the
(b) (4)
serotype 15C LLOQ (note: the serotype 15C LLOQ is
. The OPA GMTs achieved by subjects
in each of the cohorts were as follows: 58.9 (95% CI 52, 66) in Cohort A (N=234); 69.5 (95% CI
60, 80) in Cohort B (N=214); and 67.0 (95% CI 55, 81) in Cohort C (N=105).
6.3.12 Safety Analyses
6.3.12.1 Methods
Safety analyses were descriptive. Please see Section 6.3.7 for details regarding safety
surveillance/monitoring, Section 6.3.1 for a listing of safety endpoints, and Section 6.3.9 for
details regarding safety analysis populations.
6.3.12.2 Overview of Adverse Events
Solicited Local Injection Site Adverse Reactions
The proportions of participants who reported solicited local reactions within 10 days after PCV20
were generally similar across cohorts regardless of prior pneumococcal vaccination and also
were generally similar to the corresponding control groups within Cohorts A (prior PPSV23 only)
and B (prior PCV13 only) (Table 36). Across the 3 cohorts and after both PCV20 and control
vaccines, most of these local reactions were of mild or moderate severity, and the most
frequently reported local reaction was pain at the injection site (ranging from 43.0% after PCV13
in Cohort A to 61.2% after PCV20 in Cohort B).
Within each study cohort, the day of onset and duration of solicited local adverse reactions were
similar (Data not shown, CSR Tables 14.10 and 14.11). Local reactions among PCV20
recipients had a mean onset of Day 1.4 (SD 0.6) or Day 3.1 (SD 2.2) (Day 1 was the day of
vaccination) and generally resolved with mean durations of 2.0 (SD 1.3) to 3.9 days (SD 3.8)
days across all vaccine groups and cohorts.

95

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 36. Local Reactions, by Maximum Severity, Within 10 Days After Vaccination, Safety
Population, Study B7471006
Cohort Aa
Cohort Aa
Cohort Ba
Cohort Ba
Cohort Ca
PCV20
PCV13
PCV20
PPSV23
PCV20
Nb=245
Nb=126
Nb=125
Nb=253
Nb=121
Local Reaction
nc (%)
nc (%)
nc (%)
nc (%)
nc (%)
d
Any local reaction
134 (53.0)
53 (43.8)
157 (64.1)
73 (57.9)
68 (54.4)
Pain at Injection Sitee
Any
127 (50.2)
52 (43.0)
150 (61.2)
71 (56.3)
66 (52.8)
Mild
116 (45.8)
47 (38.8)
134 (54.7)
51 (40.5)
59 (47.2)
Moderate
11 (4.3)
4 (3.3)
15 (6.1)
18 (14.3)
7 (5.6)
Severe
0 (0.0)
1 (0.8)
1 (0.4)
2 (1.6)
0 (0.0)
Swellingf
Any (>2.0 cm)
25 (9.9)
8 (6.6)
23 (9.4)
18 (14.3)
5 (4.0)
Mild
13 (5.1)
8 (6.6)
14 (5.7)
8 (6.3)
2 (1.6)
Moderate
9 (3.6)
0 (0.0)
9 (3.7)
9 (7.1)
3 (2.4)
Severe
3 (1.2)
0 (0.0)
0 (0.0)
1 (0.8)
0 (0.0)
Rednessf
Any (> 2.0 cm)
20 (7.9)
3 (2.5)
21 (8.6)
16 (12.7)
6 (4.8)
Mild
9 (3.6)
2 (1.7)
7 (2.9)
6 (4.8)
2 (1.6)
Moderate
8 (3.2)
1 (0.8)
13 (5.3)
9 (7.1)
4 (3.2)
Severe
3 (1.2)
0 (0.0)
1 (0.4)
1 (0.8)
0 (0.0)
Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination;
Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and no prior PPSV23 vaccination;
Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
b
N = number of subjects with any e-diary data reported after vaccination. This value is the denominator for the
percentage calculations.
c
n = Number of subjects with the specified characteristic.
d
Any local reaction = any pain at injection site, any swelling >2.0 cm, or any redness >2.0 cm during Day 1 to Day 10
after vaccination.
e
Mild = does not interfere with activity, moderate = interferes with activity, severe = prevents daily activity. Any = mild,
moderate or severe.
f
Mild is >2.0 to 5.0 cm, moderate is >5.0 to 10.0 cm, severe is >10.0 cm. Any = mild, moderate or severe.
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 13, p46-47.
a

Solicited Systemic Adverse Reactions
The proportions of participants who reported prompted systemic events within 7 days after
PCV20 were generally similar across cohorts regardless of prior pneumococcal vaccination and
also were generally similar to the corresponding control groups within Cohorts A (prior PPSV23
only) and B (prior PCV13 only) (Table 37). The rate of fever was low; fever was reported after
PCV20 in 2 participants (0.8%) with prior PPSV23 only, and after PPSV23 in 2 participants
(1.6%) with prior PCV13 only.
Across the 3 cohorts and after both PCV20 and control vaccines, most systemic events were
mild or moderate in severity, and the most frequently reported systemic event was muscle pain
(ranging from 31.4% after PCV13 in Cohort A to 46.0% after PPSV23 in Cohort B).
Within each study cohort, the day of onset and duration of solicited systemic adverse reactions
were similar (Data not shown, CSR Tables 14.15 and 14.16). Systemic adverse reactions had a
mean onset day between Day 1.7 (SD 1.1) to Day 3.5 (SD 2.1) (Day 1 was the day of
vaccination) and generally resolved with mean durations between 2.0 days (SD 1.7) to 4.2 (SD
5.4) days for all vaccine groups and cohorts.

96

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 37. Systemic Events, by Maximum Severity, Within 7 Days After Vaccination, Safety
Population, Study B7471006
Cohort Aa
Cohort Aa
Cohort Ba
Cohort Ba
Cohort Ca
PCV20
PCV13
PCV20
PPSV23
PCV20
Nb=253
Nb=121
Nb=245
Nb=126
Nb=125
Local Reaction
nc (%)
nc (%)
nc (%)
nc (%)
nc (%)
Any Systemic Adverse
131 (51.8)
53 (43.8)
123 (50.2)
75 (59.5)
66 (52.8)
Reactiond
e
Muscle pain
Any
81 (32.0)
38 (31.4)
83 (33.9)
58 (46.0)
47 (37.6)
Mild
66 (26.1)
29 (24.0)
62 (25.3)
40 (31.7)
35 (28.0)
Moderate
14 (5.5)
6 (5.0)
21 (8.6)
15 (11.9)
11 (8.8)
Severe
1 (0.4)
3 (2.5)
0 (0.0)
3 (2.4)
1 (0.8)
Fatiguee
Any
73 (28.9)
27 (22.3)
76 (31.0)
42 (33.3)
41 (32.8)
Mild
45 (17.8)
12 (9.9)
48 (19.6)
25 (19.8)
24 (19.2)
Moderate
28 (11.1)
12 (9.9)
25 (10.2)
17 (13.5)
15 (12.0)
Severe
0 (0.0)
3 (2.5)
3 (1.2)
0 (0.0)
2 (1.6)
Headachee
Any
45 (17.8)
22 (18.2)
33 (13.5)
27 (21.4)
24 (19.2)
Mild
32 (12.6)
15 (12.4)
24 (9.8)
26 (20.6)
16 (12.8)
Moderate
12 (4.7)
7 (5.8)
9 (3.7)
1 (0.8)
7 (5.6)
Severe
1 (0.4)
0 (0.0)
0 (0.0)
0 (0.0)
1 (0.8)
Joint paine
Any
17 (6.7)
13 (10.7)
29 (11.8)
20 (15.9)
21 (16.8)
Mild
12 (4.7)
6 (5.0)
19 (7.8)
13 (10.3)
16 (12.8)
Moderate
5 (2.0)
6 (5.0)
10 (4.1)
7 (5.6)
5 (4.0)
Severe
0 (0.0)
1 (0.8)
0 (0.0)
0 (0.0)
0 (0.0)
Fever
≥38.0°C
2 (0.8)
0 (0.0)
0 (0.0)
2 (1.6)
0 (0.0)
≥38.0°C to 38.4°C
2 (0.8)
0 (0.0)
0 (0.0)
1 (0.8)
0 (0.0)
>38.4°C to 38.9°C
0 (0.0)
0 (0.0)
0 (0.0)
1 (0.8)
0 (0.0)
>38.9°C to 40.0°C
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
>40.0°C
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
Use of antipyretic
40 (15.8)
18 (14.9)
42 (17.1)
25 (19.8)
22 (17.6)
or pain medicationf
Cohort A: vaccination with PPSV23 ≥1 year and ≤5 years prior to enrollment, and no prior PCV13 vaccination;
Cohort B: vaccination with PCV13 ≥6 months prior to enrollment, and no prior PPSV23 vaccination;
Cohort C: vaccination with PCV13 followed by PPSV23 (PPSV23 vaccination ≥1 year prior to enrollment)
b
N = number of subjects with any e-diary data reported after vaccination. This value is the denominator for the
percentage calculations.
c
n = Number of subjects with the specified characteristic.
d
Any systemic adverse reaction = any fever ≥38.0℃, any fatigue, any headache, any muscle pain, or any joint pain
during Day 1 to Day 7 after vaccination.
e
Mild = does not interfere with activity, moderate = some interference with activity, severe = prevents daily activity. Any =
mild, moderate or severe.
f
Severity was not collected for use of antipyretic or pain medication. The numbers in the table reflect yes responses (i.e.,
number of events reported).
Source: STN 1259731/0.1, module 5.3.5.1, Study B7471006. Clinical Study Report, Table 14, p49-51.
a

Unsolicited Adverse Events (AEs) Reported Through 30-Days Post-Vaccination
In the PCV20 groups, the proportions of subjects reporting AEs were low and generally similar
across the 3 cohorts (7.5% in Cohort A (prior PPSV23 only), 4.9% in Cohort B (prior PCV13
only), and 10.4%, in Cohort C (prior PCV13 and PPSV23)) and were similar to the proportions
after PCV13 (9.0%) and after PPSV23 (11.0%) (Data not shown, CSR Table 15).The most
frequently reported AEs were in the SOC Infections and infestations (1.2%-3.2% across study
groups).
97

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Newly Diagnosed Chronic Medical Conditions
The proportions of participants who reported any NDCMC within 6 months after vaccination
were low (≤4.0%) in all vaccine groups and generally similar with no clear or consistent
differences between groups (Data not shown, Supplemental Table 14.29). There were no
NDCMCs (Data not shown, CSR Appendix 16.2.7.10) considered related to the study vaccine in
the study.
Immediate Adverse Reactions
Across all study groups, immediate AEs after vaccination were reported by ≤0.8% of subjects
(Data not shown, CSR Supplemental Table 14.22). Dizziness and paresthesia were reported 30
minutes after vaccination by one participant in Cohort A (prior PPSV23 only) who received
PCV20. The investigator attributed these symptoms to dehydration, anxiety and hypotension
and were not considered related to the vaccine (STN 125731/0.22). Dizziness was reported as
an immediate AE by one participant in Cohort B (prior PCV13 only) who received PPSV23 (Data
not shown, Supplemental Table 14.22); this immediate AE was considered related to PPSV23
by the investigator (CSR Appendix 16.2.7.7).
Other Significant Adverse Events
No participants reported other significant adverse events during the study.
Solicited Adverse Reactions by Subgroups
Subgroup analyses were performed by sex for the proportions of participants reporting
prompted local reactions and systemic events by maximum severity as well as for unsolicited
AEs within 1 month post-vaccination. However, the number of participants by sex reporting AEs
within 1 month after vaccination were too low to allow meaningful comparisons; therefore, this
review focuses on subgroup analyses of solicited adverse reactions by sex. Because ≥90.2% of
subjects were White and ≥90.4% of subjects were Non-Hispanic/non-Latino, subgroup analyses
by race and by ethnicity were not provided.
Subgroup Analyses by Sex
•

Local Reactions: The proportions of participants who reported injection site
erythema and swelling within 10 days after vaccination were generally similar for
males and females with no consistent trends (Data not shown, CSR Supplemental
Tables 14.12, 14.13, and 14.14, for Cohorts A (prior PPSV23 only), B (prior
PCV13 only), and C (prior PCV13 and PPSV23), respectively). There appeared to
be a trend across all study cohorts of a higher proportion of females reporting any
injection site pain and mild injection site pain compared to males; the difference
was greatest in Cohort C, with 61.5% and 56.9% of females and 43.3% and
36.7% of males reporting any and mild injection site pain, respectively.

•

Systemic reactions: In general, a higher proportion of females reported systemic
reactions than males. The greatest differences were among Cohort C (prior
PCV13 and PPSV23) followed by Cohort A (prior PPSV23 only) subjects (Data
not shown, CSR Supplemental Tables 14.17, 14.18, and 14.19, for Cohorts A, B,
and C, respectively).

6.3.12.3 Deaths
No deaths were reported during the study.
98

Clinical Reviewer: Tina Mongeau
STN: 125731/0

6.3.12.4 Nonfatal Serious Adverse Events
A total of 14 SAEs were reported in this study following vaccination through the 6-month safety
follow-up. The proportions of participants who reported any SAEs within 6 months after
vaccination were low (≤2.4%) in all vaccine groups (Data not shown, CSR Table 17). Less than
1% of participants reported any SAE within 1 month after vaccination in each vaccine group
(Data not shown, CSR Supplemental Table 14.27). None of the SAEs reported were considered
by the investigator to be related to study vaccine (Data not shown, CSR Appendix 16.2.7.9);
therefore, no narratives were provided for SAEs in this study.
6.3.12.7 Dropouts and/or Discontinuations
No participants were withdrawn from the study for safety-related reasons. Therefore, there were
no narratives for safety-related withdrawals.
6.3.13 Study Summary and Conclusions
Study B7471006 was a descriptive safety and immunogenicity study of PCV20 in adults ≥65
years of age previously vaccinated with PPSV23, PCV13, or PCV13 followed by PPSV23. At 1
month after PCV20 vaccination, OPA GMTs for most of the PCV13 serotypes were generally
higher in participants with prior PCV13 only or prior PCV13 and PPSV23 (Table 34). At 1 month
post-PCV20, OPA GMTs for the PCV13 serotypes were lowest in participants with prior
PPSV23 only. At 1 month after PCV20 vaccination, OPA GMTs for the 7 new serotypes were
generally highest in participants with prior PCV13 only. The OPA GMTs for the 7 new serotypes
were the lowest in participants with prior PPSV23 only. OPA GMTs in participants with prior
PCV13 and PPSV23 fell in between the OPA GMTs achieved by the other two study cohorts.
The safety and tolerability profile of PCV20 was generally similar in participants with different
prior pneumococcal vaccine history and was generally similar to PCV13 and PPSV23 control
groups.
In the descriptive immunogenicity analyses, OPA GMTs in participants who received PPSV23 1
to 5 years prior to Prevnar 20 were diminished compared to OPA GMTs in participants who
received Prevnar 13 at least 6 months previously and compared to OPA GMTs in participants
who received Prevnar 13 followed by PPSV23, with the last PPSV23 dose given at least 1 year
prior to Prevnar 20. These immunogenicity results from this study are reflected in the drug
interactions section of the Prevnar 20 prescribing information.
6.4 Study B7471002
Study B7471002 was a descriptive Phase 2, multicenter, randomized (1:1), active controlled,
double-blind trial to describe the safety and immunogenicity (serotype-specific OPA antibody
titers) of PCV20 in approximately 400 adults 60-64 years of age in the U.S. with no prior
pneumococcal vaccination history planned for enrollment. The treatment group received a
single dose of PCV20 followed 1 month later by saline (placebo); the control group received a
single dose of PCV13 followed 1 month later by a dose of PPSV23. PCV13 served as a control
for safety and immunogenicity of the 13 original vaccine serotypes. PPSV23 served as a control
for immunogenicity of the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F). No
formal statistical hypotheses were planned. Safety monitoring were as described for study
B7471007. MedDRA version 21.1 coding dictionary was applied in study B7471002.

99

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Summary of Study Results
Immunogenicity
Of the 222 subjects enrolled and randomized to the treatment group, 221 received PCV20 on
study day 1 and 213 received placebo on study days 28-35. Of the 222 subjects enrolled and
randomized to the control group, 222 received PCV13 on study day 1 and 214 received
PPSV23 on study days 28-35. For the 13-original vaccine-type serotypes, OPA GMTs were
generally similar to or lower following PCV20 compared to PCV13. Based on data submitted to
CBER on July 12, 2018, in support of Breakthrough Therapy Designation, the lower limit of the
95% CI for the OPA GMT ratios (PCV20/PCV13) was >0.5 for 10 serotypes. Based on CBER
review of the preliminary data submitted to support Breakthrough Therapy Designation
(received July 12, 2018), the lower limit of the 95% CI for the OPA GMT ratio was 0.47, 0.48,
and 0.43 for serotypes 1, 5 and 19F, respectively. For the 7 new serotypes, OPA GMTs were
generally higher following PCV20 compared to PPSV23, except for serotype 8.
Safety
No deaths, SAEs or newly diagnosed chronic medical conditions considered related to study
vaccination were reported. Fourteen non-related SAEs were reported overall (5 in the
PCV20/saline group and 9 in the PCV13/PPSV23 group). Within 1 month after vaccination 1,
SAEs were reported by 0 (0%) and 1 (0.5%) of PCV20 and PCV13 recipients. Within 1 month
after vaccination 2, 0 (0.0) and 4 (1.9%) of saline and PPSV23 recipients reported SAEs. From
1 month after vaccination 2 through 6 months post-vaccination 1, SAEs were reported by 5
(2.3%) and 4 (1.9%) of PCV20/saline and PCV13/PPSV23 recipients. One subject randomized
to the PCV13/PPSV23 group reported a SAE of pneumococcal meningitis, with sequelae of
hearing loss in the right ear. Serotyping identified the pneumococcal isolate as 7C, a nonvaccine serotype. The remaining non-related SAEs reported included neoplasms (4), transient
ischemic attack (2), lacunar infarction, cerebrovascular accident, nephrolithiasis, respiratory
distress, cardiomyopathy, and osteoarthritis. The proportion of subjects reporting any prompted
local reaction within 10 days after vaccination was generally higher in the PCV20 group (60.9%)
compared to PCV13 group (56.8%). Pain at the injection site was the most frequently reported
local reaction in both study groups. In the PCV20 group, 57.7% reported injection site pain,
13.2% reported injection site swelling and 11.4% reported injection site redness. Severe
injection site reactions were uncommon and reported by 1 subject following PCV20 (redness)
and 1 subject following PCV13 (pain). Rates of prompted systemic reactions reported within 7
days after vaccination appeared to be similar between the two study groups, with the exception
of higher rates of muscle pain reported in the PCV20 group (43.2%) compared to the PCV13
group (36.5%). A similar proportion of PCV20 and PCV13 recipients reported unsolicited AEs at
1 month post-Vaccination 1 (12-13%). Upper respiratory tract infection was the most frequently
reported MedDRA Preferred Term after both PCV20 (3.2%) and PCV13 (2.3%).
Conclusions
The results from study B7471002 provided safety and immunogenicity data supporting Phase 3
clinical development of PCV20. The data from this study also supported Wyeth’s request at the
time for Breakthrough Therapy Designation.
6.5 Study B7471005
B7471005 was a randomized (1:1:1), controlled, double-blind, 3-arm multicenter study that
evaluated the safety and immunogenicity of PCV20 in adults. A total of 104 healthy
pneumococcal vaccine naïve Japanese adults 18-49 years of age residing in the U.S. were
enrolled and randomized equally to receive PCV20, investigational complementary 7-valent
100

Clinical Reviewer: Tina Mongeau
STN: 125731/0

pneumococcal conjugate vaccine (c7vPnC) or PCV13 vaccine. Eligible subjects were Japanese
adults born in Japan, whose parents and 4 grandparents were born in Japan (family tree by
history), and who had not lived outside of Japan for >5 years total (confirmed by passport or
interview). This trial provided the data to help support clinical development of PCV20 in Japan.
MedDRA version 21.1 coding dictionary was applied in study B7471005.
Study Results
Immunogenicity
Before vaccination, OPA GMTs for all 20 serotypes were similar among the 3 vaccine groups.
At 1 month after vaccination, increases in OPA GMTs were observed for all 20 serotypes in the
PCV20 group. Most subjects in the PCV20 group achieved a ≥4-fold rise in OPA titers for all 20
serotypes from before to 1 month after vaccination, ranging from 54.8% of subjects (serotype
7F) to 97.0% of subjects (serotype 23F).
Safety
There were no deaths, SAEs or newly diagnosed chronic medical conditions reported during
this study. The proportions of subjects reporting solicited local reactions within 14 days after
vaccination were generally similar across the three study groups. Overall, 77%-79% of subjects
reported any local reaction (77%-79% reported pain, 6% reported swelling, and 0% 14-6%
reported redness). The proportions of subjects reporting solicited systemic events within 14
days after vaccination were generally higher following PCV20 compared to the study controls
and lowest among c7vPnC recipients. The one exception was joint pain, which was reported by
a similar proportion of subjects (11% of PCV20 recipients, 12% of c7vPnC recipients, and 9% of
PCV13 recipients). Fever was reported by 1 subject (PCV20 recipient); the temperature was
>28.4oC and ≤38.9oC. Overall, at least 1 systemic adverse reaction was reported by 77%,
64.7% and 41.2% of PCV20, PCV13, and c7VpnC recipients respectively.
Unsolicited AEs were reported by 6% of subjects in the PCV20 and c7vPnC groups and 9% of
subjects in the PCV13 group within 1 month after vaccination. Related unsolicited AEs included
injection site erythema (PCV20), injection site swelling (PCV20), fatigue (c7vPnC), vomiting
(c7vPnC) and headache (c7vPnC).
Conclusions
The results of this study supported continued development of PCV20 for use in adults.
6.6 Study B7471001
B7471001 was a first-in-human, randomized (1:1), active-controlled, observer-blinded 15 trial that
evaluated the safety and immunogenicity of PCV20 in a total of 66 healthy pneumococcal
vaccine naïve adults 18-49 years of age. The trial was conducted at the Pfizer Clinical Research
Unit (PCRU) in New Haven, Connecticut. Subjects meeting eligibility criteria were admitted to
the PCRU and randomized (1:1) to receive PCV20 or a U.S.-licensed tetanus toxoid, reduced
diphtheria toxoid, and acellular pertussis vaccine, adsorbed (Tdap manufactured by Sanofi
Pasteur (Adacel)) as the active control.

14

No 13vPnC recipients reported injection site redness within 14 days after vaccination.
The assigned treatment was given by an unblinded dispenser and administrator (a member of the study
site staff or clinic pharmacy) who was not involved in subject assessments. All other study personnel and
the subject were blinded.
15

101

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Reviewer Comment: This first-in-human trial included cardiac monitoring and risk
mitigation proposed by CBER as a result of unexpected cardiac findings (diffuse, patchy
areas of inflammation and/or irreversible necrosis) identified on histopathology in a small
number of otherwise healthy-appearing rabbits in the initial repeat-dose toxicity study
(<5%-10%). Study B7471007 was designed to monitor subjects for possible cardiac
abnormalities following vaccination with PCV20 in order to investigate the clinical
relevance of the preclinical cardiac toxicity findings.
All subjects had a baseline 12-lead triplicate electrocardiogram (ECG), echocardiogram and
cardiac troponin I (cTnI) performed at a screening visit (the echocardiogram could have been
done on Day 0 as well). Subjects meeting eligibility criteria were then admitted to the PCRU on
day 0 for a 7-day hospital stay (through Day 6). The 12-lead triplicate ECG and cTnI were
repeated to confirm eligibility on study Day 0. cTnI testing was repeated on Days 2, 3, and 6 (1,
2 and 5 days after vaccination). An elevated cTnI concentration was defined as greater than the
upper limit of normal of the lab reference range (≥0.3 ng/mL). Safety labs (complete blood
count, liver function tests, creatinine and urinalysis) were performed on Day 0 and Day 6.
Safety monitoring were as described for study B7471007. The duration of subject participation
was approximately 8 months, from screening through a 6-month telephone safety follow-up visit.
Safety oversight was provided by an external Data Monitoring Committee (DMC). The
classification of adverse events was based on MedDRA version 20.0 coding dictionary in this
study.
Select Eligibility Criteria
Eligible subjects had to have an echocardiogram and 12-lead triplicate ECG without clinically
significant findings and normal cTnI concentration at baseline. In addition to standard Phase 1
study exclusion criteria, subjects were not eligible if they had baseline laboratory test results
outside of the normal reference range considered clinically significant, smoked >5 cigarettes per
day, had a history of regular alcohol consumption in the past 6 months, high blood pressure, a
history of or suspected cardiac disease (congenital or valvular disease, congestive heart failure,
myocardial ischemia or infarction, myocarditis, pericarditis, cardiomyopathy, arrhythmia or other
benign sinus arrhythmia, etc.) or elevated cTnI concentration at baseline or family history of
sudden cardiac death or arrhythmia. Subjects were also not eligible if they had any history prior
pneumococcal vaccination, any history of culture-proven IPD, any history of severe adverse
reaction associated with a vaccine and/or a severe allergic reaction to any component of the
investigational product or any Tdap-containing vaccine, or any known or suspected
immunodeficiency.
Study Results
Subject Disposition
A total of 66 subjects were vaccinated; 33 (50%) received PCV20 and 33 (50%) received Tdap.
All subjects participated through the 2-week follow up phone call. A total of 63 subjects (95.5%)
completed the study through 6-months post-vaccination. Three PCV20 recipients were
withdrawn after the 2-week follow-up. One subject was lost to follow up prior to the 1-month
post-vaccination visit. Another subject was lost to follow up prior to the 6-month follow-up
telephone call. A third subject was withdrawn after the 1-month follow-up due to an unrelated
death due to a motor vehicle accident.

102

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Demographics
Overall, 42.4% of subjects were male, 42.4% were White, 53% were Black, 3% were American
Indian and 2% were other. By ethnicity, 24% of subjects were Hispanic (the remaining were not
Hispanic). Subject ages ranged from 18 to 48 years, with a mean of 32 years. There were fewer
males (30% vs. 55%), White subjects (33% vs. 52%), and Latino subjects (15% vs. 33%)
randomized to the PCV20 group relative to the Tdap group.
Immunogenicity
The immunogenicity results from this Phase 1 descriptive study demonstrated that PCV20 is
immunogenic in healthy adults 18-49 years of age. Pre-vaccination titers were generally low,
although baseline titers to serotypes 10A, 11A, 22F, and 33F were generally higher. A
numerical increase in OPA GMTs from before to 1 month after vaccination was observed for
each of the 20 vaccine serotypes. The OPA GMTs were essentially unchanged after vaccination
in the Tdap recipients.
Safety Laboratory Results
The cTnI testing results for all subjects at all time points (days 1 (day of vaccination), 2, 3, and
6) were below the upper limit of normal of the test (<0.3 ng/mL). One subject who had additional
cardiac troponin T tested by another lab as part of a precautionary workup also had nonelevated results. There were no other clinically significant laboratory abnormalities or changes in
any study subjects.
There were no clinically significant ECG results and no clinically significant ECG findings in
subjects who had ECGs conducted after vaccination for three events of interest.
Solicited Local and Systemic Adverse Reactions
The most common solicited local reaction within 14 days after vaccination was pain at the
injection site (69.7% and 63.6% in the PCV20 and Tdap recipients respectively) followed by
limitation of arm movement (36.4% and 18.2% in the PCV20 and Tdap recipient respectively).
Grade 3 pain and limitation of arm movement were reported by 1 subject (the same subject
reported both) on day 2 after PCV20. No other grade 3 reactions were reported. Redness and
swelling were reported by 1 (3.0%) subject each in the PCV20 group and by no subjects in the
Tdap group. Injection site redness was reported on Day 6 and Day 8 and resolved 2 days after
onset. The median duration of any injection site reaction was 2 days.
The most common solicited systemic event was new muscle pain (45.5% and 42.4% in the
PCV20 and Tdap recipients, respectively), followed by fatigue and headache (39.4% and 30.3%
in the PCV20 and Tdap groups, respectively). Most systemic events were mild or moderate in
severity. The median duration ranged from 1 to 5 days in both groups. Approximately 21% and
18% of subjects used medication to treat pain/fever in the PCV20 and Tdap groups,
respectively.
Unsolicited Adverse Events
Overall, 45.5% and 33.3% of subjects reported any AE in the PCV20 and Tdap groups
respectively. The most frequently reported AEs were in the SOC Gastrointestinal disorders
(15.2% vs. 9.1% among PCV20 and Tdap recipients, respectively). No AEs were categorized as
cardiac events. Related AEs reported by PCV20 recipients included decreased appetite and
limb discomfort those reported by Tdap recipients included limb discomfort, photophobia,
nausea, and dizziness.
103

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Serious Adverse Events, Withdrawals and New Onset Chronic Medical Conditions
There were no related SAEs, safety-related withdrawals or new onset chronic medical
conditions reported in this study. Four subjects (3 PCV20 recipients and 1 Tdap recipient)
reported non-related SAEs in this study. One subject in the Tdap group was hospitalized due to
joint dislocation, ligament rupture, muscle rupture after a motor vehicle accident 20 days after
vaccination. One subject, in the PCV20 group reported loss of consciousness secondary to
carbon monoxide exposure and was hospitalized; a second PCV20 recipient reported back pain
as an SAE 83 days after vaccination; a third subject in the PCV20 group was killed in a motor
vehicle accident 75 days after vaccination. None of these events were considered related to
vaccination.
Adverse Events of Interest
Three subjects experienced events of interest as described below.
1. A 20-year old Black female who met study eligibility criteria reported chest pain 61 days after
vaccination with onset 3 days earlier. The subject described sharp, intermittent (5
times/day), left midsternal, chest pain associated with respiration, lasting approximately 5
minutes before resolving. She denied chest pain radiating into her arm or swelling in her
arms and legs, shortness of breath, syncope, palpitations, nausea, or sweating. A physical
examination was performed approximately one week later and showed mild tenderness to
palpation in the intercostal musculature in the upper left chest, which improved with selfmassage of the area. An ECG performed at the visit was normal. Costochondritis was
suspected and follow-up over 3 weeks confirmed no change in the event. Contact with the
subject at approximately 3 months later revealed the event had resolved ~3 months after
onset. The subject contacted the site 175 days after vaccination to report that she was told
she had a heart murmur during a routine physical examination. Two and half months later,
she followed up to report that an echocardiogram had been performed, which was found to
be normal. The subject did not comply with a request to provide the medical records and
was considered lost to follow-up at approximately 9 months post-vaccination. The principal
investigator felt that there was an anxiety component to the event and that the event was not
related to study vaccination or procedures.
2. One 40-year-old American Indian/Alaskan native female subject with a history of
gastroesophageal reflux disease and anxiety who met study eligibility criteria reported
epigastric pain/discomfort in the early morning on the day after vaccination. An ECG, a
cardiac troponin T (cTnT) level, and serial cTnI levels were obtained (3 times over the 12
hours after onset of symptoms). The subject was also placed on telemetry monitoring
overnight. The cTnT result was not elevated (<0.01 ng/mL) at the time of the acute episode
nor were any of the serial cTnI levels (<0.3 ng/mL) collected through the following morning.
ECGs performed the evening of symptom onset were normal and the overnight telemetry
showed no concerning changes. On day 2 after vaccination, the subject was still
symptomatic and was assessed as having mild epigastric pain/discomfort consistent with
gastrointestinal esophageal reflux disease (GERD) and with an element of anxiety. The
symptoms resolved later that same day. The investigator discussed the event in detail with
the consulting cardiologist for the study, and based on the brevity of the symptoms, normal
cardiac troponin levels, and normal ECGs and telemetry monitoring, no further evaluation
was warranted. The investigator considered the event to be an acute episode of GERD. The
event was considered not related to the investigational product or to study protocol
procedures.

104

Clinical Reviewer: Tina Mongeau
STN: 125731/0

3. A 39-year-old White male with anxiety and muscle spasm and who met eligibility criteria
contacted the site 7 days post-vaccination to report on an unusual feeling in his chest at the
level of the diaphragm, which awoke him from sleep. He described the sensation as a
tension (a feeling of wanting to cry or “be very angry”) lasting 30 minutes and then
disappearing completely. He has experienced similar sensations prior to study participation.
The subject denied chest pain or difficulty breathing. He contacted the site 3 times after that
to describe the feeling and rated the intensity as a 4 or 5 out of 10 (twice) or a 1 out of 10
(last episode). All 3 episodes occurred over a 9-hour period and resolved spontaneously.
The subject continued to experience “unusual sensations” of brief duration (reportedly
lasting a few seconds) in the chest and abdominal areas. He was seen by the study site on
February 24, 2017, at which time he had no pain or unusual sensations; the physical
examination was normal; and an ECG performed at the visit was read as abnormal but not
clinically significant, and the investigator considered that the ECG was normal. The subject
returned to the site on March 8, 2017, for a planned study follow-up visit. Although there
were no ongoing symptoms or complaints, an ECG was again performed. The ECG on that
date was read as abnormal but not clinically significant. The episodes were determined by
the investigators to be due to muscle twitches and anxiety and not related to the
investigational product or procedures.
Reviewer Comment: On May 17, 2017, Wyeth submitted unblinded safety and
immunogenicity results from study B7471001 through 1 month post-vaccination to
support initiation of Phase 2 adult study B7471002. CBER’s review of these data
revealed no concerning safety findings. Although the study was not large enough to
identify with >95% probability events that occur at a rate of <10%, CBER agreed in a
letter dated June 19, 2017 that the lack of any abnormalities in cTnI (a sensitive marker
of cardiac tissue damage) and the lack of cardiac-related adverse events within 1 month
after vaccination supported Wyeth’s proposal to proceed cautiously into a Phase 2 study
in adults 60-64 years of age (Study B7471002) using traditional safety monitoring. CBER
considered that there was no clear need or benefit to continue cardiac screening and
monitoring in the proposed Phase 2 study in adults 60 through 64 years of age. This
Phase 2 study would include an external DMC and limited daily enrollment until the DMC
completed a safety review on the first 30 enrolled subjects.
Conclusions
The safety and immunogenicity results from study B7471001 supported initiation of Phase 2
study B7471002 in adults 60-64 years of age. This Phase 2 study included a program level
external DMC that would remain in place throughout the PCV20 clinical development program
to conduct routine, periodic safety reviews of the Phase 2 and Phase 3 studies in the clinical
program.
7. INTEGRATED OVERVIEW OF EFFICACY
As previously agreed to, Wyeth performed no formal meta-analysis of immunogenicity data
pooled across trials, because each Phase 3 study had distinct study objectives and/or a distinct
study design, including different study population with regard to age and prior pneumococcal
vaccination status. Please see Sections 6.1, 6.2, and 6.3 for the results of each individual Phase
3 study.
Of note, in post hoc analyses presented in the summary of clinical efficacy, Wyeth submitted
tables showing OPA GMT results from subjects ≥65 years of age in study B7471007 compared
to subjects ≥65 years of age previously immunized with a pneumococcal vaccine in study
105

Clinical Reviewer: Tina Mongeau
STN: 125731/0

B7471006. In general, for all 20 vaccine serotypes, OPA GMTs tended to be lowest among
subjects previously immunized with PPSV23 and highest among vaccine-naïve subjects or
subjects previously immunized with PCV13 (Data not shown, Summary of Clinical Efficacy,
Tables 12 and 13).
For the 13 original serotypes, OPA GMTs achieved by subjects who previously received PCV13
and PPSV23 were similar to the group with prior PCV13 alone. For the 7 new serotypes, OPA
GMTs achieved by subjects with prior PCV13 and PPCV23 were generally lower than the prior
PCV13 alone group but higher than the prior PPSV23 only group (Data not shown, Summary of
Clinical Efficacy, Tables 12 and 13).
Reviewer Comment: The Prevnar 13 prescribing information includes a statement
within Section 7 Drug Interactions indicating that prior receipt of PPSV23 within 1 year
results in diminished immune responses to PCV13 compared to the responses of
PPSV23 naïve individuals. This statement was based on data from pre-licensure clinical
trials showing that OPA GMTs in subjects who received PCV13 one year after PPSV23
were diminished compared to those who received PCV13 alone. The cross-study
comparisons described above from study B7471006 and from vaccine-naïve subjects
≥65 years of age in study B7471007 suggest a similar phenomenon with PCV20 (i.e.,
prior receipt of PPSV23 alone within 1-5 years of PCV20 results in diminished OPA
GMTs to PCV20 compared to those of PPSV23 naïve individuals).
8. INTEGRATED OVERVIEW OF SAFETY
8.1 Safety Assessment Methods
The integrated summary of safety includes safety results from the three Phase 3 clinical trials
(B7471007, B7471008 and B7471006) submitted to this BLA. As agreed with CBER previously,
Wyeth did not include safety data from Phase 1 and 2 studies, because the clinical trial material
for Phase 1 and 2 studies were manufactured at a different scale from those used for Phase 3
studies and the final batches used for commercialization.
Each Phase 3 trial has a distinct design and/or different subject populations with regard to age
and prior pneumococcal vaccination status. Therefore, each Phase 3 study is presented in the
integrated overview of safety in side-by-side displays, except that data are pooled for subjects
18-49 years of age. Only data from pneumococcal-vaccine-naïve adults 18-49 years of age from
study B7471007 Cohort 3 and from study B7471008 were pooled in the integrated summary of
safety, because this was the only overlapping subject population across studies.
Since age and prior pneumococcal vaccination status are important factors when interpreting
safety and tolerability results, results are summarized separately for studies with subjects of any
age who were naïve to pneumococcal vaccine at trial enrollment, and for studies with subjects
≥65 years of age by prior pneumococcal vaccination status (naïve or previously vaccinated with
PCV13, PPSV23, or both).
The methods for safety data collection and analysis were the same in all three Phase 3 trials, as
described in Section 6.1.7. In each study, the analysis population for safety endpoints was the
safety population, which included all subjects who received a study vaccination and had safety
follow-up after vaccination. Subjects were included in the vaccine group corresponding to the
vaccine actually administered.

106

Clinical Reviewer: Tina Mongeau
STN: 125731/0

8.2 Safety Database
A total of 7,048 immunocompetent adults ≥18 years of age were evaluated in six PCV20 prelicensure trials. A total of 3,928 subjects and 2,247 subjects received PCV20 or active control,
respectively and provided post-vaccination safety data from 5 randomized, double-blinded,
active controlled clinical trials conducted in immunocompetent pneumococcal vaccine naïve
adults ≥18 years of age in the U.S. and Sweden (172 subjects ≥65 years of age were
randomized/enrolled in Sweden). Additional descriptive data were available from a sixth openlabel study in adults ≥65 years of age in the U.S. and Sweden previously immunized with a
pneumococcal vaccine prior to enrollment (624 PCV20 recipients and 245 active control
recipients in B7471006).
8.2.1 Studies/Clinical Trials Used to Evaluate Safety
Table 1 in Section 5.3 includes a brief description of the three Phase 3 studies included in the
integrated overview of safety.
8.2.2 Overall Exposure, Demographics of Pooled Safety Populations
Across the Phase 3 trials, 6470 subjects were vaccinated; 4263 subjects received PCV20 and
2207 received control vaccine. See Table 1 for a breakdown by study and age group.
Pneumococcal vaccine naïve subjects (N=5597) were enrolled and vaccinated in B7471007
(≥18 years of age) and B7471008 (18-49 years of age): 3639 received PCV20 and 1958
received control vaccine (PCV13 or PCV13/PPSV23). Across vaccine groups, 2997 (53.5%)
were ≥60 years, 445 (8.0%) were 50-59 years, and 2155 (38.5%) were 18-49 years of age
(Table 1 and Module 2.7.4 Summary of Clinical Safety Table 2).
Individuals ≥65 years of age (N=1885) were enrolled and vaccinated in B7471007
(pneumococcal vaccine naïve) and B7471006 (previously vaccinated); 1138 received PCV20
and 747 received control vaccine (PCV13/PPSV23, PCV13, or PPSV23). This total sample size
includes 72 subjects ≥80 years of age (35 subjects ≥80 years of age in study B7471007 and 37
subjects ≥80 years of age in study B7471006). Across vaccine groups, 1012 (53.7%) were
pneumococcal vaccine naïve, 375 (19.9%) had prior PPSV23 only, 373 (19.8%) had prior
PCV13 only, and 125 (6.6%) had prior PCV13 followed by PPSV23 (Table 1 and Module 2.7.4
Summary of Clinical Safety Table 3).
All subjects <65 years of age were enrolled in the U.S. Among subjects ≥65 years of age in
Phase 3 studies, 305 subjects were enrolled in Sweden and 1,145 were enrolled in the U.S.
(840 pneumococcal vaccine naïve subjects ≥65 years of age in B7471007 Cohort 1 and 305
pneumococcal vaccine experienced subjects ≥65 years of age in study B7471006 Cohort A
(subjects with prior PPSV23 only). Due to the small number of Swedish subjects, by-country
subgroup safety analysis was not performed in B7471006.
Demographics of each study were previously described in Sections 6.1.10.1.1, 6.2.10.1.1, and
6.3.10.1.1. Demographic characteristics and smoking history for the pooled 18-49-year age
group (B7471007 Cohort 3 and B7471008) were similar to those described for study B7471007
(Data not shown, Module 5.3.5.3 ISS Table 3).
8.3 Caveats Introduced by Pooling of Data Across Studies/Clinical Trials
The pooling of data from 447 subjects 18-49 years of age (Cohort 3) in study B7471007 and
1708 subjects 18-49 years of age in study B7471008 were supported by the identical age of
107

Clinical Reviewer: Tina Mongeau
STN: 125731/0

study subjects, identical active control (PCV13), identical safety endpoints (including use of the
same MedDRA version for safety reporting), identical methods for safety data collection and
analysis, and overlap in the time frame when the studies were conducted as well as overlap in
the study sites within the U.S. where the studies were conducted. A total of 15 out of the 21
sites where study B7471008 was conducted were the same sites used in study B747100716,
representing 1310 out of the total 1718 subjects enrolled in study B7471008.
8.4 Safety Results
8.4.1 Deaths
Two unrelated deaths were reported in PCV20 pre-licensure studies. One was reported in a 60year old male in Cohort 1 of study B7471007. This subject died due to a self-inflicted gunshot
wound 48 days after receiving Vaccination 2. In addition, one death was reported in a 37-yearold female PCV20 recipient in study B7471001.The cause of death was due to a motor vehicle
accident 75 days after vaccination.
8.4.2 Nonfatal Serious Adverse Events
Nonfatal serious adverse events were summarized separately for each Phase 3 study in
Sections 6.1.12.4, 6.2.12.4, and 6.3.12.4. Rates of SAEs within 6 months after vaccination
among the pooled 18-49-year-old subjects in studies B7471007 (Cohort 3) and B7471008 were
0.7% among the 1,798 PCV20 recipients and 0.3% among the 357 PCV13 recipients.
8.4.3 Study Dropouts/Discontinuations
Subject disposition for each of the Phase 3 studies was summarized in Sections 6.1.10.1.3,
6.2.10.1.3, and 6.3.10.1.3. Withdrawal due to AEs were reported for 20 subjects in Cohort 1 of
Study B7471007 (see Section 6.1.12.7). No withdrawals due to AEs were reported in other
cohorts of study B7471007 nor studies B7471008 or B7471006.
8.4.4 Common Adverse Events
Common unsolicited AEs from each of the Phase 3 studies were summarized in Sections
6.1.12.2, 6.2.12.2, and 6.3.12.2. Common unsolicited AEs among pooled 18-49-year-old
subjects in studies B7471007 (Cohort 3) and B7471008 were similar to those described in
Sections 6.1.12.2 and 6.2.12.2 (Data not shown, ISS Table 5).
Other Significant Adverse Events
Seven subjects who received PCV20 (2 subjects in Cohort 3 of study B7471007 and 5 subjects
in study B7471008) and 1 subject who received PCV13 in study B7471008 became pregnant
while participating in B7471007 and B7471008. These pregnancies were not associated with
AEs and were summarized previously in Sections 6.1.12.2 and 6.2.12.2.
8.4.6 Systemic Adverse Events
Solicited systemic adverse events (AEs) were previously summarized in Sections 6.1.12.2,
6.2.12.2, and 6.3.12.2. Solicited systemic AEs among pooled 18-49-year-old subjects in studies
B7471007 (Cohort 3) and B7471008 were similar to those described in Section 6.2.12.2 (study
B7471008 results) since a large proportion of subjects come from study B7471008 (Data not
shown, Summary Clinical Safety Table 6).
16

Study B7471007 was a much larger study overall involving a total of 63 sites in the U.S. and Sweden.
Subjects 18-49 years of age in study B7471007 were only enrolled in U.S. sites.

108

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Rates of solicited systemic adverse reactions in pneumococcal-vaccine-naïve participants ≥65
years of age in study B7471007 were presented side by side with those of B7471006 subjects
previously immunized with a pneumococcal vaccine in the Summary of Clinical Safety (i.e.,
Integrated Summary of Safety). Rates of headache, muscle pain, joint pain and use of
antipyretic pain medication were generally higher among subjects previously immunized with
PCV13 and PPSV23 compared to all other subjects (i.e., subjects previously immunized with
PCV13 only or PPSV23 only and pneumococcal vaccine-naïve subjects). Rates of fatigue were
lowest among pneumococcal vaccine-naïve adults and highest among subjects previously
immunized with PCV13 and PPSV23.
Reviewer Comment: These across study comparisons are acceptable for the purpose
of the integrated summary of safety, because studies B7471007 and B7471006 were
very similar. Both studies had identical safety methods for safety data collection and
analysis, identical safety endpoints, overlap in the age of subjects enrolled (both enrolled
subjects ≥65 years of age), overlap in the time frame when the studies were conducted
as well as overlap in 31 out of the 44 study sites used in study B7471006 (representing
624 (71.3%) out of 875 subjects enrolled in the study).
8.4.7 Local Reactogenicity
Solicited local reactions were previously summarized in Sections 6.1.12.2, 6.2.12.2, and
6.3.12.2. Solicited local reactions among pooled 18-49-year-old subjects in studies B7471007
(Cohort 3) and B7471008 were similar to those described in Section 6.3.12.2 (study B7471008
results) since a large proportion of subjects come from study B7471008 (Data not shown,
Summary Clinical Safety Table 4).
Rates of solicited local injection site reactions in pneumococcal vaccine-naïve participants ≥65
years of age in study B7471007 were presented side by side with those of B7471006 subjects
≥65 years of age previously immunized with a pneumococcal vaccine. Rates of injection site
pain were generally higher in PCV20 recipients previously immunized with PPSV23, PCV13 or
both PCV13 and PPSV23 compared to pneumococcal vaccine-naïve subjects. The rate of
injection site pain was numerically highest in PCV20 recipients previously immunized with
PCV13, followed by PCV20 recipients previously immunized with PCV13 and PPSV22 or
PPSV23 alone. Rates of injection site swelling were generally higher among PCV20 recipients
previously immunized with PPSV23 or PCV13 (but not PCV13 and PPSV23). Rates of injection
site redness were similar across pneumococcal vaccine-naïve and pneumococcal vaccineexperienced subjects.
8.6 Safety Conclusions
Post-vaccination safety data were collected from 6 randomized studies in which 7,048
immunocompetent adults ≥18 years of age were immunized with either PCV20 (N=4,552) or an
active control (N=2,496). This included an open-label safety assessment among 869 (624
PCV20 recipients and 249 control recipients) adults ≥65 years of age previously immunized with
at least one dose of a pneumococcal vaccine prior to enrollment. No safety concerns were
identified when a single dose of PCV20 was administered to pneumococcal-vaccine-naïve or
pneumococcal-vaccine-experienced adults ≥18 years of age.

109

Clinical Reviewer: Tina Mongeau
STN: 125731/0

9. ADDITIONAL CLINICAL ISSUES
9.1 Special Populations
9.1.1 Human Reproduction and Pregnancy Data
Risk Summary
All pregnancies have a risk of birth defect, loss or other adverse outcomes. In the U.S. general
population, the estimated background risk of major birth defects and miscarriage in clinically
recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on Prevnar
20 administered to pregnant women are insufficient to inform vaccine-associated risks in
pregnancy (see Clinical Data).
A developmental toxicity study was performed in female rabbits administered PCV20 prior to
mating and during gestation. The dose was 0.5 mL at each occasion (a single human dose is
0.5 mL). This study revealed no evidence of harm to the fetus due to PCV20 (see Animal Data).
Animal Data
In a fertility and developmental toxicity study, female rabbits were administered PCV20 by
intramuscular injection twice prior to mating (17 days and 4 days prior to mating) and twice
during gestation (Gestation Days 10 and 24), 0.5 mL/rabbit/occasion (a single human dose). No
adverse effects on pre-weaning development were observed. There were no vaccine-related
fetal malformations or variations.
Clinical Data
Pre-licensure studies excluded females who were pregnant or breastfeeding. Under screening
criteria, a urine pregnancy test was collected on day 1 prior to vaccination of subjects 18
through 59 years of age (cohorts 2 and 3) in study B7471007 and on day 1 prior to vaccination
of subjects 18-49 in study B7471008. A total of 8 pregnancies were reported among participants
in prelicensure PCV20 studies (studies B7471007 and B7471008); this includes 7 subjects who
received PCV20 and 1 subject who received PCV13. Six of the eight total pregnancies were
conceived after vaccination.
Two pregnancies (both PCV20 recipients) had estimated conception dates that were prior to
vaccination (Day-4 and Day-19) were reported at the 1-month post-vaccination visit. The subject
with the estimated conception date 4 days prior to vaccination gave live birth to a full-term male
infant at an estimated 39 weeks gestation. The pregnancy outcome of the subject with an
estimated conception date 19 days prior to vaccination could not be determined, as the site
informed Wyeth that the subject’s telephone number was disconnected (subject (b) (6) .
Of the 5 pregnancies among PCV20 recipients with estimated conception dates after
vaccination, all resulted in full-term live births. The one PCV13 recipient who became pregnant
reported being in a motor vehicle accident 187 days after vaccination and reported a
spontaneous abortion 9 days after the accident. This PCV13 recipient’s pregnancy had an
estimated conception date of approximately 4 months after vaccination. Although the
investigator considered there was a reasonable possibility that this event was related to the
study vaccine, Wyeth considered the event was more likely triggered by the motor vehicle
accident and an associated fetal genetic anomaly post-fetal demise showed “likely trisomy 21”).

110

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Because of the small sample size of pregnancies reported during pre-licensure PCV20 studies
(N=8) and the fact that six of the eight pregnancies were conceived after vaccination, the clinical
data on pregnancy outcomes is not adequate to make meaningful conclusions about safety of
the vaccine when used during pregnancy.
9.1.2 Use During Lactation
It is not known whether PCV20 is excreted in human milk. Data are not available to assess the
effects of PCV20 on the breastfed infant or on milk production/excretion. The developmental
and health benefits of breastfeeding should be considered along with the mother’s clinical need
for PCV20 and any potential adverse effects on the breastfed child from PCV20 or from the
underlying maternal condition. For preventive vaccines, the underlying maternal condition is
susceptibility to disease prevented by the vaccine.
9.1.3 Pediatric Use and PREA Considerations
The safety and effectiveness of Prevnar 20 in persons less than 18 years of age have not been
established.
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), the submission of this
original BLA required a Pediatric Study Plan for the claimed indications. Wyeth requested a full
waiver of the pediatric study requirement in persons from birth through 16 years of age for the
pneumonia indication, because the necessary studies are impossible or highly impracticable
(505B(a)(4)(A)(i) of the Act). Because Prevnar 13 efficacy has not been demonstrated against
pneumonia in pediatric age groups, the approval of Prevnar 20 for the prevention of pneumonia
in pediatric patients would require the demonstration of efficacy in a clinical endpoint study.
Such a study would not be logistically feasible given the large number of subjects that would be
needed in order to demonstrate efficacy. In addition, there are currently no reliable methods for
detecting vaccine-type nonbacteremic pneumonia in children (the most common type of
pneumonia). A urine antigen detection assay to detect pneumonia due to the serotypes in
PCV13 was developed for adults and used in the study which supported the adult Prevnar 13
pneumonia indication. However, this assay has not been validated for use in children to date
due to high rates of pneumococcal carriage.
Wyeth requested a partial waiver of the pediatric study requirement in infants from birth to <6
weeks of age for the invasive pneumococcal disease indication, because Prevnar 20 does not
represent a meaningful therapeutic benefit over existing therapies for pediatric patients in this
age group, and Prevnar 20 is not likely to be used by a substantial number of pediatric patients
in this age group (section 505B(a)(4)(B)(iii) of the Act). Due to limitations of the neonatal
immune response, initiating vaccination at 0 to <6 weeks of age with Prevnar 20 would not
provide a meaningful therapeutic benefit over initiating vaccination at 6 weeks of age. In
addition, with the exception of Hepatitis B vaccine, for which a birth dose is routinely
recommended to prevent perinatal transmission of hepatitis B virus, infant immunizations in the
U.S. are generally not administered before 6 weeks of age.
Wyeth is requesting a deferral of pediatric studies in persons 6 weeks through 16 years of age
to support the invasive pneumococcal disease indication on the basis that Prevnar 20 is ready
for approval for use in adults and the pediatric studies have not been completed
(505B(a)(3)(A)(i) of the Act). Wyeth is conducting four studies in persons 6 weeks through 16
years of age as part of their global clinical development plan. The review team concurred with
Wyeth’s proposal that of these four studies, the three studies listed below in Section 11.6
(B7471011, B7471013, and B7471014) are sufficient to support a pediatric assessment in the
111

Clinical Reviewer: Tina Mongeau
STN: 125731/0

U.S. for this age group. During the review cycle, Wyeth revised the timelines that were
submitted in the agreed Pediatric Study Plan for these deferred studies along with a justification
for the changes. CBER and PeRC agreed to these revisions. Please see Section 11.6 of the
clinical review for timelines for conducting each of these three required pediatric postmarketing
studies under PREA.
9.1.4 Immunocompromised Patients
The safety and effectiveness of Prevnar 20 have not been established in immunocompromised
individuals.
9.1.5 Geriatric Use
The safety and effectiveness of Prevnar 20 have been established in adults ≥65 years of age.
Of the total number of Prevnar 20 recipients ≥18 years of age in Phase 3 clinical trials (N=4263),
26.7% (n=1138) were ≥65 years of age and 1.7% (n=72) were ≥80 years of age. Please refer to
Sections 6.1 and 6.3 for the data in these age groups.
10. CONCLUSIONS
The data submitted to this BLA provide evidence to support the safety and effectiveness of a
single dose of Prevnar 20 in adults ≥18 years of age for the prevention of invasive
pneumococcal disease caused by the 20 pneumococcal vaccine serotypes and pneumococcal
pneumonia caused by PCV13 serotypes contained in the vaccine.
Under the accelerated approval regulations, the available safety and immunogenicity data
submitted to this BLA support the approval of Prevnar 20 for the prevention of pneumococcal
pneumonia caused by the 7 new serotypes contained in the vaccine (8, 10A, 11A, 12F, 15B,
22F, 33F) in adults 18 years of age and older. As a condition of accelerated approval, Wyeth is
required to further study Prevnar 20 to verify and describe its clinical benefit in postmarketing
study B7471015.
This application includes data obtained from 6 clinical trials performed in 7048
immunocompetent adults ≥18 years of age in the United States and Sweden; 4552 have
received PCV20, and 2496 have received control. Overall, the safety profile of a single dose of
PCV20 was comparable to that observed following a dose of Prevnar 13.
In study B7471007, immunologic noninferiority of PCV20 compared to PCV13 (for the 13
original serotypes) and PPSV23 (for the 7 new serotypes) following a single vaccination was
demonstrated for 19 of 20 vaccine serotypes (except serotype 8) in pneumococcal vaccine
naïve adults ≥60 years of age. Serotype 8 narrowly missed the pre-specified 2-fold noninferiority margin (95% LL = 0.49). In supportive secondary analyses, 77.8% of subjects ≥60
years of age achieved a ≥4-fold increase in anti-serotype 8 OPA titers.
The effectiveness of Prevnar 20 in younger adults 18-49 years of age and 50-59 years of age
was demonstrated in study B7471007 by immunobridging to the established effectiveness in the
60-64-year-old adult age group (Cohort 1 Subset).
In study B7471008, clinical lot consistency was demonstrated based on demonstration of
immunologic equivalence of 3 separately manufactured lots of 20PnC in pneumococcal vaccine
naïve adults 18-49 years of age.

112

Clinical Reviewer: Tina Mongeau
STN: 125731/0

Study B7471006 demonstrated an acceptable safety and tolerability profile of PCV20 when
administered to adults previously immunized with PCV13 or PPSV23. In the descriptive
immunogenicity analyses, OPA GMTs in participants who received PPSV23 (one) 1 to five (5)
years prior to Prevnar 20 were diminished compared to OPA GMTs in participants who received
Prevnar 13 at least 6 months previously and compared to OPA GMTs in participants who
received Prevnar 13 followed by PPSV23, with the last PPSV23 dose given at least 1 year prior
to Prevnar 20. These immunogenicity results from this study are reflected in the drug
interactions section of the Prevnar 20 prescribing information.
11. RISK-BENEFIT CONSIDERATIONS AND RECOMMENDATIONS
11.1 Risk-Benefit Considerations
Table 38 summarizes PCV20 risk-benefit considerations in adults ≥18 years of age.

113

Clinical Reviewer: Tina Mongeau
STN: 125731/0
Table 38. Risk Benefit Considerations of Vaccination with Prevnar 20 in Adults ≥18 Years of Age
Decision
Factor

Evidence and Uncertainties
•

Analysis of
Condition

•

•

•
Unmet
Medical Need

•
•
•

•

•

Clinical
Benefit

•

S. pneumoniae can cause meningitis, bacteremia and pneumonia in adults, resulting in
substantial morbidity and mortality. Complications of pneumococcal pneumonia include
empyema and pericarditis. Pneumococcal meningitis commonly results in neurologic sequelae,
including hearing loss and brain damage.
Conditions that increase the risk of serious pneumococcal disease include immunosuppressive
conditions, functional or anatomic asplenia, chronic heart, pulmonary, liver or renal disease,
cigarette smoking, alcoholism, cerebrospinal fluid leak, and cochlear implant (Gierke et al
2021b). Adults 65 years or older are also at increased risk for pneumococcal disease.
Prevnar 13 (PCV13) and Pneumovax 23 (PPSV23) are two pneumococcal vaccines approved
for use in persons ≥18 years of age in the U.S. PCV13 includes 13 shared serotypes with
PCV20, and it is thought to elicit a T-cell dependent immune response. PPSV23 includes the
7 new serotypes in PCV20, however PPSV23 is thought to elicit a T-cell independent immune
response which is characterized by an antibody response that is of short duration, an absent
or blunted memory response, and no affinity maturation.
IPD caused by the 7 new serotypes represents one-quarter of the non-PCV13 IPD burden in
adults ≥65 years of age, despite routine administration of PPSV23 to adults ≥65 years of age.
Data suggest that PPSV23 protects adults and the elderly against IPD, however no consistent
vaccine effect has been observed for prevention of pneumonia
Effective antibiotic therapy is available for the treatment of IPD in adults; however, antibiotic
resistance is increasingly common making treatment more difficult.
Several studies note no reduction in the incidence of serotype 3 IPD in US children < 5 years
of age between 2011 and 2019, no reduction in the incidence of serotype 3 IPD in US adults ≥
65 years of age, and the relatively lower immunogenic response induced by PCV13 to this
serotype compared to the other vaccine serotypes,
The effectiveness of Prevnar 20 in pneumococcal vaccine naïve adults ≥60 years of age was
inferred by demonstrating noninferiority of OPA antibody responses after Prevnar 20 to the
corresponding OPA antibody responses after PCV13 for each of the 13 original serotypes and
to the corresponding OPA antibody responses after PPSV23 for each of the 7 new serotypes.
Prevnar 20 effectiveness against IPD in pneumococcal vaccine naïve adults 18-49 years of
age and 50-59 years of age were inferred by separate comparisons of OPA antibody
responses in each age group to the OPA antibody responses in adults 60-64 years of age
(immunobridging), in which Prevnar 20 effectiveness was established, as described above.
For the pneumonia indication, the same comparisons, using OPA antibody responses as a
surrogate endpoint as defined in the accelerated approval regulations, were used to support
the reasonable likelihood of vaccine effectiveness against pneumonia caused by the 7 new
serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F). A post-approval clinical endpoint study will be
required to verify and describe clinical benefit for the pneumonia indication for the 7 new
serotypes.
Based on post-hoc analyses from study 6115A1-3006 (“CAPiTA” study) (not adjusted for
multiplicity), serotype 3 specific PCV13 vaccine efficacy (VE) for the primary (CAP) endpoint
approached statistical significance in the per protocol population (PPP) and reached statistical

Conclusions and Reasons
•

•

•

•

Invasive pneumococcal disease (IPD) and pneumococcal
pneumonia are serious and life-threatening conditions that
can result in significant morbidity and mortality in adults ≥18
years of age.
The risk of serious pneumococcal disease is greatest in
immunocompromised adults and immunocompetent adults
with certain risk factors.
In adults ≥18 years of age, there is an unmet medical need
for effective prevention of invasive pneumococcal disease
and pneumococcal pneumonia caused by the 7 new
serotypes included in Prevnar 20 (8, 10A, 11A, 12F, 15B,
22F, 33F).
Serotype 3 continues to be a common cause of IPD in adults
and children in the US and globally.

•

The submitted immunogenicity data are adequate to establish
the effectiveness of a single dose of Prevnar 20 in adults ≥18
years of age for the prevention of vaccine-type IPD.
• Serotype 3-specific OPA GMTs induced by PCV20 were noninferior to those induced by PCV13. Thus, PCV20 vaccine
effectiveness against serotype 3 type disease is anticipated
to be similar to Prevnar 13 effectiveness, which reached
statistical significance based on the mITT population in study
6115A1-3006 (“CAPiTA” study).
• Based on the use of a surrogate endpoint under the
Accelerated Approval Regulations, the submitted
immunogenicity data provide evidence for the effectiveness
of a single dose of Prevnar 20 in adults ≥18 years of age for
the prevention of vaccine-type pneumonia.

114

Clinical Reviewer: Tina Mongeau
STN: 125731/0

•

•
•
•
•
Risk

Risk
Management

•
•

significance in the modified intent-to-treat population (mITT). Serotype 3 was one of the four
most frequently isolated serotypes from primary endpoint (CAP) cases in study 6115A1-3005.
VE against serotype 3 CAP was 56.3% (95% CI -12.4, 84.8%) in the per-protocol population
(PPP). In the modified intent-to-treat population (mITT), VE for serotype 3 reached statistical
significance (60.0% (95% CI 5.2, 84.8). For the secondary endpoints listed below, VE
estimates did not reach statistical significance. Fewer cases were observed for these two
secondary endpoints.
For non-bacteremic CAP, VE was 58.3% (95% CI -27.1, 88.5) in the PPP. Results were similar
in the mITT.
For IPD, VE was 75.0% (95% CI -152.6, 99.5) in the PPP. Results were similar in the mITT.
In descriptive immunogenicity analyses in study B7471006, OPA GMTs are diminished when
PCV20 is administered 1-5 years after PPSV23 compared to when it is given ≥ 6-months after
PCV13 or after PCV13 followed by PPSV23 with the last PPSV23 dose at least 1 year prior.
The most common risks of vaccination with Prevnar 20 include injection site pain, muscle pain,
fatigue and headache. The vast majority of reactions are mild or moderate in severity and
resolve quickly. Severe reactions were infrequent (≤3.0%)
No other safety signals were apparent in adults ≥18 years of age who are either pneumococcal
vaccine naïve or adults who previously received PPSV23 1 through 5 years prior, PCV13 ≥6
months prior, or PCV13 followed by PPSV23 (PPSV23 given ≥1 year prior).
Wyeth’s pharmacovigilance plan consists of routine postmarketing safety surveillance
(monitoring for any unanticipated risks in surveillance systems and postmarketing adverse
reaction reports).

•

All the evidence indicates that the safety profile of Prevnar
20 is acceptable in pneumococcal-vaccine-naïve adults, in
adults previously immunized with PPSV23 at least 1 year
prior and in adults previously immunized with PCV13 ≥6
months prior.

•

If Prevnar 20 were approved for adults ≥18 years of age,
routine pharmacovigilance measures would be adequate to
manage the risks.

115

Clinical Reviewer: Tina Mongeau
STN: 125731/0

11.2 Risk-Benefit Summary and Assessment
Data submitted to this BLA establish the benefit of vaccination with Prevnar 20 with respect to
the prevention of disease caused by twenty S. pneumoniae serotypes contained in the vaccine
in adults ≥18 years of age. The risks of vaccination with Prevnar 20 in this population have been
found to be minimal. Therefore, the overall risk-benefit profile of this product for adults ≥18
years of age is determined to be favorable.
The greatest benefit is expected among a subpopulation of adults who are at increased risk of
invasive pneumococcal disease or pneumococcal pneumonia due to age, underlying medical
conditions or other risk factors.
11.4 Recommendations on Regulatory Actions
According to my review of the clinical data, the safety and effectiveness of a single dose of
PCV20 in pneumococcal vaccine naïve adults ≥18 years of age are supported for the prevention
of vaccine-type IPD and vaccine-type pneumococcal pneumonia.
The approval of Prevnar 20 for the prevention of pneumonia caused by the 7 new serotypes (8,
10A, 11A, 12F, 15B, 22F, and 33F) is based on an immunologic surrogate endpoint (OPA
antibody titer), as defined in the Accelerated Approval regulations, that is reasonably likely to
predict prevention of pneumococcal pneumonia caused by the 7 new vaccine serotypes in
PCV20. As a condition of accelerated approval for the pneumonia indication for the 7 new
serotypes, Wyeth commits to conduct a post-approval confirmatory study to verify and describe
clinical benefit (Study B7471015).
11.5 Labeling Review and Recommendations
CBER communicated with Wyeth to achieve consistency with CBER’s current
guidance on the intent and format of prescribing information. Specific comments on the
prescribing information were provided by CBER to Wyeth who made the requested revisions. All
issues were satisfactorily resolved. The final prescribing information was reviewed by the clinical
team and found to be acceptable.
11.6 Recommendations on Postmarketing Actions
The clinical review of the data submitted to this BLA did not identify safety concerns that would
prompt the need for a postmarketing safety study. Wyeth’s proposal to monitor for any
unanticipated risks in surveillance systems and postmarketing adverse reaction reports (i.e.,
routine pharmacovigilance) is acceptable.
As a condition of the accelerated approval of PCV20 for the prevention of pneumonia caused by
the 7 new serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F) in adults, Wyeth is required to further
evaluate PCV20 in an adequate and well-controlled confirmatory clinical study to verify and
describe clinical benefit (21 CFR 601.41). Wyeth has made a commitment to conduct study
B7471015, a Phase 4 real-world study using a test-negative design to evaluate the
effectiveness of Prevnar 20 against CAP caused by the 7 new serotypes (8, 10A, 11A, 12F,
15B, 22F, and 33F) in adults ≥65 years of age. Study B7471015 is a postmarketing requirement
under the accelerated approval regulations. A draft protocol for study B7471015 was submitted
to STN 125731/0.8 on January 15. 2021. A final protocol will be submitted by August 31, 2020.
Study completion is estimated to occur on May 31, 2027. The final clinical study report will be
submitted by November 30, 2027. Given that the uptake of Prevnar 20 will largely depend on
116

Clinical Reviewer: Tina Mongeau
STN: 125731/0

the ACIP recommendation expected in October 2021, enrollment may need to be conducted
over 5 respiratory seasons beginning in October 2022.
Postmarketing studies that Wyeth is required to conduct under PREA after licensure are listed
below. The protocols for each of these studies were submitted and reviewed by CBER in 2020.
Pediatric Research Equity Act Postmarketing Requirements
1. Deferred pediatric study, B7471011, under PREA to evaluate the safety and effectiveness
(immunogenicity) of the 2, 4, 6, and 12-month schedule of Prevnar 20 in U.S. infants 6
weeks through 12 months of age.
Final Protocol Submission: May 8, 2020
Study Completion: August 31, 2022
Final Report Submission: December 31, 2022
2. Deferred pediatric study, B7471013, under PREA to evaluate the safety of the 2, 4, 6, and
12-month schedule of Prevnar 20 in U.S., European, and Canadian infants.
Final Protocol Submission: March 23, 2020
Study Completion: August 31, 2022
Final Report Submission: December 31, 2022
3. Deferred pediatric study, B7471014, under PREA to evaluate the safety and effectiveness
(immunogenicity) of Prevnar 20 in children and adolescents 15 months through 17 years of
age.
Final Protocol Submission: September 11, 2020
Study Completion: December 31, 2021
Final Report Submission: December 31, 2022
In addition, Wyeth has an ongoing trial evaluating the safety and immunogenicity of PCV20 coadministered with seasonal inactivated influenza vaccine in adults ≥65 years of age. (b) (4)

117

